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 “Chronic disease will never reach its clinical horizon to compromise health if it is 
attacked at its origin” [1]. Knowledge that one’s risk for cardiovascular events is related to the 
severity of endothelial dysfunction, and evidence that exercise training can improve endothelial 
function, has prompted speculation that measures of vascular function may serve as a 
“barometer” for cardiovascular health. This dissertation consists of three experiments intended to 
study vascular function and the manner in which it may influence or may be influenced by 
physical function.  
 Project one examined the influence of high and low volume circuit weight training on 
forearm vascular function. Thirty-five individuals participated in a program consisting of 3 
sessions/week for 5 weeks. Results indicated significant but similar strength gains in both groups 
(Hand Grip: Δ15.55%, Knee Extension: Δ21.00%, Bench Press: Δ35.31%; p<0.05). Reactive 
hyperemic responses, a measure of vascular function, only changed in those individuals with the 
lowest pre-training vascular measures, independent of group assignment.   
 Project two examined the link between vascular and physical function in peripheral 
neuropathy patients. Reactive hyperemic responses were significantly related to the time up and 
go test (r=-0.31, p=0.02) and the 6-minute walk distance (r=0.37, p=0.007). These data suggest a 
link between measures of vascular and physical function in these patients, indicating that those 
with better vascular function have greater physical function. 
 Project three examined the effects of an acute bout of exercise on nitric oxide, oxidative 
stress and anti-oxidants, and brachial vasoreactivity, before, at peak exercise, and in recovery, in 
trained individuals. The results indicated a significant increase in reactive oxygen species and 
peroxynitrite, and a decrease in the anti-oxidant glutathione peroxidase at peak exercise. Brachial 
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vasoreactivity was significantly lower immediately after exercise, but returned to pre-exercise 
levels at 20 minutes into recovery. These findings suggest an acute bout of exercise contributes 
to a significant rise in oxidative stress, which can in part be buffered by anti-oxidants systems, 
but may cause temporary blunting of arterial reactivity. Collectively, these findings indicate the 
importance of examining vascular function, and its controllers, and may extend the current 











Chapter 1                                                                                                                          
Introduction 
The purpose of this introductory chapter is to provide a foundation upon which the 
subsequent doctoral work is based. Chapter 2 is an extensive review of the scientific literature 
pertinent to this dissertation. Chapters 3 to 5 are original investigations conducted by this 
investigator. Finally, chapter 6 is a conclusion chapter designed to give the reader a summary 
and connect the findings of the projects outlined.                                                                        
 The endothelium regulates vascular homeostasis by elaborating a variety of paracrine 
factors that act locally in the blood vessel wall and lumen [2]. Under normal conditions, the sum 
total effect of these endothelial factors is to maintain normal vascular tone, blood fluidity, and 
limit vascular inflammation and smooth muscle cell proliferation [2]. Endothelial function may 
be measured invasively or non-invasively. For example, invasive measures involve the intra-
arterial administration of substances (e.g. acetycholine and bradykinin) that enhance the release 
of endothelial nitric oxide and lead to measurable vasodilatation in normal subjects but 
vasoconstriction in states of endothelial dysfunction [3]. However, the obvious disadvantage 
with such a method is that its invasive nature precludes its widespread use in the population. 
Therefore, the development of non-invasive techniques could easily be used to evaluate 
endothelial function in conditions where the invasive techniques could not be implemented 
properly.                                                                                                                              
 Vascular function assessments in this laboratory are done using non-invasive techniques 
in order to assess vascular reactivity and structure in a variety of populations. The non-invasive 
techniques commonly used in this laboratory are: (a) mercury strain gauge plethysmography, it is  
used to determine upper and/or lower regional blood flow, and (b) the brachial artery flow 
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mediated dilation model using ultrasonography, is a tool used to evaluate functional and/or 
structural changes and alterations of one single conduit artery. Generally it has been observed 
that individuals who are less fit, are older, or have chronic diseases, have lower vascular 
reactivity than fitter, younger and healthier individuals [4].  
 The main focus of this dissertation was to determine how the vasculature may be 
influenced or may influence physical function. The first step in the research process started with 
a follow-up study of previous work from this laboratory. Previous data from this laboratory, has 
reported regional vascular adaptations when a localized forearm training stimulus was used [5,6]. 
These studies were used as a foundation to keep exploring the effects of training on the 
vasculature, specifically the effects of resistance training on blood flow responses. Consequently 
the goal of the first study was to examine the influence of two volumes (high and low) of whole-
body circuit weight training on reactive hyperemia blood flow, venous capacitance and outflow 
in younger healthy college individuals. The findings revealed significant and similar increases in 
strength for the high and low volume groups. Although vascular function did not change 
following circuit weight training, those individuals with the lowest pre-training vascular 
measures did have significant increases in forearm reactive hyperemia blood flow and venous 
outflow, independent of group assignment.                                                                                   
 The second project in this dissertation focused on individuals who may have lower 
vascular function due to some sort of pathologic condition. The prevalence of peripheral 
neuropathy increases significantly in the older adult population and nearly one-third of all 
diabetics suffer from this condition [7]. In addition, irrespective of etiology, pathological 
changes associated with peripheral neuropathy are in many cases consistent with ischemia, 
secondary to vascular insufficiencies [8]. Thus the second study was intended to examine the 
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relationship between measures of vascular (both arterial and venous) and physical function 
(mobility and lower extremity strength) in individuals with peripheral neuropathy. These data 
indicated a relationship between measures of vascular and physical function in peripheral 
neuropathy. Indeed, individuals with greater physical function scores exhibited more favorable 
measures of arterial inflow and venous outflow.  
Although the previous studies were able to provide important information on how the 
vasculature may be influenced or may influence physical function, these findings also 
demonstrated how complex the study of vascular function could be. Finally, last step in this 
process was to begin the exploration in some putative factors thought to control vascular 
function. Clearly, vascular homeostasis is important to maintain vascular function. In that regard, 
Deanfield et al., [9] have speculated the vascular function is very much influenced by the balance 
of pro- and anti-oxidants. Thus the last study investigated the effects of an acute bout of exercise 
on nitric oxide bioavailability, oxidative stress markers, and antioxidants markers at three time 
points, before, at peak exercise, and at 20 minutes into the recovery phase in aerobically trained 
individuals. These data suggest that an acute bout of exercise contributes to a significant rise in 
reactive oxygen stress on the brachial artery, which can in part be buffered by anti-oxidants 
systems, but may cause temporary blunting of the reactivity of the brachial artery. In summary 
the findings of this dissertation further add to the current understanding of the role of the 




Chapter 2                                                                                                                                        
Review of Literature 
2.1 Introduction                                                                                                         
 Cardiovascular diseases remain the leading cause of death in the United States and most 
western countries. Mortality data show that cardiovascular disease total mentioned in 2002 
constituted about 58% of all deaths that year [10]. Furthermore, cardiovascular disease is the 
underlying cause of death accounted for 36.3% of all deaths in 2004, or 1 of every 2.8 deaths in 
the United States. In fact, an estimated 79 million American adults (1 in 3) have 1 or more types 
of cardiovascular disease. Of these, 37 million are estimated to be age 65 or older [11]. Finally, 
the economic burden of cardiovascular disease is enormous [12]. In fact, in 2004 the costs of 
cardiovascular disease totaled an estimated $352 billion dollars in the United States [12].  
 Proper treatment of cardiovascular disease includes risk factor modification, pharmaco-
therapy, and surgery. Among the modifiable behaviors that increase risk of cardiovascular 
disease are cigarette smoking, high blood pressure, obesity, and physical inactivity. In regard to 
this last factor, there is no doubt that physical activity is beneficial for improving health. 
Therefore, the role of physical activity will be addressed in this review, in part because of the 
interest by the author, and second because evidence suggests that regular physical activity, as a 
therapeutic intervention, not only beneficially effects symptoms and enhances myocardial 
perfusion but also reduces mortality in patients with coronary artery disease/myocardial 
infarction [13,14].                                                                                                                   
 Over the last decade, exercise training has emerged as a very important intervention for 
primary and secondary prevention of coronary artery disease [15]. Position statements developed 
by the Surgeon General [16], the National Institutes of Health Consensus Development Panel on 
5 
 
Physical Activity and Cardiovascular Health [17], and the Centers for Disease Control and 
Prevention and the American College of Sports Medicine [18] call for every adult to accumulate 
at least 30 minutes of moderate-intensity physical activity on most, preferably all, days of the 
week to prevent cardiovascular heart disease and other chronic diseases. Furthermore, exercise 
should promote all aspects of physical conditioning, including aerobic capacity and muscular 
endurance, range of motion and flexibility, and muscular strength.                                           
 Importantly, despite the evidence of the benefits of regular physical activity in the 
management of individuals with cardiovascular disease, the manner in which exercise is 
prescribed is often “generic” rather than tailored to an individual’s state, severity and type of 
cardiovascular disease. This is particularly important given the evidence that individuals’ 
responses, adaptations, and compensations to a disease are often highly variable. In fact, the 
problems with cardiovascular disease are not just limited to the cardiovascular system. In most 
cases cardiovascular disease is the “tip” of the iceberg, as many other physiologic systems 
attempt to compensate for the problems incurred by the cardiovascular system. These 
“compensatory changes” are critical to understand as they to a large degree contribute to the 
clinical course of patients afflicted by cardiovascular diseases.                                                    
 This is particularly relevant in terms of choosing an appropriate treatment path. More 
specifically, a “generic” recommendation to accumulate 30 minutes of exercise over the course 
of a day may be insufficient to truly alter the disease progression or could in fact be harmful. For 
example, clinicians may need to recognize that in many cases compensatory changes to a 
particular form of cardiovascular disease is dramatically different from other manifestations of 
the same disease. This is critical as we need to move from generic exercise programs to 
individualized targeted treatment plans that may be more effective in its delivery. It is with this 
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concern in mind that has led me to examine the literature more closely. In doing so, two 
interesting distinctive outcomes of cardiovascular disease are discussed: (a) Heart Failure, and 
(b) Peripheral Arterial Disease.                                                                                                               
 The first one, heart failure is a condition that results from myocardial dysfunction that 
impairs the heart's ability to pump blood at a rate sufficient to maintain the metabolic needs of 
peripheral tissues and various organs. As a result of the cardiac problems, skeletal muscle blood 
flow decreases contributing to the cardinal symptoms of heart failure including breathlessness 
and fatigue on exertion. Although the primary defective organ in heart failure is the heart, the 
periphery, including skeletal muscle becomes a secondary defective organ of major clinical 
significance in the manifestation of the disease. Of major concern is preferential skeletal muscle 
atrophy, in that more oxidative muscle fibers (Type I) are lost, and non-oxidative muscle fibers 
(Type IIa and IIb) are preferentially maintained.                                                                         
 The second condition included is peripheral arterial disease, a manifestation of systemic 
atherosclerosis in the lower limb distal to the aortic bifurcation. As with heart failure, peripheral 
arterial disease is associated with significant morbidity and mortality. Anatomically peripheral 
arterial disease is defined as atherosclerotic arterial disease, while functionally it is defined as 
arterial narrowing, causing a decrease in muscle blood flow, and consequently a mismatch 
between the oxygen supply and metabolic demand resulting in symptoms of intermittent 
claudication, exercise limitations, or tissue loss. Patients with peripheral arterial disease also 
undergo significant compensatory changes in skeletal muscle. However, in contrast to heart 
failure, peripheral arterial disease patients show significant atrophy in non-oxidative (Type IIa 
and IIb) skeletal muscle fibers, and preferentially retain the oxidative fibers (Type I). Thus, two 
conditions, which essentially have a common underlying problem of reduced muscle blood flow 
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and subsequent exercise intolerance, have vastly different physiological and morphological 
compensatory changes. It is this differential compensatory adaptation that serves as the major 
stimulus for this review. The reason being that if patients with such a different compensation to 
essentially the same problem, that is reduced blood flow, a generic recommendation for exercise 
cannot be effective. Thus ultimately the quest is to determine the most effective exercise 
strategies for individuals with cardiovascular disease. Those strategies can only evolve from a 
detailed understanding of the underlying pathophysiological changes. Therefore, it is with that in 
mind that this review is written. Consequently, the main focus of this review is to discuss the 
central and peripheral mechanisms of exercise intolerance in patients with heart failure and 
peripheral arterial disease.                                                                              
2.2 Heart Failure                                                                                                                            
 A major physiologic problem for patients with heart failure is a reduction in muscle blood 
flow. As a consequence the cardinal symptoms of this disease are exercise intolerance, shortness 
of breath, and chronic fatigue. In this section the following issues will be addressed: (a) the 
definition, (b) the incidence and prevalence, (c) the etiology and pathophysiology, (d) the 
cardinal symptoms and clinical outcomes, (e) the diagnostic tests and the prognostic value of 
exercise testing, and finally (f) the classification of heart failure related to the degree of symptom 
severity. Next, this section will present information regarding the principal circulatory and 
muscular compensatory adaptations in heart failure patients. Finally, this section will discuss the 
acute exercise responses, and the response to exercise training in heart failure patients. The 
purpose of this section is to increase the understanding of the manner in which patients with  





Heart failure is defined as "the pathophysiological state in which an abnormality of 
cardiac function is responsible for failure of the heart to pump blood at a rate commensurate with 
the requirements of the metabolizing tissues and/or to be able to do so only from an elevated 
filling pressure" [19]. This definition implies that there is an alteration in the normal 
physiological pumping capacity of the heart.  
Heart failure is a complex clinical syndrome that can result from any structural or 
functional cardiac disorder (e.g. myocardial dysfunction) that impairs the heart's ability to 
circulate blood at a rate sufficient to maintain the metabolic needs of peripheral tissues and 
various organs [20]. The cardinal manifestations of heart failure are fatigue or dyspnea on 
exertion progressing to dyspnea at rest [20].  
Patients with heart failure suffer from decreased exercise capacity, impaired quality of 
life, and poor prognosis [21]. Furthermore, the inability to perform exercise without discomfort 
may be one of the first symptoms experienced by patients with heart failure and is often the 
principal reason for seeking medical care. Therefore, exercise intolerance is inextricably linked 
to the diagnosis of heart failure [22]. 
2.2.2 Incidence and Prevalence 
 Heart failure is a major and growing public health problem in the United States.  
Approximately 5 million patients in this country have heart failure, and over 550 000 patients are 
diagnosed with heart failure for the first time each year [23]. The disorder is the primary reason 
for 12 to 15 million office visits and 6.5 million hospital days each year [24]. Indeed, heart 
failure is the most common Medicare diagnosis-related group (i.e. hospital discharge diagnosis), 
and more Medicare dollars are spent for the diagnosis and treatment of heart failure than for any  
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other diagnosis [25]. In addition, the estimated direct and indirect cost of heart failure in the 
United States for 2007 is $33.2 billion [11]. 
The incidence of heart failure approaches 10 per 1000 population after age 65 [23]. Heart 
failure is primarily a condition of the elderly [26], and thus the widely recognized “aging of the 
population” also contributes to the increasing incidence of heart failure. Furthermore, a 
community-based cohort study using the resources of the Rochester Epidemiology Project 
conducted in Olmsted County, Minnesota [27], showed that the incidence of heart failure has not 
declined during 2 decades, but survival after onset has increased overall, with less improvement 
among women and elderly persons. Finally, the Framingham Heart Study [28] have revealed that 
at age 40, the lifetime risk of developing heart failure for both men and women is 1 in 5, and the 
lifetime risk of heart failure occurring without antecedent of myocardial infarction is 1 in 9 for 
men and 1 in 6 for women. 
The Framingham Heart Study and the Framingham Offspring Study [29] indicated that 
hypertension is a very common risk factor for heart failure. Truly, seventy-five percent of heart 
failure cases have antecedent of hypertension [28], and the lifetime risk doubles for people with 
blood pressure greater than 160/90 mm Hg versus those with blood pressure less than 140/90 
mm Hg [28]. In addition, the Heart and Estrogen/progestin Replacement Study (HERS) of the 
predictors of heart failure among women with coronary heart disease found that diabetes was the 
strongest risk factor [30]. Furthermore, it is relevant to mention that heart failure is a common 
manifestation of the later stages of various cardiovascular diseases, including coronary artery 
disease, hypertension, valvular disease, and primary myocardial disease [11]. 
Heart failure total-mentioned mortality in 2002 was 286 700 [11]. On the basis of the 44-
year follow-up among Framingham Heart Study participants, 80% of men and 70% of women 
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under age 65 who have heart failure will die within 8 years [28]. After heart failure is diagnosed, 
survival is poorer in men than in women, but fewer than 15% of women survive more than 8 to 
12 years. In people diagnosed with heart failure, sudden cardiac death occurs at 6 to 9 times the 
rate of the general population [28]. The 2004 overall death rate for heart failure was 19.1 %. 
Death rates were 20.3% for white males, 22.9% for black males, 18.3% for white females, and 
19.0% for black females [31]. 
2.2.3 Etiology and Pathophysiology 
The etiology of heart failure is displayed in table 2.1. The clinical syndrome of heart 
failure may result from disorders of the pericardium, myocardium, endocardium, or great vessels, 
but the majority of patients with heart failure has symptoms due to an impairment of left 
ventricular myocardial function [32]. Heart failure may be associated with a wide spectrum of 
left ventricular functional abnormalities, which may range from patients with normal left 
ventricular size and preserved ejection fraction to those with severe dilatation and/or markedly 
reduced ejection fraction [32].  
In most patients, abnormalities of systolic and diastolic dysfunction coexist, regardless of 
ejection fraction. Patients with normal ejection fraction may have a different natural history and 
may require different treatment strategies than patients with reduced ejection fraction, although 
such differences remain controversial [32]. The most common causes of heart failure in the 
United States are coronary artery disease, systemic hypertension, non-ischemic dilated 
cardiomyopathy, and valvular heart disease [23].  
Other frequent causes are myocarditis and diabetes mellitus, but there are a great many 
less common causes [20]. As a result, when an excessive workload is imposed on the heart by  
increased systolic blood pressure (pressure overload), increased diastolic volume (volume 
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overload), or loss of myocardium, normal myocardial cells hypertrophy in an effort to enhance  
contractile force of the normal areas [33]. The subsequent alterations in biochemistry, 
electrophysiology, and contractile function lead to mechanical alterations of myocardial function.  
             Table 2.1 Etiology of heart failure  
 
Etiology 
Coronary artery disease 
Hypertension 











Toxins (chemotherapy, cocaine) 
Peripartum 
 
The rate of contraction slows, the time to develop peak tension increases, and myocardial 
relaxation is delayed. Peak force development may be well preserved with enough viable 
myocardium and adequate time for the development of force. Thickening of the ventricular wall 
limits the rate of ventricular filling (diastolic dysfunction), which is worsened by increased heart 
rate because it shortens the duration of ventricular filling [34].  
The force of myocardial contraction is eventually reduced as cell loss and hypertrophy 
continues, leading to significant geometric ventricular alterations and increased volumes [20]. 
After the initial compensatory phase, the increase in intracavitary volume is usually associated 
with further reductions in ventricular ejection fraction (progressive systolic dysfunction) and  
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eventually abnormalities in the peripheral circulation from activation of various neurohumoral 
compensatory mechanisms [33].  
Finally, the abnormal neurohumoral responses lead to increased systemic sympathetic 
tone and activation of the renin-angiotensin system [35]. Production of angiotensin increases, 
causing peripheral vasoconstriction. The increase in peripheral arterial resistance limits cardiac 
output during exercise. The increased levels of angiotensin II also stimulate release of 
aldosterone by the adrenal glands, enhancing sodium retention and thus leading to fluid retention 
and peripheral edema [33]. 
2.2.4 Symptoms 
The symptoms of heart failure can be caused by either an abnormality in systolic function 
that leads to a defect in the ejection of blood from the heart (systolic heart failure) or an 
abnormality in myocardial diastolic function that leads to a defect in ventricular filling (diastolic 
heart failure) [32]. Reduced left ventricular filling caused by diastolic dysfunction leads to 
decreased stroke volume and associated symptoms of low cardiac output, whereas increased 
filling pressures lead to symptoms of pulmonary congestion [20]. Thus, some characteristics of 
heart failure (e.g. the inability of the left ventricle to provide adequate forward output to meet the 
demands of the skeletal muscles during exercise while maintaining normal filling pressures) may 
result primarily from diastolic dysfunction, which, in some patients, can occur with normal left 
ventricular systolic function [32]. There are no exact data on the prevalence of diastolic 
dysfunction leading to heart failure in the presence of normal systolic function.  
Several studies have shown, however, that as many as 40% of all patients with a clinical 
diagnosis of heart failure may have preserved LV systolic function, and many of these patients 
have evidence of diastolic dysfunction [32]. The following section will present a brief overview  
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of the clinical findings in heart failure patients. First, the major symptoms that affect heart failure 
patients will be outlined. 
2.2.4.1 Shortness of Breath 
Dyspnea or breathlessness (a subjective feeling of air hunger), is the earliest and most 
frequent symptom in heart failure. Initially, dyspnea on exertion will be noted by a change in the 
extent of physical activity that causes shortness of breath. As heart failure worsens, the intensity 
of exertion required will decrease. The patient with heart failure will progressively develop 
paroxysmal nocturnal dyspnea, orthopnea, and eventually dyspnea at rest [36]. 
 2.2.4.1.1 Paroxysmal Nocturnal Dyspnea   
Paroxysmal nocturnal dyspnea normally occurs after the patient has been asleep and in 
the supine position for some time. Suddenly, the patient wakes up with a sensation of choking 
and air hunger; assuming an upright posture usually relieves the symptoms. Frequently the 
patient will feel better after opening a window or going outside to catch a breath of fresh air. 
Paroxysmal nocturnal dyspnea usually precedes orthopnea; it may be associated with 
bronchospasm and wheezing (cardiac asthma) and can be confused with an attack of bronchial    
asthma, especially in patients with prior known chronic obstructive pulmonary disease [33]. 
Many patients with heart failure also have chronic obstructive pulmonary disease; it may be 
difficult to distinguish between the dyspneic symptoms secondary to heart failure and those that 
are due to chronic obstructive pulmonary disease.  
 Most severe episodes of paroxysmal nocturnal dyspnea can cause a feeling of intense 
suffocation and may leave the patient gasping for breath. The uncomfortable sensation may 
persist for 30 minutes or more after the patient has assumed an upright posture [37]. Paroxysmal 
nocturnal dyspnea is primarily caused by mobilization of interstitial fluid (especially in patients 
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with edema). The result is increased circulating blood volume and increased pulmonary venous 
pressure, especially in patients with left ventricular diastolic dysfunction [38]. 
 2.2.4.1.2 Orthopnea  
Orthopnea is defined as dyspnea that occurs often within a few minutes when the patient 
assumes a supine position; sitting up or standing usually improves the symptoms. The most 
severely affected patients usually sleep sitting upright in a chair. Orthopnea has the same cause 
as paroxysmal nocturnal dyspnea, but it represents more severe cardiac impairment [33]. 
 2.2.4.1.3 Nocturnal Dyspnea or Exertional Dyspnea  
Nocturnal dyspnea is a dry or nonproductive cough. This is due to pulmonary congestion 
and in patients with heart failure is usually relieved by successful treatment of the heart failure 
[36].    
2.2.4.2 Fatigue and Weakness 
Fatigue and generalized weakness are present in heart failure patients particularly in the 
limbs. These symptoms are secondary to low cardiac output with decreased perfusion of skeletal 
muscles and can occur with exertion or at rest; they may be worsened after eating because of the 
increased splanchnic demand for blood flow, which may stress the limited reserve. Low-output 
syndromes can be present, without evidence of pulmonary congestion, and limit performance 
during exercise testing [37]. It is important to emphasize that breathlessness and fatigue on 
exertion are the dominant symptoms of heart failure [39]. Indeed, these symptoms are the 
primary determinants of their health- related quality of life [22].  
A traditional view of the pathophysiology of the symptoms runs as follows: first, the 
failing heart has an impaired response to exercise. In turn, this leads to failure to perfuse the 
exercising muscle adequately; the unhappy skeletal muscle signals the brain, and this sensation is 
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interpreted as fatigue. Second, the failing heart requires an ever higher left ventricular filling 
pressure to maintain output, particularly during exertion; the filling pressure can rise high enough 
to cause either stiff lungs or even transudation of fluid into the alveoli, which causes 
breathlessness [39]. 
2.2.4.3 Nocturia and Oliguria 
Nocturia is a common and early symptom in heart failure. Renal filtration of sodium and 
water is decreased in patients with compromised left ventricular function, in part, because of the 
redistribution of blood flow away from the kidneys in the upright position and during physical 
activity. Urine formation is enhanced in the recumbent position when renal stimulus for 
vasoconstriction decreases and venous return to the heart increases. Oliguria is associated with a 
markedly reduced cardiac output and is usually a sign of terminal heart failure; it indicates a poor 
prognosis [36].  
2.2.4.4 Cerebral Symptoms  
Elderly patients with advanced heart failure may develop confusion, memory impairment, 
anxiety, headaches, insomnia, nightmares, and, occasionally, disorientation, delirium, and 
hallucinations. These cerebral symptoms are predominantly related to reduce cardiac output and 
poor perfusion of brain and other neurologic tissues [33]. 
2.2.4.5 Abdominal Symptoms  
Patients with heart failure may also develop gastrointestinal complaints because of 
hepatic congestion and edema of the abdominal wall and intraabdominal organs [36]. Congestion 
of abdominal organs may be present with ascites, abdominal fullness and enlargement, easy 
satiety, bloating, anorexia, nausea, vomiting, constipation, and upper abdominal discomfort. The 
abdominal discomfort is usually described as a dull ache or heaviness that can be enhanced or 
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reproduced by upper abdominal or hepatic palpation. This is consistent with the likely cause, the 
stretching of the hepatic capsule [40]. Patients can frequently detect early re-accumulation of 
fluid by the recurrence of abdominal fullness before the signs become obvious. This symptom 
can be easily overlooked, however. Asking the patient about a recent change in waist size or 
atightening of the clothing at the waist is often helpful [40].                                                 
 After describing the major symptoms among heart failure patients, it is necessary to 
review the clinical outcomes obtained in a medical examination. Normally, during a physical 
examination, patients with heart failure of recent onset appear acutely ill but well nourished. On 
the other hand, patients with advanced stages of heart failure frequently appear malnourished, 
and occasionally cachectic. Thus, some of the clinical outcomes or signs revealed throughout a 
physical examination will be outlined in the next section. 
2.2.5 Clinical Outcomes 
2.2.5.1 Cardiomegaly  
Cardiomegaly with a laterally displaced, enlarged, and sustained ventricular impulse may 
be found on physical examination, but this is a nonspecific finding and can be absent, 
particularly in patients with acute heart failure. The decrease in ventricular compliance may 
initially become apparent by the presence of a late diastolic atrial sound (S4 gallop). A 
protodiastolic sound (S3 gallop) occurs in patients with more advanced heart failure and is 
caused by acute deceleration of ventricular inflow after the early filling phase [41]. An S3 gallop, 
however, can also be detected in other conditions such as mitral and tricuspid regurgitation and a 
left-to-right shunt.  
Gallop sounds are more readily audible in the presence of a rapid heart rate. The presence 
of a third heart sounds appears to be associated with an increased risk of death, death from pump 
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failure, and hospitalization for heart failure [41]. Systolic murmurs are common in heart failure 
and are largely secondary to mitral or tricuspid regurgitation that can result from ventricular 
dilatation. These murmurs frequently diminish or disappear after adequate treatment and 
reduction of ventricular size [40]. 
2.2.5.2 Systemic Venous Hypertension                                                                              
Can be detected by abnormal distension of the jugular veins (the upper limit of the 
jugular venous pressure is about 4 cm above the sternal angle with the patient recumbent at a 45° 
angle) [41]. Although the jugular venous pressure normally declines on inspiration, it can rise in 
patients with right heart failure (Kussmaul's sign). Persistent elevation of the jugular venous 
pressure is one of the earliest and most reliable signs of right-heart failure [41]. The inability of 
the right ventricle to accept transient increases in venous return (hepatojugular reflux) is 
observed during transient compression (≥30 s) of the upper abdomen [40].  
Systolic pulsations of the liver may be felt in patients with tricuspid regurgitation. Liver 
enlargement and tenderness on palpation are marked by epigastric fullness and dullness to 
percussion in the right upper quadrant. These findings may persist after other signs of heart 
failure have disappeared because it takes longer for hepatic congestion to disappear. In some 
cases, the liver enlargement does not disappear because of structural changes in patients with 
long-standing heart failure. The presence of an elevated jugular venous pressure appears to be 
associated with an increased risk of death, death from pump failure, and hospitalization for heart 
failure [36,41]. 
2.2.5.3 Pulsus Alternans   
Pulsus alternans is common in patients with heart failure; when severe, it can be detected 
by sphygmomanometry or by palpation of peripheral pulses, particularly the femoral pulse. This 
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sign is characterized by a regular rhythm of alternating strong and weak pulsations [42]. 
Sometimes the weak beat may be so small that the aortic valve does not open and no aortic or 
arterial pulse is produced, resulting in total alternans and a pulse that is only half as fast as the 
apical beats [40]. With total alternans, a first heart sound will occur, but no second heart sound if 
both the aortic and pulmonic valves fail to open.  
Pulsus alternans appears to be due to an alternation in the stroke volume of the left 
ventricle, possibly because of an incomplete recovery of myocardial cells and thus a decrease in 
the responsiveness of contracting cells on alternate beats [43]. It can be persistent or paroxysmal, 
or it may occur only after a premature beat or with the Valsalva maneuver. The hemodynamic 
response to the Valsalva maneuver has been found useful in the clinical evaluation of patients 
with heart failure [43].  
In this maneuver the blood pressure cuff is inflated to just about 15 mm Hg above the 
systolic blood pressure before the maneuver. In a normal response, the Korotkoff sounds 
disappear during sustained maneuver and reappear after completion of the maneuver. An 
abnormal response, in which blood pressure sounds either do not disappear or are maintained 
throughout the maneuver, has been found in patients with heart failure [42]. In normal patients, 
the decrease in blood pressure during the maneuver is associated with tachycardia and the 
increase in blood pressure after release with bradycardia. No changes in heart rate are observed 
in heart failure patients.                 
Although heart failure is a clinical diagnosis based on a careful history and physical 
examination, there are diagnostic tests that have shown being reliable in the evaluation of 
patients with heart failure [40]. Thus, the following section will present information regarding 
these diagnostic tests. 
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2.2.6 Diagnostic Tests  
 2.2.6.1 Chest Radiograph  
Cardiomegaly (cardiothoracic ratio > 50%) can be found on chest film in 87% of patients 
when first diagnosed with primary dilated cardiomyopathy [40]. The lower lobes of the lung are  
normally better perfused than are the upper lobes; with heart failure, there is progressive 
vasoconstriction of vessels in the lower lobes and redistribution of the pulmonary flow to the 
upper lobes. Interstitial and perivascular edema develop with acute increases in pulmonary 
capillary wedge pressure above 20-25 mm Hg; bronchovascular markings at the bases are 
prominent.  
 Interstitial edema can present as perivascular or peribronchial edema (initially in perihilar 
and then in peripheral zones) [36]. Kerley's lines, spindle-shaped linear opacities at the periphery 
of the lung bases, occur in the later stages of heart failure; pleural fluid can produce discrete 
interlobular-type linear opacities and subpleural fluid accumulation between the lung and 
adjoining pleura [40].  
The accumulation of fluid in major and minor lung fissures can be of considerable size 
and may be incorrectly diagnosed as a tumor mass in the lung [37]. These "phantom tumor" 
shadows, however, have smooth margins and disappear with resolution of heart failure. With 
acute increases in pulmonary capillary wedge pressures above 25 mm Hg, alveolar edema, 
pleural effusions, or both may occur. Heart failure patients may show elevated pulmonary 
capillary pressures in the range of 25-35 mm Hg or more without interstitial or alveolar edema, 
reflecting associated increased lymphatic flow [44]. After therapy that lowers pulmonary 
capillary pressure, there may be a delay of 24-48 h before improvement and clearing of 
pulmonary infiltrates can be seen on chest radiograph [40]. 
20 
 
2.2.6.2 Electrocardiography   
Changes in the 12-lead electrocardiography are generally nonspecific. Sinus tachycardia 
is usually present in uncompensated heart failure or in end-stage disease with a low stroke 
volume that requires tachycardia to maintain the cardiac output. Isolated premature ventricular 
beats are common, and complex ventricular arrhythmias can be detected in most patients during 
prolonged (24-48 h) Holter monitoring. Electrocardiographic findings suggestive of atrial and 
ventricular chamber enlargement may be evident. Intraventricular conduction delays are also 
common and include left bundle branch block as well as other, nonspecific repolarization  
changes [40]. 
2.2.6.3 Exercise Stress Testing 
There are three major types of exercise tests used to obtain an objective measurement of 
exercise performance in heart failure patients [45]; (a) the symptom-limited progressive exercise 
test carried to the point of exhaustion (cardiopulmonary exercise stress testing); (b) the test of 
endurance at a predetermined level of exercise (which is submaximal); and (c) tests of 
submaximal exercise performance, such as the time taken to complete a typical walking task or 
the distance covered at a comfortable walking speed along a corridor (the corridor walking test) 
or a self-propelled treadmill [46]. The first two tests are done using a bicycle ergometer or 
treadmill [47]. For the last one, submaximal exercise performance, the 6-min walk test has been 
promoted as a safe, well-tolerated, and a simple measure of functional capacity in heart failure 
patients [48].  
In addition, the most common measure of fatigue in practice is the Borg scale [49], which 
can be graded separately for fatigue and dyspnea. Although fatigue remains a major complaint of 
patients, it is rare in practice to monitor this symptom or its progression [50]. It is important to 
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emphasize the prognostic value of some of the above exercise tests used to evaluate patients with 
heart failure. Therefore, two specific modalities will be addressed in the next section. The first 
one, an incremental test with metabolic gas exchange measurement, which is the most useful 
[39]; the second, the 6-minute walk test, which is commonly used and simple to administer [51]. 
The prognostic value of exercise testing in heart failure is as follow: 
 2.2.6.3.1 Cardiopulmonary Exercise Stress Testing  
A cardiopulmonary exercise stress testing properly performed provides an objective  
measurement of peak functional capacity, and has become an important clinical tool with which 
to define disease severity and to predict outcome in patients with heart failure due to left 
ventricular systolic dysfunction [52]. Indeed, cardiopulmonary exercise stress testing plays a 
pertinent role in decision-making about the workup of the heart failure patient [47].  
During a cardiopulmonary exercise stress testing, the subject exercises to exhaustion, 
breathing through a tight fitting mask or mouthpiece, and the expired air is collected and 
analysed [53]. Contrary to what is observed in athletes or fit subjects, what is measured at the 
end of exercise in a heart failure patient is not a plateau of maximum oxygen consumption 
(VO2max) [54]. Heart failure patients generally stop exercising early because of fatigue or 
dyspnea. Other reasons for stopping a test include chest pain, ischemia, decrease in blood 
pressure, arrthymias [53].  
The cardiopulmonary exercise stress testing provides information concerning three 
important variables [39]; (a) peak oxygen consumption (VO2), (b) the slope of the relation 
between ventilation and carbon dioxide production (VE/VCO2), and (c) the respiratory exchange 
ratio (RER). Peak oxygen consumption is defined as the maximum rate of oxygen consumption  
achieved and is used as an index of exercise performance. The slope of the relation between 
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ventilation and carbon dioxide production is used as an index of the ventilatory response to  
exercise. Finally, the respiratory exchange ratio is defined as the ratio of carbon dioxide 
production to peak oxygen consumption.  
There is overwhelming evidence of the role played by peak oxygen consumption in 
stratifying risk in heart failure [39,55,56]. In fact, a study by Mancini et al., [57] is considered to 
be the cornerstone of the documentation of the prognostic power of peak oxygen consumption. 
In that regard, the study by Mancini et al., [57] divided heart failure patients into the following  
three groups (see table 2.2).  











Patients with peak VO2 of < 14 mL/kg/min who 





Patients with peak VO2 of ≥ 14 mL/kg/min who 
had transplant deferred 
94% 
 
3 Patients with peak VO2 of < 14 mL/kg/min but 




Furthermore, a peak VO2 of < 10 mL/kg/min was associated with significantly poorer 
predicted survival [45]. Lastly, the results of the study by Mancini et al., [57] were adopted by 
the American Heart Association/American College of Cardiology consensus statement on the 
selection and treatment of candidates for heart transplantation [58].  
In addition, the anaerobic threshold has been proposed as a submaximal index of exercise 
capacity, independent of the patient’s motivation, and has been classically defined as the point 
where lactate increases in plasma during exercise, as a consequence of the transition from total 
aerobic to aerobic plus anaerobic metabolism [45]. A failure to reach the ventilatory anaerobic 
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threshold strongly suggests poor motivation or non-cardiovascular limitation of exercise 
tolerance. Indeed, Opasich et al., [59] evaluated the predictive role of peak VO2 in 505 heart 
failure patients when the ventilatory anaerobic threshold (VAT) was or was not detected (see 
table 2.3).                      
These findings were also reported by Corra et al., [45]. Indeed, the study by Corra et al., 
[45] concluded that when ventilatory anaerobic threshold is detected, patients with a peak VO2 
of < 10 mL/kg/min have a high event rate, whereas those with a peak VO2 of > 18 mL/kg/min 
havea good prognosis. However, it is important to recognize that a multiplicity of factors 
influence any given peak VO2 value [45]. In fact, it is well-known that peak VO2 is affected by 
age, gender, body weight, muscle mass, and conditioning status [60,61]. 
      Table 2.3 Predictive role of peak VO2 and VAT in heart failure patients 
 
Peak VO2 
VAT was identified 
cardiac event rates 
VAT was not detected 
cardiac event rates 
≤ 10 mL/kg/min 59% 46% 
32% 29% > 10 to ≤ 14 mL/kg/min 
> 14 to ≤ 18 mL/kg/min 32% 23% 
> 18 mL/kg/min 15% 22% 
 
 In addition, many studies have revealed that ventilatory expired gas parameters obtained 
from symptom-limited cardiopulmonary exercise stress testing represent prognostic value in 
heart failure patients [62,63]. In that regard, figure 2.1 displays the relationship between 
ventilation and carbon dioxide production (VE/ VCO2). The VE/ VCO2 slope is highly linear, and 
the slope is increased with increasing severity of heart failure that is, for any given level of 




Finally, Corra et al., [45] after reviewing some of those findings have suggested that the 
risk stratification procedure with symptom-limited cardiopulmonary exercise stress testing in 
heart failure patients, traditionally based on peak oxygen consumption and ventilator anaerobic 
threshold, should be replaced by a new prognosticating algorithm that is structured on a 
multiparametric decoding scrutiny employing the stepwise introduction of peak VO2, VE/VCO2 
slope, and peak respiratory exchange ratio [45]. 
 
Figure 2.1. Ventilation/carbon dioxide production (VE/ VCO2) slope in heart failure. 
Note that the relation between VE and VCO2 remains linear but that the slope 
increases with worsening heart failure. Thus, for a VCO2 of 1 L/min, a normal subject 
has to ventilate at 22 L/min and the patient with moderate heart failure ventilates at 
42 L/min [39]. 
 
  2.2.6.3.2 The 6- Minute Walk Test 
The 6-minute walk test is considered to be realistically related to daily physical activity  
[64]. Furthermore, the 6-minute walk test is used to estimate functional capacity in patients with 
a variety of medical conditions, and can be performed by those who are unable or unwilling to 
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undertake formal treadmill or bicycle exercise tests [65]. Thus, among heart failure patients, it 
has been incorporated into studies of assessment of exercise capacity [66], of quality of life [67], 
of efficacy of new therapeutic agents [68] including beta-blockers [69], of physical training 
programs [70], and of prognostic stratification [71,72].  
According to the American Thoracic Society (ATS) Statement for Guidelines for the Six-
Minute Walk Test [73], the 6-minute walk test should be performed indoors, along a long, flat, 
straight, enclosed corridor with a hard surface that is seldom traveled. If the weather is  
 comfortable, the test may be performed outdoors. The walking course must be 30 m in length. A 
100-ft hallway is, therefore, required. The length of the corridor should be marked every 3 m. 
The turnaround points should be marked with a cone (such as an orange traffic cone). A starting 
line, which marks the beginning and end of each 60-m lap, should be marked on the floor using 
brightly colored tape. 
In order to study the potential usefulness of the 6-minute walk test, the Studies of Left 
Ventricular Dysfunction (SOLVD) Registry Substudy followed 833 heart failure patients for an 
average of 242 days [71]. This cohort reported that the 6-minute walk test is a safe and simple 
clinical tool that strongly and independently predicts morbidity and mortality in patients with left 
ventricular dysfunction. Indeed, table 2.4 displays the significance of the 6-minute walk test in 
estimating a patient’s prognosis in heart failure [71]. Furthermore, previous studies have 
identified that walking <300 m during the 6-minute walk test is a simple prognostic marker of 
subsequent cardiac death in patients with mild-to-moderate heart failure [74]. 
 However, studies that have evaluated the relationship between the 6-minute walk test to 
peak oxygen consumption (VO2) in heart failure patients have reported that the 6-minute walk 
test cannot be used in the individual heart failure patient as an alternative to, or as a surrogate of, 
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peak VO2 [48,64,75]. In that regard, Opascih et al., [64] found no significant correlation between 
the distance walked during the 6-minute walk test and hemodynamic indices (left ventricular 
ejection, cardiac index, right and left filling pressures) and found only a moderate correlation 
with functional capacity indicators (peak VO2).  
 Therefore, these investigators concluded that the walking performance does not provide 
prognostic information which can either complement or substitute that provided by peak VO2 or 
the New York Heart Association (NYHA) classification for heart failure [64].  
    Table 2.4 Relationship between 6-minute walk test distance and heart failure   
     readmission rates and mortality  
 





<300 m 22.16% 10.23% 
300–374.9 m 11.20% 7.88% 
375–449.9 m 3.72% 4.19% 
≥450 m 1.99% 2.99% 
 
Furthermore, the prediction of peak VO2  based on regression equations derived from the 
relationship between peak VO2 and 6-minute walk test results in too much variability to be 
clinically useful [48]. While 6-minute walk test may be appealing based on its ease of application 
and potential prognostic value in a subset of heart failure patients, this variable does not correlate 
well with peak and submaximal exercise parameters that have proven validity and reliability in 
heart failure patients [48]. This investigator concluded that when an accurate determination of 
functional capacity is required, direct measurements of peak VO2 and ventilatory anaerobic 
threshold are still the preferred outcome measures in heart failure patients.                                  
 In summary, peak VO2 is a convincing, strong, and independent predictor of outcome, 
supporting the value of cardiopulmonary exercise stress testing as a clinical tool in heart failure.  
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However, in the last few years recent research have discovered that a single arbitrary cut point 
value for peak VO2 is unlikely to describe the true risk of events, and that a multiparametric 
stepwise approach may be more successful. Finally, the 6-minute walk test, a submaximal 
exercise test, may serve as a more straightforward clinical tool to assess functional capacity 
when the cardiopulmonary exercise stress testing could not be evaluated in heart failure patients. 
 The above section have outlined the significant prognostic value of two exercise tests 
modalities, the cardiopulmonary exercise stress testing and the 6-minute walk test. The next 
section will continue addressing the additional diagnostic tools used in patients with heart failure. 
2.2.6.4 Echocardiography  
The single most useful diagnostic test in the evaluation of patients with heart failure is the 
comprehensive 2-dimensional echocardiogram coupled with Doppler flow studies to determine 
whether abnormalities of myocardium, particularly cardiomyopathy (dilated, restrictive, 
hypertrophic), heart valves, or pericardium are present and which chambers are involved [40]. 
2.2.6.5 Laboratory Blood Tests  
In severe heart failure, neurohumoral compensatory mechanisms frequently lead to hyponatremia 
and other significant electrolyte abnormalities, even without the use of diuretics, which 
(especially the thiazide type) may contribute to hyponatremia [76]. This effect is less prominent 
with furosemide, the only diuretic that increases free water clearance through a mechanism that 
is resistant to the action of vasopressin [43]. In fact, furosemide may be necessary to correct 
hyponatremia in patients with heart failure [43]. Hypokalemia is also very common with use of 
diuretics, especially the long-acting thiazides. Hyperkalemia may occur in patients with very low 
cardiac output or renal insufficiency. It can also occur in patients who are ingesting additional 
potassium through salt substitutes, especially when given in addition to a potassium-sparing 
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diuretic or angiotensin-converting-enzyme inhibitor, such as captopril, which also blocks the 
release of aldosterone. Reduced renal blood flow can lead to moderate increases in the blood 
urea nitrogen and mild increases in sodium creatinine [40].                                                   
 2.2.6.6 Cardiac Catheterization                                                                                        
 Left-heart catheterization and angiography are necessary when the presence and extent of 
coronary artery disease need to be determined, particularly if cardiac surgery (valve replacement, 
aneurysmectomy, coronary artery bypass surgery) can possibly improve ventricular dysfunction. 
Right-heart catheterization may be useful in evaluating and selecting patients with refractory 
heart failure who require customized treatment [40]. 
2.2.6.7 Radionuclide Ventriculography  
This method is helpful in documenting the severity of left ventricular systolic dysfunction 
and indicating whether the wall motion abnormalities are global or regional. This test is 
especially helpful in patients who present technical difficulties for echocardiography; it can, for 
example, be obtained easily even in obese patients. Comparison of right and left ventricular 
stroke volumes is also helpful in establishing the severity of regurgitant lesions [76]. 
So far, this review has presented the major symptoms, signs and diagnostic tools in heart 
failure patients that help physicians to determine the current clinical status of these patients. In 
addition, the information presented until now is needed to properly quantify the degree of 
functional limitation in heart failure patients.   
2.2.7 Classification According to the Symptom Severity 
The approach that is most commonly used to quantify the degree of functional limitation 
imposed by heart failure is one first developed by the New York Heart Association (NYHA) 
[77]. The NYHA classification has 4 classes. This system assigns patients to 1 of 4 functional 
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classes, depending on the degree of effort needed to elicit symptoms (see table 2.5).                      
 In addition, The American College of Cardiology (ACC) and the American Heart 
Association (AHA) have jointly engaged in the production of guidelines in the area of 
cardiovascular disease since 1980. This effort is directed by the ACC/AHA Task Force on 
Practice Guidelines. The 2001 report by the ACC/AHA Guidelines for the Evaluation and 
Management of Chronic Heart Failure in the Adult [78] have identified 4 stages involved in the  
development of the heart failure syndrome (see table 2.6). Stages A and B patients are best 
defined as those with risk factors that clearly predispose toward the development of heart failure. 
     Table 2.5 The NYHA classification for heart failure 
 
Class The New York Heart Association Classification 
Class I Patients with cardiac disease but without resulting limitations of 
physical activity. Ordinary physical activity does not cause 
undue fatigue, palpitation, or dyspnea 
Class II Patients with cardiac disease resulting in slight limitation of 
physical activity. They are comfortable at rest. Ordinary physical 
activity results in fatigue, palpitation, or dyspnea 
Class III Patients with cardiac disease resulting in marked limitation of 
physical activity. They are comfortable at rest. Less than 
ordinary activity causes fatigue, palpitation, or dyspnea 
Class IV Patients with cardiac disease resulting in inability to carry on 
any physical activity without discomfort. Symptoms are present 
even at rest or minimal exertion 
 
This classification recognizes that there are established risk factors and structural 
prerequisites for the development of heart failure and that therapeutic interventions introduced 
even before the appearance of left ventricular dysfunction or symptoms can reduce the 
population morbidity and mortality of heart failure. Furthermore, this classification system is 
intended to complement but in no way to replace the New York Heart Association functional 
classification [77], which primarily gauges the severity of symptoms in patients who are in Stage 
C or Stage D.  
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     Table 2.6 The ACC/AHA classification for heart failure 
 
Stage The American College of Cardiology and the American Heart 
Association Classification 
Stage A Patients with coronary artery disease, hypertension, or diabetes 
mellitus who do not yet demonstrate impaired left ventricular 
(LV) function, hypertrophy, or geometric chamber distortion 
Stage B Patients who are asymptomatic but demonstrate LV 
hypertrophy (LVH) and/or impaired LV function 
Stage C Patients with current or past symptoms of heart failure 
associated with underlying structural heart disease (the bulk of 
patients with heart failure)   
Stage D 
 
Patients with truly refractory heart failure who might be 
eligible for specialized, advanced treatment strategies, such as 
mechanical circulatory support, procedures to facilitate fluid 
removal, continuous inotropic infusions, or cardiac 
transplantation or other innovative or experimental surgical 
procedures, or for end-of-life care, such as hospice 
  
In summary, heart failure is a major and growing public health problem in the United 
States. Heart failure is a clinical syndrome that impairs the heart's ability to circulate blood at a 
rate sufficient to maintain the metabolic needs of peripheral tissues and various organs. The 
cardinal manifestations of heart failure are fatigue or dyspnea on exertion. In addition, exercise 
intolerance is inextricably linked to the diagnosis of heart failure. Finally, the New York Heart 
Association classification is used to quantify the degree of functional limitation imposed by heart 
failure. The next section will present information regarding the principal circulatory and 
muscular compensatory adaptations in heart failure patients. 
2.2.8 Compensatory Adaptations to Heart Failure 
 Heart failure develops in response to an insult to the cardiovascular system [79]. This 
alteration is principally due to three distinct etiologies [80]; (a) intrinsic myocardial disease 
secondary to coronary heart disease, cardiomyopathy, and infiltrative disease; (b) excess work 
load due to increased resistance to ejection (pressure load) secondary to hypertension and 
hypertrophic cardiomyopathy or increased stroke volume (volume load) secondary to aortic 
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insufficiency and valvular insufficiency; and (c) iatrogenic myocardial damage from drugs 
(doxorubicin and disopyramide) or radiation therapy for mediastinal tumors or Hodgkin's 
disease. 
 The insult to the cardiovascular system is frequently met with a variety of compensatory 
adaptations with short-to long-time constants aimed to maintain cardiac output and arterial 
pressure to adequately perfuse the brain and the heart. These compensatory adaptations include: 
(a) an increase in ventricular end-diastolic volume and pressure (ventricular dilatation); (b) 
sympathetic nervous system activation; (c) neurohumoral vasoconstriction; (d) renal sodium and 
water retention; (e) myocardial hypertrophy; (f) impaired vasodilatory capacity; and (g) intrinsic 
changes in skeletal muscle. Although, these compensatory adaptations may be remarkably 
effective under resting conditions, the capacity to sustain cardiac performance in the face of 
hemodynamic overload relative to myocardial contractility is finite and exacts a price [81]. 
Indeed, it is those compensatory mechanisms that ultimately contribute significantly to the 
clinical severity of the disease.                                                                                            
 Therefore, the focus of this section of this review is on the morphological, biochemical, 
cellular, and neurohumoral changes characteristic of heart failure and how these relate to the 
exercise tolerance, a marker of the clinical severity of the disease. A particular focus of the 
review is the manner in which these changes alter skeletal muscle blood flow, thereby 
significantly affecting the patient’s functional abilities.                                                                                                                             
2.2.8.1 Cardiovascular Compensatory Adaptations 
It is important to reinforce that regardless of the etiology, heart failure results from 
myocardial dysfunction that impairs the heart's ability to circulate blood at a rate sufficient to 
maintain the metabolic needs of peripheral tissues and various organs [82]. This applies to both 
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the resting and active states and results in significant vasoconstriction and the shunting of blood 
toward vital organs and away from peripheral structures [83].  
In addition, the manifestations of heart failure depend on the rate at which the syndrome 
develops [82]. Generally, if the underlying cardiac abnormality develops slowly, compensatory 
mechanisms have time to become activated, and the patient will be able to adjust to the altered 
cardiac output [40]. In contrast, if the underlying condition develops rapidly or an acute 
precipitating factor is present, the result may be inadequate organ perfusion or acute congestion 
of the venous bed draining into the affected ventricle, causing sudden cardiac decompensation, 
with a concomitant reduction in cardiac output and an acute onset of symptoms [40,82].         
 Thus, the development and progression of heart failure depend on the etiology and 
severity of the underlying disease. Furthermore, there are basically four mechanisms that initiate 
the sequence leading to heart failure: (a) pressure overload, (b) volume overload, (c) primary 
myocardial disease (myocarditis, cardiomyopathy), and (d) myocardial infarction [40,84]. In 
each case, through different mechanisms, the myocardium mechanically compensates for the 
primary defect before the stage of overt myocardial failure develops. In addition, complex 
neuroendocrine changes [84,85] attempt to maintain the circulation and normal organ perfusion 
in the face of decreasing myocardial function. These changes engage activation of the renin-
angiotensin and other systems that cause peripheral vasoconstriction, thereby maintaining the 
blood pressure while punishing the heart by increasing the afterload [83,84]. Although the 
central hemodynamic abnormalities are the primary pathophysiological features of heart failure, 
the neurohumoral responses play an important role in its progression and prognosis. Therefore, 
this section will review first the major hemodynamic adaptations, and then the neurohumoral 
reactions.    
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  2.2.8.1.1 Hemodynamic Adaptations 
  2.2.8.1.1.1 The Heart  
In healthy circumstances, the anatomy and physiology of the heart are carefully construed 
and maintained so as to perform compressive mechanical work at near-maximal efficiency to 
deliver an adequate cardiac output over the normal range of rest and exertional pressure-volume 
conditions, commensurate with the demands of the body’s metabolizing tissues [83]. On the 
other hand, chronic heart failure is the pathophysiological state in which either the delivery of 
cardiac output is inadequate to meet the metabolic demands of tissues or an adequate cardiac 
output is delivered only under conditions of abnormally elevated intracardiac pressures, which 
prematurely precipitate systemic or pulmonary venous congestion [86].                              
 Although still debated, the primary ‘‘locus’’ of dysfunction in most instances of heart 
failure appears to reside largely within the myocyte compartment of the heart [83]. Indeed, 
studies support a marked reduction in ‘‘contractility reserve’’ in response to increasing heart rate 
of sympathetic stimulation [87]. The normal integrated function of the heart depends upon a host 
of factors that include: (a) normal ultrastructural and gross architecture of the heart, (b) an 
adequate number of myocytes, (c) normal myocyte contractile and relaxant function, (d) normal 
structure and function of cardiac valves, (e) normal structure, composition, and metabolism of 
the myocardial extracellular matrix, (f) adequate myocardial perfusion, and (g) normal 
myocardial metabolism [40,83].  
However, heart failure patients exhibit abnormalities in any of these major anatomic and 
functional components. Indeed, heart failure patients can present: (a) loss of myocytes (ischemic, 
inflammatory or toxic necrosis, apoptosis), (b) acute or chronic contractile dysfunction of 
myocytes (inflammation, alcohol, chemotherapeutic agents, sepsis, hypoxia), (c) excessive 
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myofiber architectural disorganization or disarray (hypertrophic cardiomyopathy), (d) infiltrative 
cardiomyopathy, (e) extracellular matrix structural or functional abnormalities (excessive fibrosis 
leading to abnormal force transduction, myocyte linkage, and inadequate compressive force 
efficiency), (f) distortion of the three-dimensional shape of the heart itself (aneurysm, infarction, 
chronic valvular disease), and (g) intractable pressure or volume overload (hypertension,   
valvular heart disease) [83,87]. As a result, an initial injury causes dysfunction of the left 
ventricle that leads to decrease in cardiac output and blood pressure [83]. 
  2.2.8.1.1.2 Cardiac Hypertrophy 
Left ventricular dysfunction is generally a progressive process, even in the absence of a 
new identifiable insult to the heart [40]. The principal manifestation of such progression is a  
change in the geometry and structure of the left ventricle, so the chamber dilates and/or 
hypertrophies and becomes more spherical, a process referred to as cardiac remodeling [88]. Left 
ventricular remodeling is defined as the alterations in ventricular mass, chamber size, and shape 
that result from myocardial injury, or pressure or volume overload [88]. This change in chamber 
size and structure not only increases the hemodynamic stresses on the walls of the failing heart 
and depresses its mechanical performance but may also increase regurgitant flow through the 
mitral valve. These effects, sequentially, serve to sustain and exacerbate the remodeling process. 
 Cardiac remodeling generally precedes the development of symptoms (occasionally by 
months or even years), continues after the appearance of symptoms, and contributes substantially 
to worsening of symptoms despite treatment [88]. The increase in pressure as a result of aortic 
stenosis or sustained severe hypertension requires that the left ventricular pressure must increases 
in order to overcome the resistance to the ejection of blood [40,88]. The initial mechanism for 
the increase at a cellular level is probably a stretch-induced increase in the inotropic state, 
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involving mechanoreceptors and increased cytosolic calcium. The result is that the left 
ventricular systolic pressure rises, the obstruction to the outflow of blood from the left ventricle 
is overcome, and the cardiac output is maintained [40,84]. However, the disadvantage of this 
form of adaptations is that the left ventricle wall stress is greatly increased.  
As a result cardiac concentric hypertrophy develops, it means that the left ventricle 
becomes thicker without increasing in radius, and the wall stress normalizes. However, the 
compensatory hypertrophy in chronic heart failure patients has a greater susceptibility to  
ischaemia and abnormal diastolic function [84]. In addition, left ventricular hypertrophy is 
characterised by an increased left ventricular wall thickness and mass, with abnormal diastolic 
properties [37]. There is a triad of loss of (a) distensibility (so that the ventricle is stiffer), (b) 
impaired relaxation and (c) decreased early diastolic filling. This pattern is responsible for the 
exertional shortness of breath that chronic heart failure experience. [84,89].  
In contrast, the increase in volume due to valvular regurgitation (incompetence) of either 
the mitral valve or the aortic valve requires that the heart respond in a different way. First, the 
preload increases, so that the heart functions at the length limit of the Frank-Starling curve [38]. 
Second, the sustained volume load causes longitudinal hypertrophy, thereby increasing the size 
of the left ventricle cavity, which, in turn, could increase the chamber size without increasing the 
wall thickness [90]. The end-result of the volume overload is enhanced early diastolic filling and 
decreased left ventricular stiffness [91]. As a result, the diastolic function improves rather than 
deteriorates, as in a pressure overload. Nonetheless, as the chamber size increases, wall tension  
must rise. The consequence will be modest and proportional hypertrophy, to allow the left 
ventricle cavity to regain a normal wall stress [40,84]. At the cellular level, myocardial 
pathologic changes accompany left ventricular remodeling and involve myocyte hypertrophy and 
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fibroblast hyperplasia accompanied by an increase in collagen deposition within the interstitium. 
These processes, which occur in the noninfarcted myocardium, contribute to progressive left 
ventricular remodeling and left ventricular dysfunction [50]. 
Progression of coronary artery disease, diabetes mellitus, hypertension, or the onset of 
atrial fibrillation may also contribute to the progression of heart failure. The development of 
structural abnormalities can have 1 of 3 outcomes: (a) patients die before developing symptoms 
(in Stage A or B of the New York Heart Association Classification for Heart Failure), (b) 
patients develop symptoms controlled by treatment, or (c) patients die of progressive heart 
failure. Sudden death can interrupt this course at any time. Although several factors can 
accelerate the process of left ventricular remodeling, there is substantial evidence that the 
activation of endogenous neurohormonal systems plays an important role in cardiac remodeling 
and thereby in the progression of heart failure. Indeed, substantial amounts of experimental and 
clinical data now exist that support the pivotal role of the Renin-Angiotensin-Aldosterone-
System in contributing to these cellular processes [32,84,89].  
Patients with heart failure have elevated circulating or tissue levels of norepinephrine, 
angiotensin II, aldosterone, endothelin, vasopressin, and cytokines, which can act (alone or in 
concert) to adversely affect the structure and function of the heart. These neurohormonal factors 
not only increase the hemodynamic stresses on the ventricle by causing sodium retention and 
peripheral vasoconstriction but may also exert direct toxic effects on cardiac cells and stimulate 
myocardial fibrosis, which can further alter the architecture and impair the performance of the 
failing heart. Neurohormonal activation also has direct deleterious effects on the myocytes and 
interstitium, altering the performance and phenotype of these cells [78]. Finally, it is important to 
mention that in response to a sustained pressure or volume load, the myocardium passes from a 
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compensated phase to a dilated failing phase. It is speculated that the hypertrophied myocardium 
is susceptible to an imbalance in the ratio of oxygen supply and demand [84,92]. 
  2.2.8.1.1.3 Cardiac Output  
Cardiac output is defined as the amount of blood ejected from the ventricles per minute, 
and it represents a measure of the pumping ability of the heart. It is determined by the heart rate  
and the stroke volume [83]. Among healthy individuals the average resting cardiac output is 
around 5.00 L/min [93]. Early in the process of heart failure, cardiac output may be normal at  
 rest [20]. During stressful conditions, such as physical exercise and other periods of increased 
metabolic demand, however, cardiac output fails to increase normally.  
As a result the glomerular filtration rate declines and the renal mechanism for salt and 
water retention becomes activated [20,83]. Furthermore, ventricular filling pressure as well as 
pressures in the atrium and venous system behind the affected ventricle may rise abnormally 
during periods of stress. This may cause transudation of fluid and symptoms of tissue congestion 
during exercise [20,40]. In such early stages, physical rest may induce diuresis and relieve 
symptoms in many patients with mild heart failure; however, excessive and repeated strenuous 
physical activities will worsen the compromised hemodynamic state and cause progression of 
heart failure [37,38]. The impaired left ventricular function causes inadequate blood flow to  
active skeletal muscle secondary to reduced cardiac output and consequently low maximal 
oxygen uptake in these patients [83].  
 2.2.8.1.2 Neuroendocrine (neurohumoral) Reaction   
The impaired contraction and/or relaxation of the heart, which is the major component in 
the pathophysiology of heart failure patients, result in the inability to fulfill its pumping function 
normally. In addition, left ventricular dysfunction leads to reduction in cardiac output and blood 
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pressure. As a result, a complex series of events leading to a neuroendocrine reaction, also called 
the neurohumoral response [84], which creates the self-perpetuating vicious circle of heart 
failure (see figure 2.2).  
  
             Figure 2.2. The neuroendocrine vicious circle in chronic heart failure [84].  
 
 The initial activation of the neuroendocrine system would restore the hemodynamic 
balance through vasoconstriction and retention of salt and water. However, at the same time this 
also contributes to progression of heart failure due to the hemodynamic effects and the direct 
harmful hormonal effects on the cardiomyocytes [89]. Several neurohumoral systems are 
activated in heart failure. Furthermore, extensive reviews discussing the impact the 
neuroendocrine system and heart failure can be found elsewhere [85,94-96]. 
Although several neurohormonal systems are activated in heart failure patients, the next 
section will outline the more important of those systems with emphasis on prognostic and 
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diagnostic of heart failure. The topics presented will include; (a) alterations in cardiovascular 
reflexes, (b) catecholamines and the sympathetic nervous system, (c) humoral activation, (d) 
renin-angotensin-aldosterone system, (e) vasopressin, (f) atrial natriuretic peptide, (g) 
endothelin-1, (h) cytokines, and (i) the ergoreflex.  
  2.2.8.1.2.1 Alterations in Cardiovascular Reflexes 
The arterial baroreflexes include an afferent limb, a central neural component, and an  
autonomic neuroeffector component. A rise in pressure stretches the baroreceptors located in the 
heart, lungs, and great vessels and causes them to transmit signals to the central nervous system 
[97]. These signals normally inhibit sympathetic outflow as well as suppress renin and 
vasopressin release while increasing parasympathetic outflow.  
 Conversely, a sudden reduction in arterial pressure results in a strong sympathetic 
discharge throughout the body. The short-term effect of the sympathetic discharge is to enhance 
stroke volume, cardiac output and increase vasoconstriction in an effort to compensate for a loss 
in arterial pressure [98]. However, the long-term consequences are thought to be deleterious [99]. 
In the acute phase of low-output heart failure, arterial and cardiopulmonary baroreflexes are 
activated to help maintain systolic blood pressure. However, both arterial and cardiopulmonary 
baroreceptors become desensitized in heart failure [100]. The absence of baroreflex inhibitory 
input to medullary centers results in excessive sympathetic excitation [39,84]. It is thought that 
the marked desensitization of this reflex contributes to the neurohumoral abnormalities [89]. 
  2.2.8.1.2.2 Catecholamines and the Sympathetic Nervous System 
A rise in systemic vascular resistance is accomplished initially, by activation of the 
sympathetic nervous system. Activation of the sympathetic nervous system is very effective over 
the short term to maintain blood pressure [101]. Plasma norepinephrine concentration [102,103], 
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an index of the activity of this system, is generally two or three times higher in patients with 
heart failure in comparison to healthy controls, and it is usually correlated to the degree of left 
ventricular dysfunction and  hemodynamic abnormalities [104], and it carries an ominous  
prognosis [102,103]. In addition, it has been shown that plasma norepinephrine reflects 
sympathetic activity in heart failure patients fairly well [105].  
The increase in sympathetic activation is to maintain cardiac output and arterial pressure 
through stimulation of myocardial contractility and α-1 adrenoreceptors in the vascular wall. 
Stimulation of the α-1 adrenoreceptors causes an increase in vasomotor tone and systemic 
vascular resistance. However, any supportive effect of the increased sympathetic nervous system 
activity on arterial blood pressure is, in time, superseded by a number of organ-specific 
consequences. The potential adverse effects of sympathetic activation on cardiac muscle, the 
kidneys, and the vasculature are numerous and contribute to the clinical manifestations of heart 
failure [106].  
  2.2.8.1.2.3 Humoral Activation 
Humoral activation is one of the biochemical hallmarks in patients with heart failure 
[107,108]. The main function of the humoral activation is to maintain arterial pressure despite a 
loss in myocardial function. However, as a result of chronic humoral activation two vicious 
cycles develop: (a) vasoconstriction and (b) sodium and water retention. Arterial 
vasoconstriction causes an increase in systemic vascular resistance and inevitably an increase in 
afterload and systolic wall stress.  
The sodium and water retention causes an increase in circulating volume, which may be 
beneficial at first, but ultimately results in an increased ventricular filling pressure and diastolic 
wall stress. Together, these vicious cycles may eventually lead to progressive myocardial and 
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vascular dysfunction, peripheral tissue abnormalities, fluid accumulation, and finally the clinical 
picture of heart failure [109].    
  2.2.8.1.2.4 Renin-Angiotensin-Aldosterone System 
Renin is a proteolytic enzyme synthesized and secreted into the blood by the 
juxtaglomerular cells located in the macula densa in the afferent arterioles of the glomeruli [110]. 
Renin, itself, is not a vasoactive substance. Instead it acts on another plasma protein called 
angiotensinogen, produced by the liver, to release a 10-amino acid peptide, angiotensin I [110]. 
Although angiotensin I has mild vasoconstrictor properties, within a few seconds following its 
formation two additional amino acids are split to form an 8-amino acid peptide, angiotensin II. 
The formation of angiotensin II is catalyzed by angiotensin converting enzyme which is located 
in the endothelium of the vascular tree [110].  
The effects of angiotensin II are multiple and include: (a) raising peripheral resistance 
through vasoconstriction, (b) enhancing renal sodium reabsorption, (c) facilitating catecholamine 
release from sympathetic nerve endings, and (d) stimulating mineralcorticoid production in the 
adrenal gland [89,111]. More recently angiotensin II has also been implicated as a growth factor 
or growth modulator in the cardiovascular system [112-114]. In fact, Dzau et al., [112] have 
reported that the renin-angiotensin-aldosterone system is markedly activated in patients with 
decompensated heart failure. In addition, data from the Study of Left Ventricular Dysfunction 
(SOLVD) Registry report resting values for plasma renin activity in healthy adults ranging from 
0.3 to 0.8 (mean 0.6) ng•ml-1•h-1  [115]. In the same study, plasma renin activity in patients with 
heart failure ranged from 0.5 to 8.7 (mean 2.5) ng•ml-1•h-1 [115]. The mechanism of the 
increased plasma renin activity in heart failure is not entirely known but is thought to be 
secondary to (a) a reduction in renal perfusion, (b) elevated efferent renal sympathetic nerve 
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activity, (c) increased circulating catecholamines, (d) alterations of sodium load presented to the 
macula densa, or (e) a combination of all the above [108,116].  
As a result of the increased renin-angiotensin-aldosterone system activation systemic 
vascular resistance increases [89]. In addition, the formation of angiotensin II causes sodium and 
fluid retention secondary to production of the mineralcorticoid, aldosterone.  Aldosterone causes 
a marked increase in sodium reabsorption from the renal tubules, thereby raising extracellular 
sodium, followed by fluid expansion [110]. The function of the increased fluid is to increase 
preload in patients with heart failure secondary to myocardial dysfunction. It is thought that the  
increase in preload subsequently stretches the sarcomeres in the myocardium to a more optimal 
 length during the intermediate period until myocardial hypertrophy develops.  
Angiotensin II is potentially a stimulus to fibrosis, as is aldosterone. Indeed, in animal 
experiments it has been shown that angiotensin II has a direct effect on the myocardium which 
eventually leads to hypertrophy, remodeling and fibrosis [117,118] and thereby to loss of 
function. In physiological amounts, collagen may help to limit ventricular dilation when it is 
increased in proportion to the degree of myocardial hypertrophy. On the contrary, when there is 
an excessive collagen response to ischaemia or endocrine signals such as angiotensin II, then 
compliance decreases with an increase in chamber stiffness, or a decrease in distensibility [119]. 
 These modifications promote poor diastolic relaxation and, hence, diastolic failure. The 
wall tension therefore rises more than expected, with a corresponding increase in the oxygen 
demand. Therefore, it contributes to relative ischaemia of the hypertrophied myocardium and 
further promotes interstitial fibrosis. With the discovery that the renin-angiotensin-aldosterone 
system is markedly activated in heart failure, it is not surprising that a significant number of 
investigators have focused on the role of angiotensin-converting-enzyme (ACE) inhibitors 
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as a strategy to treat patients with heart failure. Results from clinical trials, The SOLVD 
Investigators [120] and The CONSENSUS Trial Study Group [121], have shown that 
cardiovascular morbidity and mortality can be reduced in patients with left ventricular 
dysfunction (ejection fraction < 40%) secondary to ischemic heart disease following long-term 
use of ACE-inhibitors.  
Interestingly, the precise mechanism(s) of action of ACE-inhibitors are still not fully 
understood. It is thought that the mechanism of action of ACE-inhibition is in part 
cardioprotective and vasculoprotective. A reduction in systemic vascular resistance secondary to 
inhibition of angiotensin II generation may reduce afterload and myocardial work. Mechanisms 
for the vasculoprotective properties include in addition to a reduction in angiotensin II 
production, decreased bradykinin degradation, antagonism of macrophage function and 
migration as well as inhibition of sympathetic nervous system and thrombotic activity [122]. All 
of these could result in plaque stabilization, protection against plaque rupture, and prevention of 
acute coronary occlusion [122].  
  2.2.8.1.2.5 Vasopressin 
Vasopressin is synthesized as a larger pre-hormone in nerve cells located in the 
hypothalamus. Then, it is transported through the axons of the nerve cells to their end located in 
the neurohypophysis [110]. The physiological actions of vasopressin are vasoconstriction 
mediated via V1-receptors and decrease in free-water clearance mediated via renal V2-receptors. 
In heart failure patients the vasopressinergic system is activated, contributing to vasoconstriction 
and water retention. It has been shown that the sensitivity of the vasopressin system for changes 
in osmolality and volume is decreased in heart failure [123,124]. In addition, some studies have 
reported that vasopressin is increased in heart failure [125,126] and that the increase could not be 
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explained by changes in osmolality. Vasopressin is especially elevated in heart failure with 
hyponatraemia. Hyponatremia is a common manifestation of severe heart failure and occurs 
when water is retained in excess of sodium. It has been shown to be a powerful independent 
predictor of cardiovascular mortality [127]. 
  2.2.8.1.2.6 Atrial Natriuretic Peptide   
Atrial natriuretic peptide is primarily produced in the atria and released by atrial 
distention. Atrial natriuretic peptide dilates arterioles and increases sodium excretion from the 
kidneys and is an antagonist to both the sympathetic and the renin-angiotensin-aldosterone 
system. Three known natriuretic receptors exist, A, B and C. Atrial natriuretic peptide has 
highest affinity for the A receptor [110]. Thus, the action of atrial natriuretic peptide is to 
decrease plasma volume. It have been reported that atrial natriuretic peptide caused a net transfer 
of fluid from the vascular to the interstitial space. This raises the possibility that atrial natriuretic 
peptide may have a vascular effect which may contribute to edema formation in heart failure  
 [128].  
 The plasma concentration of atrial natriuretic peptide is elevated in heart failure and in 
general correlates with the degree of heart failure [103,126,129,130]. In addition, the activation 
of the atrial natriuretic peptide in heart failure patients initially counteracts the effect of the 
vasoconstrictor systems, but the effect is not lasting. Hence, it has been reported that the 
natriuretic response to atrial natriuretic peptide is blunted in heart failure [131].  
  2.2.8.1.2.7 Endothelin-1 
Endothelin-1 is synthesized from a larger pre-propeptide which after enzymatic cleavage 
becomes the propeptide “big endothelin-1”. Endothelin-1 levels are increased in heart failure 
patients [132,133], and it has been reported that correlates strongly with the pulmonary pressure 
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[132,134]. Endothelin-1 acting via selective receptors has strong vasoconstrictor effects and 
possibly also a trophic effect on cardiac myocytes, found in in vitro studies [135]. In addition, 
endothelin-1 was found to contain prognostic information, in a multivariate analysis including 
other hormones (atrial natriuretic peptide and noradrenaline) and hemodynamic measures [136].  
  2.2.8.1.2.8 Cytokines 
Cytokines act locally in one of several manners: (a) autocrine; active on the cells of 
origin, (b) paracrine; acting on neighboring cells, or (c) justacrine; acting on adjacent cells [84]. 
Among the cytokines that appear to be involved in heart failure, tumor necrosis factor-alpha has 
drawn special attention. Indeed, Bozkurt et al., [137] have reported that tumor necrosis factor-
alpha causes dilatation and remodeling of the left ventricle in rats. In addition, tumor necrosis 
factor-alpha is increased in heart failure and seems to reflect the severity of the disease  
[138,139]. 
  2.2.8.1.2.9 The Ergoreflex 
Ergoreceptors are intramuscular receptors sensitive to work performed. They are 
stimulated by metabolites formed during skeletal muscular activity. Their stimulation increase 
ventilation and sympathetic activation (the ergoreflex). The stimulus is in part sensitive to work 
performed by each unit of muscle mass. This effect can be seen in normal subjects, where the 
ventilation and carbon dioxide production slope is considerably greater when arms are used than 
when legs are used to perform the same external workload [140].  
In addition Piepoli et al., [141] showed how these receptors were more active in patients 
with heart failure and that the increased ventilatory response to exercise was proportional to the 
ergoreflex activity. The signal is due to metabolic stimulation of receptors rather than being 
merely a response to movement. Possible stimuli for initiating the ergoreflex are local release of 
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prostaglandins, potassium, and hydrogen ion. Furthermore, in heart failure there is enhanced 
activity of these receptors (“Coats hypothesis”) [142], which contributes to the excessive 
neuroendocrine response.  
2.2.8.2 Skeletal Muscle Compensatory Adaptations 
The result of impaired cardiac pumping capacity and limited vasodilatory capacity is an 
inadequate blood supply to metabolizing tissues [143]. Therefore, a reduction in skeletal muscle 
perfusion may be an important contributor to the decreased exercise capacity and tolerance in 
heart failure patients. However, even when oxygen availability to skeletal muscle is improved 
oxygen uptake remains unchanged [144,145]. This observation suggests the presence of intrinsic 
alterations of skeletal muscle. Recently, considerable attention has been given to identify those 
intrinsic alterations in skeletal muscle which may contribute to the clinical severity of patients 
with heart failure [146-152].  
These studies strongly suggest the presence of skeletal muscle abnormalities including (a) 
ultrastructural abnormalities, such as significant atrophy of muscle fibers classified as Type I 
[144,148,150,151]; (b) a marked decline in mitochondrial enzyme concentration and activity 
(Succinate dehydrogenase, Citrate synthase and cytochrome oxidase); and (c) a reduction in 
mitochondrial volume and density [144,146].  
 2.2.8.2.1 Skeletal Muscle Atrophy 
 Muscle atrophy is common in patients with heart failure [144,148,150,153,154]. Indeed, 
Minotti et al., [154] found that maximal cross-sectional area of the thigh, measured by magnetic 
resonance imaging, was markedly reduced in patients with end-stage heart failure compared to 
age-matched controls. These data have been confirmed by Magnusson et al., [155] who reported 
a 13% smaller muscle cross-sectional area of the quadriceps in heart failure patients. In addition, 
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Mancini et al., [156] noted a 15% reduction in muscle volume in the lower legs of patients with 
mild-to-moderate heart failure.  
 The mechanism for the muscle atrophy in heart failure is presently not clear but has been 
linked to malnutrition, deconditioning, an increased catabolic state due to sympathetic nervous 
system hyperactivation, an increase in serum cortisol, corticotropin, and/or tumor necrosis factor 
[126]]. Consequently, it appears that skeletal muscle atrophy could be an important and 
potentially reversible contributor to exercise intolerance in patients with heart failure. However, 
it should be noted that parameters of muscle mass only show a weak correlation with peak 
oxygen consumption (VO2peak), suggesting that muscle atrophy contributes only modestly to 
exercise intolerance in heart failure [156].                                              
  2.2.8.2.2 Skeletal Muscle Blood Flow 
 Many studies have reported reduced resting blood flow to the arm and leg in heart failure 
[143,144,157,158]. On the other hand, Wiener et al., [159] found no evidence of reduced blood   
flow at rest in ambulatory, optimally diuresed heart failure patients. Although the reason for 
these different findings at rest are speculative it may be related to (a) the level of circulatory 
dysfunction,  (b) the position in which the measurements were obtained (supine or standing), (c) 
the amount of muscle atrophy present, and/or (d) the pharmacotherapy of the patient.         
 2.2.8.2.3 Histologic and Biochemical Alterations in Skeletal Muscle 
It appears that skeletal muscle atrophy in heart failure is selective and more pronounced 
in the type I (oxidative) muscle fibers. Indeed, Lipkin et al., [160] have reported atrophy of type I 
and type II fibers, increased interstitial cellularity, and excess lipid accumulation, in patients with 
heart failure. Mancini et al., [146] and Sullivan et al., [148] also reported a relative greater 
decrease of highly oxidative, fatigue resistant, type I fibers in the calf muscle of patients with 
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heart failure secondary to coronary artery disease. In addition, Drexler et al., [149] found a shift 
in fiber type distribution to type II fibers. In this comprehensive study, the authors indicate that 
because type IIb fibers possess less oxidative capacity than type IIa or even I, a reduction in 
oxidative capacity could be attributed to a shift in fiber type distribution.  
Furthermore, to these morphologic changes, Sullivan et al., [148] reported a decrease in 
the number of capillaries per fibers for type I and type IIa fibers. The apparent loss in oxidative 
capacity in heart failure is further evident from studies which have performed biochemical 
analysis of skeletal muscle. In fact, Lipkin et al., [160] was the first to demonstrate an 
accumulation of intracellular lipids in heart failure suggesting a possible abnormality in lipid 
metabolism. Sullivan et al., [148] examined patients with long-standing heart failure and found 
significant reductions in mitochondrial enzyme concentration for succinate dehydrogenase and 
citrate synthetase. Furthermore, they found a decrease in 3-hydroxacyl-coenzyme A-  
dehydrogenase and glycogen content.  
 Drexler et al., [144] reported that the ultrastructural morphometry of muscle biopsies of 
the vastus lateralis indicated significant abnormalities of skeletal muscle as compared to normals. 
The volume density of mitochondria and surface density of mitochondrial cristae, markers of 
structural correlates of oxidative capacity, were significantly reduced by 20% in patients with 
severe heart failure.  
 In addition, capillary length density was reduced and fiber type distribution of skeletal 
muscle was shifted to type II fibers. Cytochemical analysis of cytochrome oxidase activity also 
revealed significant decreases in heart failure. Both the volume density of mitochondria and 
surface density of mitochondrial cristae were significantly related to oxygen consumption 
(VO2peak), but inversely related to the duration of heart failure.  
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 These studies support the notion that a major component of heart failure is a reduction in 
oxidative capacity due to intrinsic alterations in skeletal muscle. This reduction in oxidative 
capacity may play an important role in the clinical syndrome of heart failure by adversely 
affecting exercise capacity. Although, the mechanisms for the alterations in skeletal muscle 
metabolism in heart failure patients are unknown, several factors (neurohumoral, chronic 
reductions in muscle perfusion, and deconditioning) may be involved [144].  
 Chronic deconditioning may be a key factor in the alterations in skeletal muscle 
metabolism, since recent studies have shown that physical training can improve exercise capacity 
in patients with heart failure by delaying the onset of anaerobic metabolism [161-163]. However, 
chronic muscle underperfusion (at rest or during exercise) and/or increased sympathetic 
stimulation could also cause many of the above mentioned abnormalities in skeletal muscle 
metabolism.  
2.2.8.3 Summary of Compensatory Adaptations in Heart Failure 
In summary the "Heart Failure Syndrome" is characterized by a series of compensatory 
mechanisms designed to maintain cardiac output and arterial pressure at a level compatible with 
life. There are compensatory mechanisms designed to cope quickly with a reduction in stroke 
volume, and there are mechanisms which operate over a longer period of time.  
 The cardiac compensatory changes include (a) ventricular dilation to stretch the 
sarcomeres (fast adaptation); (b) ventricular hypertrophy (slow adaptation) and aim to preserve 
cardiac output. The circulatory changes include (a) autonomic nervous system activation (fast 
adaptation); (b) humoral activation (intermediate to slow adaptation); (c) impaired vascular 
responsiveness (slow adaptation), and aim to maintain blood pressure. Alterations in skeletal 
muscle include (a) skeletal muscle atrophy (slow adaptation) and (b) impaired oxidative  
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metabolism (slow adaptation). Although speculative, it is thought that those mechanisms with an 
intermediate to long-time constant eventually contribute to the severe clinical manifestations. 
2.2.9 The Role of Exercise in Heart Failure 
2.2.9.1 The Acute Exercise Response in Heart Failure 
Under normal resting conditions, patients with heart failure generally do not exhibit signs 
or symptoms of their disease. It is not until a physiologic stress, such as exercise, is introduced 
that the morbidity associated with heart failure becomes apparent. Therefore, the purpose of this 
section is to review the effects of a single bout of exercise on patients with heart failure. In 
particular, this review will focus on: (a) the cardiovascular responses and (b) the skeletal muscle 
responses.  
 2.2.9.1.1 Cardiovascular Responses to an Acute Bout of Exercise 
  2.2.9.1.1.1 Cardiac Output  
Normally, the capacity for performing aerobic exercise depends on the ability of the heart 
to increase cardiac output to the exercising muscles and the ability of these muscles to utilize 
oxygen from the delivered blood. The increase in cardiac output during acute exercise can be 
accomplished through an increase in heart rate and/or stroke volume. In general, patients with 
heart failure demonstrate characteristic responses to dynamic exercise. However, as functional 
class declines there is a progressive decrease in peak cardiac output, stroke volume, and heart 
rate [164]. Cardiac output is the product of heart rate and stroke volume. It has been shown that 
the increase in heart rate contributes to cardiac output throughout exercise [165], whereas stroke 
volume is thought to be most important during the early stages of exercise [166]. Normally, 
during maximal upright exercise, cardiac output increases 4 to 6 fold in healthy subjects. This is 
accomplished by a 2- to 4-fold increase in heart rate and a 20% to 50% augmentation of stroke 
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volume. The stroke volume increase is accomplished both by use of the Frank-Starling 
mechanism to maintain left ventricular end-diastolic volume and by more complete left 
ventricular emptying to reduce end-systolic volume. Both enhanced left ventricular contractility 
and peripheral vasodilation contribute to the more complete left ventricular emptying observed 
during exercise. Studies have reported that cardiac output is reduced at any given peak oxygen 
consumption (VO2max) in patients with heart failure [163,167]. The reduction in aerobic capacity 
in heart failure patients seems to be largely mediated by inadequate blood flow to active skeletal 
muscle secondary to impaired cardiac output [157,168]. Indeed, patients with heart failure may 
achieve < 50% of the maximal cardiac output attained by healthy individuals at peak exercise.   
Stroke volume, which is already decreased at rest, rises only modestly up to a peak of 50 to 65 
mL, compared with ≥ 100 mL in healthy subjects.    
Stroke volume is determined by four factors; [97] (a) the volume of blood returned to the 
heart, (b) ventricular distensibility, or the capacity to enlarge the ventricle, (c) ventricular 
contractility, and (d) aortic and/or pulmonary artery pressure, or the pressure against which the 
ventricles must contract. Although there are conflicting reports about stroke volume changes 
during exercise, the traditional thought in healthy individuals suggests that stroke volume 
increases with increasing rates of work, and seems to level off at approximately 50-60% of 
maximal capacity [166]. The explanation for the increased stroke volume in healthy individuals 
is that the Frank-Starling mechanism, defined by an increase in left ventricular end-diastolic 
volume, operates at lower work rates, whereas an increased degree of contractility, defined by a 
decrease in left ventricular end-systolic volume, has its greatest effect at higher work rates.  
In patients with heart failure stroke volume is consistently lower at any given work load 
compared to normals [169]. In fact, Weber et al., [169] have reported that the stroke volume 
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response to exercise was related to severity of disease as defined by functional class. Using this 
classification they showed that as functional class declined so did stroke volume at rest.  In 
addition, they indicated that those patients with the most severe impairments lost the reserve 
capacity to raise stroke volume during exercise. Studies have shown that the mechanism to 
increase stroke volume during exercise in heart failure patients with diastolic dysfunction is 
further impaired [36]. In these patients changes in ventricular relaxation and filling may increase 
diastolic pressure in the absence of an increase in left ventricular end-diastolic volumes. This 
indicates that the exercise intolerance in patients with diastolic dysfunction may be secondary to 
an inability to rely on the Frank-Starling mechanism to increase left ventricular end-diastolic 
volumes and stroke volume. This has been confirmed in several studies indicating a close 
association between indices of ventricular filling and exercise tolerance. In that regard, Sullivan 
et al., [163] have reported increases in left ventricular filling pressures in patients with heart 
failure without an increase in left ventricular end-diastolic volume suggesting the presence of  
diastolic dysfunction. These data suggest that in patients with diastolic dysfunction ventricular  
filling may be attenuated and contribute to a reduction in stroke volume and exercise tolerance.  
The increase in heart rate observed during exercise is linearly related to the work 
intensity. In patients with heart failure heart rates at rest and during submaximal exercise are 
increased, possibly indicating an increased demand on the heart. There is an inverse relationship 
between resting heart rate and mortality in patients with heart failure [170]. In contrast, peak 
heart rate (HRpeak) responses to an incremental exercise test are generally lower when compared 
to age-matched healthy normals. This indicates that the heart rate reserve for patients with heart 
failure is also reduced. The inability to raise the heart rate during exercise is termed chronotropic 
incompetence [171]. The mechanism responsible for chronotropic incompetence in patients with 
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heart failure has been linked to abnormal reflex control and down-regulation or decreased 
responsiveness of beta-receptors. 
  2.2.9.1.1.2 Autonomic Responses   
The sympathetic nervous system has an important role in mediating the response to 
exercise in healthy individuals [172]. Normally, during exercise plasma norepinephrine levels 
increase in normal subjects, which is thought to be indicative of increased participation of the 
sympathetic nervous system [172]. In contrast, patients with heart failure have much greater rise  
 in plasma norepinephrine levels at submaximal exercise work-loads, although at peak exercise, 
healthy subjects exhibit higher levels of norepinephrine [126]. It is generally believed that the 
rise in sympathetic nervous system with exercise causes blood to be shunted away from non-
exercising tissue to working skeletal muscle [173]. Although the release of epinephrine and 
norepinephrine is affected by a variety of factors, plasma levels increase gradually with 
increasing intensities until approximately 50-70% of peak oxygen consumption (VO2peak). At this 
point plasma levels increase markedly reaching an apex at peak exercise. During exercise, 
patients with heart failure exhibit greater-than-normal increases in plasma norepinephrine levels 
at submaximal workloads than healthy controls [126].  
It has been speculated that this may result in significant sympathetic vasoconstrictor 
activity and contributing to muscle underperfusion [173]. In addition, studies have reported that 
patients with heart failure had significant higher resting muscle sympathetic nervous system 
activity than age-matched controls [174]. Wilson et al., [175] have reported that exercise did not 
produce a major increase in plasma norepinephrine and sympathetic vasoconstriction in 
ambulatory patients with marked reduced exercise capacity. In fact, blood flow to non-exercising 
tissue remained unchanged during exercise. 
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 Based on this research, Wilson et al., [175] have suggested that patients with heart 
failure do not develop major redistribution of blood flow from non-exercising beds to working 
muscle. Thus, the current contention does not necessarily support that the reduced exercise 
tolerance in heart failure is governed by an activated sympathetic nervous system. Nevertheless, 
it does appear reasonable to postulate that vasoconstriction mediated in part by the sympathetic 
nervous system could play a role in limiting skeletal muscle blood flow during exercise in heart 
failure patients [101].     
  2.2.9.1.1.3 Vascular Responsiveness  
During acute exercise the ability of the peripheral vasculature to dilate plays an important 
role in determining blood flow to exercising muscle. The ability to dilate the vasculature is 
largely dependent on the integrity of the vascular wall, including the endothelial lining. The 
vasodilatory response to increased shear stress is markedly abnormal in patients with heart 
failure [153,176,177]. Jondeau et al., [153] have linked the impaired endothelium-dependent 
vasodilatation to exercise capacity, and found a strong correlation between peak hyperemic 
response and peak oxygen consumption (VO2peak) in patients with heart failure. Therefore, these 
data suggest that patients with heart failure exhibit impairment in endothelium-dependent 
vasodilatation following exercise induced hyperemia, which may contribute to the exercise 
intolerance.  
 2.2.9.1.2 Skeletal Muscle Responses to an Acute Bout of Exercise 
  2.2.9.1.2.1 Skeletal Muscle Strength 
Lipkin et al., [160] measured muscle strength in patients with severe heart failure and 
found a 45% reduction in quadriceps strength compared to age-matched controls.  In addition, 
Magnusson et al., [155] have observed low muscular strength in patients with heart failure and 
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attributed the reduced strength to a smaller muscle cross-sectional area. In contrast, Minotti et al., 
[154] found no difference in isometric strength between heart failure and controls, although there 
was evidence of a marked decline in muscular endurance. This suggests that the specific tension 
(i.e. tension per unit of cross-sectional area) may not be altered as a result of the disease.  
 Furthermore, Buller et al., [178] confirmed this finding showing no difference in maximal force 
produced during 3 repetitions, but a marked decline in force production during prolonged knee 
extension exercise in heart failure. In both studies the degree of muscle dysfunction as defined by 
muscle endurance, correlated with peak oxygen consumption (VO2peak) as measured by cycle 
ergometry [154,178]. Thus, reduced muscle strength in patients with heart failure is probably due  
to skeletal muscle atrophy, rather than a change in the contractile apparatus. In contrast, the  
impaired muscle endurance appears to reflect a qualitative change in skeletal muscle.   
  2.2.9.1.2.2 Skeletal Muscle Blood Flow  
As previously stated a number of studies have reported reduced limb blood flow at rest in 
heart failure [101,179]. In addition, there is substantial evidence that the increase in blood flow 
to working muscle is attenuated for each given workload in heart failure [143,157]. In fact, 
Wilson et al., [157] have reported reduced leg blood flow during submaximal and peak exercise 
in patients with heart failure using the thermodilution technique. Furthermore, Sullivan et al., 
[143] have confirmed these findings and found a strong relationship between the leg blood flow 
response to exercise, and peak oxygen consumption (VO2peak) and functional class. The failure of 
skeletal muscle blood flow to increase normally during exercise appears to be primarily related 
to an impaired vasodilatory capacity. In patients with heart failure, arteriolar vasodilatation is 
impaired, as evidenced by a failure of leg vascular resistance to decrease normally with exercise 
[101,157,180]. The mechanisms involved in the impaired metabolic vasodilatory capacity within 
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skeletal muscle in heart failure include [158]; (a) excessive sympathetically mediated 
vasoconstriction, (b) increased levels of angiotensin II and vasopressin, (c) chronic vascular 
deconditioning, and (d) endothelial dysfunction.  
Another explanation for the alterations in skeletal muscle perfusion observed in heart 
failure patients may be related to the distribution of blood during exercise. It is generally 
accepted that exercise is associated with an increase in sympathetic vasoconstrictor activity and 
angiotensin II [181]. This increase in neurohumoral activation serves to increase vascular 
resistance in non-working tissue and helps to increase arterial blood pressure. However, Wilson 
et al., [175] have reported that patients with heart failure do not develop major re-distributions of 
blood flow from non-exercising beds to exercising muscle. The mechanism for the failure to 
shunt blood to working tissue was attributed to a reduced sympathetic vasoconstrictor activity. 
Certainly, this hypothesis appears to go in the face of traditional views, suggesting that increased 
sympathetic nervous system activity enhances vasoconstriction in heart failure. Irrespective of 
the precise mechanism, the above studies provide convincing evidence that skeletal muscle 
perfusion is altered in heart failure patients during exercise. It is therefore not surprising that 
exertional fatigue in heart failure has traditionally been attributed to muscle underperfusion 
[182].  
  2.2.9.1.2.3 Skeletal Muscle Metabolic Responses  
Anaerobic metabolism occurs early during exercise in heart failure and is likely an 
important cause of exercise intolerance. Studies using 31P-MRI have demonstrated that early 
anaerobic metabolism occurs independently of reduced muscle blood flow [147,183]. In 
addition, abnormalities in skeletal muscle metabolism occur in patients with heart failure when 
compared with healthy individuals during exercise under ischemic conditions [147]. These 
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skeletal muscle characteristics have important ramifications on substrate and oxygen utilization 
during exercise. However, it appears that these metabolic alterations are independent of skeletal  
 muscle blood flow. In fact, studies demonstrating a greater increase in the inorganic phosphate 
to phosphocreatine ratio, a measure of oxidative stress, and more pronounced drop in acid-base 
balance (pH) during progressive forearm exercise in heart failure compared to healthy controls 
despite similar forearm blood flows [159,183]. In addition, Massie et al., [184] explored the 
metabolic responses in exercising muscle under ischemic conditions. In this study, it was 
demonstrated that skeletal muscle metabolic responses of the flexor digitorum were still 
markedly different in heart failure patients, when exercise was performed with a cuff 
sphygmomanometer inflated to 250 mmHg. These data indicate an increased reliance on 
anaerobic glycolytic metabolism and decreased oxidative phosphorylation during exercise in 
skeletal muscle in heart failure compared to controls. This may have implications for 
understanding the symptoms reported by heart failure patients after repeated submaximal efforts 
during their daily activities.  
 2.2.9.1.3 Summary of the Acute Exercise Response in Heart Failure 
Exercise capacity is one of the most powerful predictors of mortality in heart failure 
[170,185-187]. Nearly all patients with heart failure suffer from rapid onset fatigue that results in 
a markedly reduced exercise capacity. Yet, the physiologic responses to an acute bout of exercise 
in heart failure are, for the most, characteristic to those observed in healthy normal. Close 
examination of cardiac and circulatory responses in heart failure do reveal a marked decreased 
reserve capacity from pre-exercise to maximal exercise conditions. The capacity to raise skeletal 
muscle blood flow during exercise is reduced, secondary to changes in neurohumoral and  
vascular responsiveness.  It is thought that the decreased reserve capacity in cardiac output, 
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stroke volume, heart rate, and vascular responsiveness contribute to the reduced skeletal muscle  
blood flow and impaired exercise tolerance in patients with heart failure. Additional factors that 
contribute to the early onset of fatigue in heart failure are an increased reliance on anaerobic 
metabolic pathways, and impaired oxidative metabolism of skeletal muscle. Therefore, the 
exercise intolerance characteristic of heart failure patients appears to be related to a change in 
oxygen and nutrient delivery to the musculature, as well as a reduced oxidative capacity of 
skeletal muscle.  
2.2.9.2 The Response to Exercise Training in Heart Failure 
The first report indicating that heart failure patients could safely participate and benefit 
from a cardiac rehabilitation program dates to 1979 [188]. Since that study many randomized 
clinical trials have been conducted and demonstrate that exercise-based cardiac rehabilitation 
favorably improves exercise tolerance, disease-related symptoms, and quality of life in patients 
with heart failure, without negatively impacting left ventricular function. No adverse exercise 
training–related effects have been reported despite that these patients would appear to be at 
higher risk for events given their left ventricular dysfunction and heightened state of sympathetic 
activity. In fact, exercise training contributes to a reduction of the fatigue- and dyspnea-limiting 
exercise intolerance that is common in these patients [189,190].  
However, despite these consistent findings, the mechanism of the training response in 
heart failure is not fully understood. It appears that the improvements in exercise capacity are 
more related to reversing the peripheral compensatory abnormalities, rather than improvements 
in cardiac function. Therefore, this section of this review will outline the response to exercise 
training in heart failure. First, this section will present the information regarding (a) the 
cardiovascular responses, and (b) the skeletal muscle responses.  
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 2.2.9.2.1 Cardiovascular Responses to Exercise Training in Heart Failure 
  2.2.9.2.1.1 Cardiac Output 
Cardiac output shows either no change [182], or a small increase [191] following a period 
of chronic exercise training. In the study by Sullivan et al., [182] patients exercised 
approximately 60 min, 3-5 days/wk at 75% of peak heart rate reserve. Although there was a trend 
toward an increase in maximal exercise cardiac output, indices of left ventricular function did not 
change [182]. On the other hand, in a randomized cross-over trial by Coats et al., [191] exercise 
training was associated with an increase in both submaximal and maximal cardiac output during 
exercise in eleven patients with mild to moderate ischemic heart failure.  
The increase in peak cardiac output was in large extent due to changes in stroke volume, 
and was achieved at a greater absolute work load. The apparent differences between these studies 
are difficult to interpret, but could be a function of several factors such as (a) etiology, severity 
and duration of disease, (b) training modality and intensity, (c) length of the training program, 
(d) method of cardiac evaluation, or (e) a combination of all the above. Therefore, Coats et al., 
[191] is the only study to report an enhanced stroke volume response to exercise following 
training.  
  2.2.9.2.1.2 Heart Rate  
Perhaps one of the most consistent response to exercise training is a reduction in resting 
heart rate and at any given submaximal workload [192]. The reduction in resting heart rate is 
thought to reflect a change in the balance between sympathetic and parasympathetic activity 
towards greater dominance of the vagal nerve. The reduction in heart rate during exercise is,  
generally, attributed to a larger stroke volume, secondary to myocardial hypertrophy [192] or an 
increase in blood volume [193].  
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 In the study by Sullivan et al., [182] and Coats et al., [191] resting and submaximal 
exercise heart rates also decreased in patients with heart failure following training. Finally, a 
slight but significant increase in peak heart rate reserve was observed by Coats et al., [191].  
  2.2.9.2.1.3 Vascular System  
Hornig et al., [194] are the first to suggest that a local exercise program can enhance 
vasodilatory capacity in patients with heart failure. In this cross-over trial, patients participated in 
4 weeks of training which consisted of handgrip exercise at 70% of peak handgrip strength for 30 
min per day. Exercise training restored flow-dependent dilation in patients with heart failure. 
Furthermore, a study by Hambrecht et al., [195] have reported that moderate-intensity aerobic 
exercise training significantly improved endothelium-mediated vasodilation of the peripheral 
vasculature after 24 weeks in patients with heart failure and that these changes were significantly 
correlated with changes in peak oxygen consumption [195]. A similar study has shown that 
lower-limb bicycle ergometer exercise training leads to a correction of endothelial dysfunction of 
the upper extremity, indicating a systemic effect of local exercise training on endothelial  
function [196].  
Furthermore, there is a need for long-term exercise training for maintaining improvement 
of vascular function; improvement of endothelial function after 4 weeks of handgrip exercise is 
lost after the cessation of training, with a return to baseline vascular function after 6 weeks [194]. 
 These results indicate that exercise training has the potential to reverse the deleterious 
effects of increasing peripheral resistance and reducing oxygen delivery to the working skeletal 
muscle caused by endothelial dysfunction, although the improvement in vascular resistance may 




 2.2.9.2.2 Skeletal Muscle Responses to Exercise Training in Heart Failure 
  2.2.9.2.2.1 Muscular Function 
Resistance training was not routinely prescribed to patients with heart failure because this 
type of exercise was associated with undesirable and pathological cardiovascular responses 
[198,199]. However, during the last decade, increasing evidence indicated that dynamic 
resistance training alone [200-202] or in combination with aerobic exercise [203-205] is 
beneficial and counteracts the negative peripheral side effects exhibited in patients with heart 
failure. In  addition, localized skeletal muscle training has been shown to improve symptoms of 
heart failure and exercise capacity; even localized calf skeletal muscle training improves 
oxidative capacity without changes in calf blood flow, and it significantly improved a subjective 
fatigue score [206].  
Finally, selective respiratory muscle training in 3 weeks improved respiratory muscle 
endurance and strength, with an enhancement of submaximal and maximal exercise capacity in 
patients with heart failure. Dyspnea quantified by the Borg scale was significantly reduced 
during progressive isocapnic hyperpnea, and dyspnea during activities of daily living was 
subjectively improved in most patients who underwent training [207].  
  2.2.9.2.2.2 Skeletal Muscle Blood Flow  
There is evidence from both human and animal studies that exercise training may 
improve skeletal muscle blood flow [182,208]. In fact,  Sullivan et al., [182] have reported 
significant improvements in peak leg blood flow and arterio- venous oxygen difference in heart  
failure patients with significantly reduced left ventricular ejection fraction (24%), following 4-6 
months of exercise training. The exercise prescription during this training protocol consisted of 
approximately 60 min of cardiovascular activity performed 3-5 days/wk at 75% of peak heart 
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rate reserve. The improvement in skeletal muscle blood flow is not related to improved central 
hemodynamics and appears to be directly related to exercise capacity [209,210]. 
  2.2.9.2.2.3 Skeletal Muscle Metabolism 
Studies have reported on the ability of skeletal muscle to significantly improve metabolic 
capacity following exercise training in patients with heart failure [211,212]. For example, 
Minotti et al., [212] examined the ability of skeletal muscle to adapt in patients with a mean left 
ventricular ejection fraction of 27%.  Patients participated in a 28-day localized unilateral 
forearm training program. Training consisted of multiple sets (8 min in duration) of wrist flexion 
exercise performed 6 days/week.  Following training, muscle bioenergetics, as assessed by 31P-
NMR spectroscopy, improved in the trained forearm, whereas muscle mass, limb blood flow and 
cardiac output remained unchanged. In addition, the authors reported an impressive 260% 
increase in muscle endurance measured as the number of minutes that a submaximal load could 
be lifted until exhaustion [212].  
In addition, Stratton et al., [213] have reported that after training there were significant 
improvements in skeletal muscle responses to exercise with lesser phosphocreatine utilization, 
higher muscle pH at submaximal workloads, and improvement in phosphocreatine reserve, 
which is also an indicator of mitochondrial adenosine triphosphate synthesis rate. These findings 
suggest that skeletal muscle abnormalities in heart failure are, in part, due to a deconditioning 
process, and can be partially reversed through exercise training. 
 2.2.9.2.3 Summary of the Response to Exercise Training in Heart Failure  
Therefore, there is growing evidence that exercise training may reverse many of the 
peripheral abnormalities present in the heart failure patient. Exercise training may improve 
autonomic function, skeletal muscle blood flow and localized oxidative capacity. Together, these 
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changes may translate in an increased exercise tolerance, reduction in activity-related symptoms, 
and improved quality of life. These findings assume added importance in light of previous 
reports that exercise capacity is the most powerful predictor of survival of heart failure patients. 
Whether exercise training can improve long-term functional and prognostic outcomes in heart 
failure patients is presently uncertain. Furthermore, the improvement in exercise tolerance in 
heart failure patients following training equals that achieved in controlled trials of ACE-
inhibitors [214]. Finally, since exercise tolerance is known to be an independent marker of 
prognosis, an increased exercise capacity following training may itself indicate a prognostic 
benefit. 
2.3 Peripheral Arterial Disease 
Just as with heart failure patients a major physiologic problem for patients with 
peripheral arterial disease is a reduction in muscle blood flow. However in peripheral arterial 
disease patients the cardinal symptom is pain on exertion that is normally relieved by rest. As the 
disease progresses the pain may also occur at rest. In this section the following issues will be 
addressed: (a) the definition, (b) the incidence and prevalence, (c) the etiology and 
pathophysiology, (d) the cardinal symptoms, (e) the diagnostic tests and the prognostic value of 
exercise testing, and lastly (f) the classification of peripheral arterial disease related to the degree 
of symptom severity. This section will present information regarding the principal circulatory 
and muscular compensatory adaptations in peripheral arterial disease patients. Finally, this 
section will discuss the acute exercise responses, and the response to exercise training in 
peripheral arterial disease patients. The purpose of this section is to increase the understanding of 
the manner in which patients with peripheral arterial disease compensate to their reduction in 




Peripheral arterial disease is defined as obstruction of blood flow through a section of the 
arterial tree excluding the intracranial or coronary circulations [215]. In fact, peripheral arterial 
disease is a chronic manifestation of systemic atherosclerosis in the lower limb distal to the 
aortic bifurcation in which the arterial lumen of the lower extremities becomes progressively 
occluded by atherosclerotic plaque [216]. As a result, the obstruction impedes blood flow to the 
lower extremities that leads to a mismatch of oxygen delivery and metabolic demand that 
becomes more evident during physical activity [215,217].  
Peripheral arterial disease is mostly silent in its early stages but may manifest as 
intermittent claudication when the luminal obstruction is greater than 50% [215] (see figure 2.3 ). 
As the disease progresses, the symptoms typically intensify to pain at rest, with the potential for 
frank tissue loss [218]. As a result, peripheral arterial disease patients have impaired function and 
quality of life [219]. This is true even for persons who do not report leg symptoms. Furthermore, 
peripheral arterial disease patients, including those who are asymptomatic, experience significant 
decline in lower-extremity functioning over time [220].  
2.3.2 Incidence and Prevalence 
Peripheral arterial disease is a major cause of disability, loss of work, and lifestyle 
changes in the United States [221]. In addition, peripheral arterial disease affects approximately 
12 million persons in this country [222]. It is a prevalent but underdiagnosed and undertreated 
disorder associated with significant morbidity and mortality [223].  
The prevalence of peripheral arterial disease increases with advancing age, as 
approximately 12 to 20% of people older than 70 years suffer this condition [224,225]. 
Furthermore, one half of all peripheral arterial disease patients older than 55 years are 
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asymptomatic. Among the symptomatic, 40% experience intermittent claudication, and 10% 
have critical limb ischemia [226]. 
  
 
Figure 2.3. Arterial obstructions exceeding 50% of the internal lumen diameter of a 
peripheral artery, such as the superficial femoral artery (A), may result in IC. The 
most common cause of such symptomatic obstructions is atherosclerosis, resulting 
from a buildup of fatty, cholesterol-laden plaque within the arterial wall (B) [215].  
 
The Rotterdam Study [227] assessed the age- and sex-specific prevalence of peripheral 
arterial disease and intermittent claudication in a group of 7715 old individuals. The Rotterdam 
Study reported that the prevalence of peripheral arterial disease in the elderly is high whereas the 
prevalence of intermittent claudication is rather low, although both occurrences clearly increase 
with advancing age. In fact, the same study showed a frequency of claudication ranging from 1% 
in those 55 to 60 years of age to > 5% in those over age 80 [227].  
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Finally, in the Cardiovascular Health Study [228], the ankle-brachial index, a frequently 
used marker of peripheral arterial disease, was measured in patients older than 65 years of age at 
a baseline examination. Those with an ankle-brachial index < 0.8 were more than twice as likely 
to have had a myocardial infarction, angina, heart failure, stroke, or transient ischemic attack as 
patients with normal values. Furthermore, cumulative data after 6 years of follow-up on 5888 
patients showed that an ankle-brachial index < 0.9 was an independent risk factor for occult 
cardiovascular disease, recurrent cardiovascular events, and mortality [229]. 
Despite its prevalence and cardiovascular risk implications, only 25% of patients with 
peripheral arterial disease are undergoing treatment [230]. The risk factors associated with 
peripheral arterial disease are similar to those for coronary heart disease and include increasing 
age, diabetes mellitus, cigarette smoking, hypertension, elevated lipid levels, and elevated 
homocysteine levels [217,231]. In addition, persons with peripheral arterial disease, compared 
with those without, have 4 to 5 times the risk of dying of a cardiovascular vascular disease event, 
resulting in a 2- to 3-times higher total mortality risk [217,229].  
2.3.3 Etiology and Pathophysiology 
 Atherosclerosis (arteriosclerosis obliterants), a primarily systemic inflammatory process, 
is the leading cause, more than 90%, of occlusive arterial disease of the extremities in patients 
over 40 years of age [232,204, 205]. Peripheral arterial disease is the result of atherosclerotic 
disease of the lower extremities, and it is one of the major causes of disability in middle age and 
the elderly [233]. The segmental lesions responsible for the stenosis or occlusion are usually 
localized in large and medium-sized blood vessels [234]. It is important to emphasize that 
inflammation is currently considered to be a key factor in all stages of atherogenesis in non- 
diabetic as well as diabetic patients [235]. The histopathological basis of disease is identical to 
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that seen in the coronary vasculature and other vascular beds [236]. In general, atherosclerosis 
results from an excessive inflammatory and fibroproliferative response to numerous vascular 
insults, which leads to alteration of the normal homeostatic properties of the endothelium [237]. 
 The initial changes that precede the formation of atherosclerotic lesions occur in the 
endothelium, and they include: (a) increased endothelial permeability to lipoproteins and other 
plasma constituents, (b) up-regulation of leukocyte adhesion molecules, (c) upregulation of 
endothelial adhesion molecules, and (d) migration of leukocytes into the artery wall [234,238]. 
These processes are mediated by many vasoactive molecules, cytokines, and growth factors 
[237]. Afterward, if the inflammatory response cannot counteract or remove the insulting factors, 
the inflammatory response will stimulate migration and proliferation of smooth muscle cells that 
participate in the formation of fatty streaks in atherosclerosis along with lipid-laden monocytes, 
macrophages (foam cells), and T lymphocytes [237,239].  
The resulting inflammatory process leads to increased amounts of macrophages and 
lymphocytes, and it promotes cholesterol and calcium deposition and, ultimately, the buildup of  
 plaque [232]. These macrophages and lymphocytes can emigrate from the blood and multiply in 
the lesion and result in further damage and eventually lead to focal necrosis [237,239]. These 
changes causes further enlargement and restructuring of the lesion, so it becomes covered by a 
fibrous cap that overlies a core of lipid, a mixture of leukocytes, and necrotic tissue. The necrotic 
core is the result of (a) apoptosis and necrosis, (b) increased proteolytic activity, and (c) lipid 
accumulation [237].  
 The lesions may be stable, or they may develop a thin, unstable fibrous cap, that is caused 
by continuing influx and activation of macrophages. As a result, the lesion is vulnerable to 
ulceration [240]. Once the lesion ulcerates, the underlying plaque is exposed to the bloodstream, 
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and the potential for thrombotic occlusion or embolization increases [241]. Therefore, 
atherosclerosis is a multistage, multigenic, and very complicated inflammatory disease [239]. 
Indeed, during atherogenesis, growth factors, cytokines, lipids, and enzymes modulate critical 
cell functions by inducing (a) lipid accumulation and oxidation, (b) cell-mediated inflammatory 
response, (c) smooth muscle proliferation, (d) vasoconstriction, and (e) a prothrombotic 
environment within the artery wall [237,240].  
The primary sites where the lesions are located include the abdominal aorta and iliac 
arteries (30% of symptomatic patients), the femoral and popliteal arteries (80 to 90% of patients), 
and the more distal vessels, including the tibial and peroneal arteries (40 to 50% of patients) 
[242]. In addition, the atherosclerotic lesions have a predilection for arterial branch points where 
increased turbulence, altered shear stress, and intimal injury occur [232]. Typically, the 
narrowing of a proximal artery was considered the only factor responsible for the reduced 
oxygenation in the skeletal muscle. However, the hemodynamics limitations are poor predictors 
of exercise performance among individuals with peripheral arterial disease [243].               
 In addition, the natural history of peripheral arterial disease is slow progression of  
symptoms over time [244]; however, there is considerable variation within this overall pattern. In 
most patients, the disease progression is benign [215]. A great majority of patients will remain 
asymptomatic or with fairly stable symptoms; some may even show improvement. In that regard, 
a large population study found that 5 years after diagnosis of peripheral arterial disease , 63% of 
patients showed angiographic progression, but 66% still had no limiting intermittent claudication 
[245]. Many patients will simply adjust or adapt their lifestyles to accommodate their 
symptomatic limbs in the same way many patients with heart failure adjust their lifestyles to 




The symptoms and signs of peripheral arterial disease are displayed in table 2.7 [246]. 
The decreased blood flow to the legs caused by peripheral arterial disease may be mild or severe, 
resulting in a broad range of symptoms. The symptoms may range from pain on exertion that is 
normally relieved by rest, also known as intermittent claudication, which is the primary 
manifestation of peripheral arterial disease [218,247], to pain at rest also known as critical limb 
ischemia [216,248]. In the general population, only about 10% of persons with peripheral arterial 
disease have the classic symptoms of intermittent claudication. About 40% do not complain of 
leg pain, whereas the remaining 50% have a variety of leg symptoms different from classic 
claudication [223,249]. 
2.3.4.1 Intermittent Claudication  
Intermittent claudication is described as a cramp, ache, fatigue, tightening discomfort, or 
frank pain located in the muscles of the buttocks, thighs, or calves [250,251]. Intermittent 
claudication is the result of poor oxygenation of the muscles of the lower extremities, induced by 
walking or exercise and relieved by rest [252]. Classic intermittent claudication, as defined by 
the World Health Organization (WHO)/Rose Claudication Questionnaire, is calf pain that occurs 
during exercise and ceases within 10 minutes of rest [253].  
Intermittent claudication is usually reproducible, occurring at approximately the same 
distance, pace, and grade from day to day, and resolves within 2 to 5 minutes with rest. The 
location of the pain often corresponds to the level of stenosis [254]. For instance, patients with an 
iliac lesion often experience claudication in the thigh or buttock, whereas popliteal lesions are 
more often associated with calf claudication [216]. In addition, peripheral arterial disease 
patients may develop Leriche syndrome, which includes (a) claudication, (b) impotency, and (c) 
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global atrophy of the lower extremities due to aortoiliac obstructive disease [255]. Intermittent 
claudication is present in less than 1% of individuals under age 50 and approximately 5% or 
more of those older than age 80 [217].  
   Table 2.7 Symptoms and signs of Peripheral Arterial Disease  
 
Symptoms and signs 
Exertional leg pain and relief with rest 
Cool or cold feet to palpation 
Nocturnal and rest pain relieved with dependency 
Absent pulses 
Blanching or pallor on elevation 
Delayed venous filling after elevation 
Dependent rubor 
Atrophy of subcutaneous fatty tissue 
Shiny skin 
Loss of hair on foot and toes 
Thickened nails, often with fungal infections 
Gangrene or non-healing ulcer 
 
Intermittent claudication prevalence rates vary, but in a vascular laboratory population, 
only 1/3 of peripheral arterial disease subjects reported classic WHO/Rose claudication [256] 
[247]. This indicates that the remaining 2/3 of individuals with peripheral arterial disease are 
reportedly asymptomatic or have atypical symptoms. Daily activity is reduced up to 45% in 
patients with intermittent claudication, as compared with healthy subjects of similar age [251]. 
Although intermittent claudication incidence has declined since 1950, the mortality has remained 
high and unchanged [11].  
 2.3.4.2 Critical Limb Ischemia 
Critical limb ischemia is defined as limb ischemia that could occur during rest [216,217]. 
Clinically, ischemia in the limb at rest is manifested first in the cutaneous tissues of the foot, 
where factors regulating perfusion differ from those governing calf muscle circulation, and 
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reflexive sympathetically mediated vasoconstrictor activity may reduce foot blood flow even 
under conditions of ischemia [255]. Critical limb ischemia is typically described as worse at 
bedtime with horizontal positioning (and relieved by dependent positioning), or evidence of 
distal tissue necrosis (non-healing ulcers, gangrene) [257]. It is a severe manifestation of 
peripheral arterial disease, which threatens the viability of the extremity because arterial 
perfusion is insufficient to meet even the basal metabolic demands of the tissue [258]. Other 
symptoms of ischemia at rest include hypesthesia, cold sensitivity, muscular weakness, joint 
stiffness, and contracture [255].  
Normally, pain at rest indicates severe, often multilevel arterial occlusive disease. It 
characteristically occurs as a dull, aching sensation in the toes or fore foot, or as a severe, 
nagging burning at night with the patient lying supine [246,255]. The patient may hang the foot 
or leg over the side of the bed or get up to walk around to obtain relief. Some patients with 
severe rest pain sleep sitting in a chair with the legs dependent, resulting in edema [258]. 
Therefore, it has a profound effect on functional capacity and quality of life among the patients, 
and it requires an aggressive management, which usually includes angiographic examination and 
therapeutic intervention by percutaneous angioplasty or surgical revascularization. When these 
are not feasible, gangrene commonly ensues leading to amputation [255]. Critical limb ischemia 
results in some 150,000 amputations annually in the US, with perioperative mortality rates of 5–
10% for below-knee amputation and up to 50% for above-knee amputation because of comorbid 
conditions [217]. Finally, the annual incidence of critical limb ischemia approximates 500 per 
one million population [221]. Among patients with intermittent claudication, approximately 10% 
progress to limb-threatening ischemia in 5 years, and 25% of those with critical limb ischemia 
require amputation [244].  
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2.3.5 Diagnostic Tests  
This particular section will describe various diagnostic tools that are currently available 
in the diagnosis and management of patients with peripheral arterial disease. However, the main 
focus of this section is to present information regarding two of the most practical and frequently 
used tests in the diagnosis of patients with peripheral arterial disease, the ankle-brachial index 
test and exercise testing with the ankle-brachial index.  
2.3.5.1 The Ankle–Brachial Index Test   
The ankle-brachial index is a simple, inexpensive, non-invasive vascular tool that 
correlates well with angiography disease severity and functional symptoms [259, 256]. Under  
normal conditions, systolic blood pressure in the legs is equal to or slightly greater than the 
systolic pressure in the upper limbs. In the presence of an arterial stenosis, a reduction in 
pressure occurs distal to the lesion [223]. The ankle-brachial index, which is calculated from the 
ratio of ankle to brachial systolic pressure, is a sensitive marker of arterial insufficiency. The 
highest pressure measured in any ankle artery is used as the numerator in the calculation of the 
index; a value greater than 1.0 is normal and a value less than 0.90 is abnormal [260].  
Normally, an ankle-brachial index less than 0.90 is considered diagnostic of peripheral 
arterial disease. There are three categories; (a) mild disease correlates with an ankle-brachial 
index ranging from 0.70 to less than 0.90, whereas (b) moderate disease correlates with an ankle-
brachial index ranging from 0.40 to less than 0.70, and finally (c) severe disease is associated 
with an ankle-brachial index less than 0.40 [221,261]. Patients with intermittent claudication 
tend to have an ankle-brachial index in the range of 0.5 to 0.9, whereas those with critical 
ischemia usually have an index of less than 0.50 [223]. The ankle-brachial index also has 
prognostic significance because of the association with arterial disease elsewhere, especially 
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coronary heart disease. Recent studies indicate an association of elevated ankle-brachial index 
levels with increased all-cause and cardiovascular mortality [242]. 
 2.3.5.1.1 Ankle-Brachial Index Technique  
The ankle-brachial index measurement sites are displayed in figure 2.7. An ordinary 
blood pressure cuff is positioned over the upper arm and inflated above systolic blood pressure. 
Next, a Doppler ultrasonic velocity signal probe is placed over the brachial artery to detect the 
resumption of blood flow with cuff deflation. Measurement of systolic blood pressure is repeated 
on the other arm. The higher of the 2 systolic blood pressures is used in the calculation. The 
measurement of the ankle systolic blood pressure is detected with the Doppler probe over the 
posterior tibial artery and then over the dorsalis pedis artery. The higher value from the two 
arteries is used into the calculation. The process should be repeated for the other leg. Finally, the 
lowest ankle-brachial index between both legs is the ankle-brachial index that stratifies the 
patient’s risk [217]. 
  2.3.5.1.2 Limitations of Ankle-Brachial Index  
In some patients with diabetes, renal insufficiency, or other diseases that cause vascular 
calcification, the tibial arteries at the ankle become non-compressible. This leads to a false high  
ankle-brachial index value. In those cases, additional measures would be necessary (e.g. a toe- 
brachial index, pulse volume recordings or other noninvasive testing) [221]. 
2.3.5.2 Exercise Testing  
The addition of ankle-brachial index measure with exercise testing provides more 
information on the dynamics of claudication [262]. Studies have reported that exercise testing is 
useful in those patients with claudication symptoms who have a normal ankle-brachial index or  
normal pulse at rest [263]. The typical treadmill protocol for persons with peripheral 
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arterial disease is either a graded or a constant load protocol [264]. The graded protocol utilizes a 
fixed speed while grade increases every two or three minutes to a symptom limited maximal (or 
“peak”) performance [265]. The constant load protocol has both speed and grade fixed, and it is 
done on a treadmill allowing the patient to walk at a standard speed and grade for a pre-
determinated period (2 mph at 12% incline for 5 minutes) or until claudication appears [221]. 
Both types of protocol have shown very good reproducibility [266].   
The next section is intended to present information regarding the prognostic value of these 
diagnostic tools used in patients with peripheral arterial disease. This section will address the 
outcomes of the ankle-brachial index technique, and then, the exercise testing with the addition 
of ankle-brachial index. The prognostic value of exercise testing in peripheral arterial disease is 
as follow:  
    2.3.5.2.1 Ankle-Brachial Index Test 
Although not a direct measure of function, the ankle-brachial index is of key importance 
to assess peripheral arterial disease severity [267]. The ankle-brachial index test is a non-invasive 
measure that is made in the peripheral arterial disease patient first while resting in the supine  
position, and second, post exercise (also supine) by assessing systolic blood pressure in the ankle 
and arm with a Doppler ultrasonic instrument [264]. In addition, many studies have reported that 
the ankle-brachial index decreases with age. In fact, the Rotterdam Study [227] showed that the 
ankle-brachial index decreased sharply with advancing age. These investigators concluded that 
the high prevalence of peripheral arterial disease and unfavorable cardiovascular risk profile of 
patients with peripheral arterial disease, illustrates the need to explore the use of the ankle-
brachial index as a risk indicator in cardiovascular screening and risk profiling in medical 
practice. Finally, the ankle-brachial index test also provides significant information regarding; 
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(a) the disease progression, (b) the functional capacity, and (c) its role as predictor of 
cardiovascular morbidity and/or mortality among peripheral arterial disease patients [221].  
  2.3.5.2.1.1 Disease Progression 
The changes in the ankle-brachial index values over time represent a useful tool to 
monitor disease progression [268]. For example, changes in the ankle-brachial index that exceed 
±0.15 are considered to be outside the range of experimental error and indicate disease 
progression [262].  
  2.3.5.2.1.2 Functional Capacity  
Many studies have shown that the ankle-brachial index is independently linked with 
impaired lower extremity functioning, even in asymptomatic patients. In that regard, the 
Women’s Health and Aging Study [269] revealed that decreasing ankle-brachial index values 
were associated with progressive worsening in functional scores, even after adjustment for age, 
sex, race, smoking status, and comorbidities. For example, in asymptomatic women, lower 
ankle-brachial index scores were associated with slower walking velocity, poorer standing 
balance, slower time to arise, and fewer blocks walked per week. In addition, the Study of 
Osteoporotic Fractures [270] showed that patients with an ankle-brachial index less than 0.90 
had significantly lower hip abduction force, knee extension force, walking velocity, and number 
of blocks walked than those with an ankle-brachial index of 0.90 or greater. Finally, other studies 
have reported that progressive peripheral arterial disease is associated with muscle fiber loss, 
poorer leg strength, and slower walking velocity [271]. 
  2.3.5.2.1.3 Predictor of Cardiovascular Morbidity and/or Mortality  
The Cardiovascular Health Study [229] was conducted among 5888 adults 65 years of  
age or older in order to monitor for cardiovascular events after establishing a baseline 
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cardiovascular disease and ankle-brachial index measurement. The results reveal that mortality 
rate at 6 years was higher in those patients who had cardiovascular disease and a low ankle-
brachial index (<0.90) at baseline (32.3%), in contrast it was lowest in patients with neither of 
these risks factors at baseline (8.7%). A study conducted by McKenna et al., [272] showed that 
mortality from cardiovascular disease was highest among patients with an ankle-brachial index 
less than 0.40 and lowest among patients with an ankle-brachial index of 0.85 to 1.50.  
Interestingly, several studies had revealed the importance of the ankle-brachial index as a 
predictor of cardiovascular mortality among asymptomatic peripheral arterial disease patients 
[273,274]. The study by Criqui et al., [273] showed the survival curves based on mortality from 
all causes among normal subjects and subjects with symptomatic and asymptomatic peripheral 
arterial disease. This study confirms the overall poor prognosis with advancing age and the 
alarmingly high risk in asymptomatic patients whose disease would not be detected clinically. 
However, a hemodynamic measure such as ankle-brachial index should not be used as a primary 
measure of the functional effects of an intervention such as exercise rehabilitation since the 
correlation between ankle-brachial index and treadmill walking is often weak [264].  
 2.3.5.2.2 Exercise Testing 
The exercise testing assessment has been considered the gold standard for evaluating 
exercise performance in peripheral arterial disease patients [264]. Normally, in healthy subjects 
ankle systolic blood pressure is maintained during moderate exercise. On the other hand, in 
patients with claudication their ankle systolic blood pressure falls to low or is undetectable with 
low level workloads and returns to baseline after a few minutes [262]. The two main measures 
that are obtained from treadmill testing are pain-free walking time, also called initial claudication 
distance and maximal walking time, also called absolute claudication distance [264,275]. Pain-
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free walking time is the time a patient can walk before the onset of claudication, while maximal 
walking time is the amount of time a patient can walk before being stopped by severe 
claudication [251,264]. Finally, among patients with peripheral arterial disease the post-exercise 
ankle-brachial index will drop significantly [263]. However, any pain or discomfort related to the 
exercise while the ankle-brachial index remains normal or unchanged are not produced by 
peripheral arterial disease [221].     
2.3.6 Classification According to the Symptom Severity  
Two major classification systems have been used to rate the symptom severity and to 
assess the impact of intervention programs in peripheral arterial disease patients. The first one is 
the older Fontaine system [276]. This system assigns patients to 1of 4 clinical stages (I-IV), 
depending on the manifestation of clinical signs (see table 2.8).    
      Table 2.8 Fontaine’s classification  
 
Stage Clinical description and objective criteria 






Intermittent claudication, pain during walking 
Relief of symptoms when standing 




Ischemia-driven symptoms at rest 
Ankle Pressure Index ≥ 50 mm Hg 








In addition, a new classification has now been proposed by Rutherford et al., [277]. It 
comprises six clinical categories (see table 2.9), and its use is recommended by the Trans-
Atlantic Inter- Society Consensus (TASC) Working Group for the diagnosis and assessment of 
the progression of peripheral arterial disease [278].  
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   Table 2.9 Rutherford categories 
 
Category Clinical description Objective criteria 
0 Asymptomatic Normal treadmill test 
1 Mild claudication Treadmill exercise limited to 5 
min; ankle pressure after 
exercise >50 mmHg, but at 
least 20 mmHg lower than at 
rest 
2 Moderate claudication Between Rutherford 2 and 3 
disease 
3 Severe claudication Treadmill exercise limited to 
<5 min; ankle pressure after 
exercise <50 mmHg 
4 Ischemic rest pain Ankle pressure <40 mmHg 
and/or great toe pressure <30 
mmHg; pulse volume 
recording barely pulsatile or 
flat 
5 Minor tissue loss Ankle pressure <60 mmHg 
and/or great toe pressure <30 
mmHg; pulse volume 
recording barely pulsatile or 
flat 
6 Major tissue loss 




In summary, peripheral arterial disease is a major and growing public health problem  
in the United States. In fact, peripheral arterial disease is a prevalent but underdiagnosed and 
undertreated disorder associated with significant morbidity and mortality. Peripheral arterial 
disease is a clinical syndrome that causes a reduction of blood flow to the lower extremities, and 
it produces a mismatch of oxygen delivery and metabolic demand that becomes more evident 
during physical activity.  
 The cardinal manifestation of peripheral arterial disease is intermittent claudication. 
Finally, the Rutherford system is currently the recommended classification used to quantify the 
severity of symptoms among peripheral arterial disease patients. The next section will present 
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information regarding the principal circulatory and muscular compensatory adaptations in 
peripheral arterial disease patients.    
2.3.7 Compensatory Adaptations to Peripheral Arterial Disease 
Peripheral arterial disease is defined as an obstruction of blood flow to the lower 
extremity, due to atherosclerosis. Peripheral arterial disease is mostly silent in its early stages and 
its symptoms progress slowly over time. Eventually, patients with peripheral arterial disease 
might suffer from pain at rest and/or ischemic ulceration and gangrene due to hypoperfusion, 
which is known as critical limb ischemia.  
The primary pathophysiology of peripheral arterial disease is impaired perfusion that 
forces a series of functional and structural modifications in the affected limb. These 
compensatory modifications determine the functional ability of patients with peripheral arterial 
disease. Thus the purpose of this section of the review is to discuss the compensatory 
modifications associated with the disease. Particular focus will go toward discussing: (a) the 
vascular compensatory adaptations, and (b) the skeletal muscle compensatory adaptations as a 
result of peripheral arterial disease.  
2.3.7.1 Vascular Compensatory Adaptations  
Atherosclerosis is a disease of the large and medium sized arteries. The small arteries 
such as the digital vessels generally are not affected in atherosclerosis, but, on occasion, may 
become involved secondarily [279]. Traditionally, atherosclerosis research has mainly focused 
on investigating risk factors for plaque development and its complications. However, 
considerably less is known about compensatory phenomena of the vasculature in atherosclerosis. 
In that regard, few experimental studies encouraged the hypothesis that vessels dilate in response 
to atherogenesis, thereby restoring normal blood flow and delaying the onset of clinically 
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important stenosis [280-282]. The vasculature is recognized as a complex organ capable of 
sensing its environment (e.g. shear stress), transducing signals to effector cells or surrounding 
tissue and responding to various stimuli by releasing local regulatory mediators such as growth 
factors and vasoactive peptides [282-284].  
 Many studies have described atherosclerosis as a diffuse and progressive process with a 
variable distribution and clinical presentation that is dependent on the regional circulation 
involved [217,251,285]. Factors that may influence these differences include the size and 
structure of the affected artery, local and regional flow, changes in microcirculatory alterations, 
and end-organ damage.  
 Generally, the reduction of blood flow as a result of the atherosclerotic lesion would 
favor the installation of distal modifications far away from the original stenotic vessel [251]. The 
local blood flow control can be divided into two phases: (a) acute control, and (b) long-term 
control. Acute control is achieved by rapid changes in local vasodilation or vasoconstriction of 
the arterioles, metarterioles, and pre-capillary sphincters. This response occurs within seconds to 
minutes in order to provide a rapid means for maintaining appropriate local tissue blood flow.  
 The long-term control results in slow changes in flow over a period of days, weeks, or 
even months. These changes are the result of an increase or decrease in the physical sizes and 
numbers of actual blood vessels [110]. Furthermore, the understanding of atherosclerotic 
vascular disease has evolved most dramatically over the past 25 years with the growth of the 
field of vascular biology [286]. With that in mind, the purpose of this section of this review is to 
outline the major vascular compensatory adaptations in peripheral arterial disease. The topics 
included in this section are: (a) large and medium-sized arteries, (b) collateral arteries, and (c) 
microcirculatory disturbances.  
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   2.3.7.1.1 Large and Medium Sized Arteries  
When a large or medium sized artery becomes occluded, secondary vascular channels 
immediately develop around the blockage and allow, at least, partial resupply of blood to the 
tissue below the blockage. Vascular loops above the blockage begin to dilate, and are in part 
secondary to neural and/or metabolic relaxation of the smooth muscle surrounding the blood 
vessels. Obviously, the compensation is less then optimal, but is able to maintain cellular 
function under resting conditions. The compensation continues and within a few days may 
eventually be sufficient to normalize flow under even low levels of activity [110].  
Whereas the initial compensation is more than likely the consequence of rapid neural 
changes and metabolic dilation, the long-term collateral formation more than likely involves 
structural changes in the circulatory tree that contribute to vessel growth and enlargement [110]. 
In fact, it has been reported that compensatory enlargement of the vessel at the site of active 
atherosclerosis effectively preserves normal lumen size [285]. However, whereas the 
compensation is clearly aimed at improving blood flow to the compromised region, vascular 
remodeling does alter the normal pressure/flow relationships. It is believed these alterations 
contribute to the degree of disability the patient suffers [287]. In fact, it is not uncommon to 
observe, within the same vessel, both a decrease in lumen size (due to advancing atherosclerosis) 
and an increase in lumen diameter [288]. Consequently, the flow profile (from laminar to more 
frequent turbulent flow), and vessel shear will change throughout the affected artery thereby 
increasing the stress on an already vulnerable vessel. 
 2.3.7.1.2 Collateral Arteries  
The importance of the collateral arteries was described in the previous section. However, 
given its importance this section will describe in greater detail the underlying factors that 
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contribute to the formation of these vessels. Collateral arteries may already be present in the 
body, and are only stimulated and subsequently opened in times of need. However, collaterals 
also “grow” as the need remains or the extent of the disease worsens.  
Many factors are well known and accepted regarding collateral arteries [279]. The 
collateral arteries consist of three components: the exit, mid-zone, and re-entry vessel [289]. An 
example of an exit collateral would be the profunda femoris with the geniculate arteries 
representing the reentry channel(s). Normally the mid-zone connecting the two will not be 
visible on an arteriogram because of their small size. However, this is the zone that will undergo 
the greatest change in diameter when ischemia develops. In fact, with acute arterial occlusion, 
limb survival will often depend on the ability of the mid-zone collaterals to increase in diameter 
and carry enough nutritive blood flow to permit limb survival [279]. The problems with 
collateral arteries is that they present an increase in resistance to flow (due to their relatively 
small size) which limits their capability of providing enough blood flow to reach the levels 
necessary to prevent claudication from occurring. Thus, they may be sufficient for resting flow 
needs but cannot respond to the added stress of exercise.  
Another problem that is often encountered with collaterals is that when more than one set 
of collateral arteries are in series in a limb with multisegmental obstructions, there is a significant 
increase in the resistance to flow. Thus the peripheral vascular resistance rises further adding to 
the vascular problems. For this reason multisegment arterial disease is nearly always more severe 
than single-segment occlusion [287]. Indeed, it is the patient with multisegment disease who 
presents the greatest challenges in management. Finally, anatomically, there are profound 
differences in the collateral capabilities of some areas of the circulation that are important 
hemodynamically [279]. For instance, the aorta and iliac arteries received their collateral arteries 
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(called parietal) from intercostals and subcostal arteries. Visceral collaterals to supply the limb 
can also come from the inferior mesenteric arteries that connect with the arteries of the pelvis; 
however, they are not able to supply enough blood to the ischemic limb to prevent claudication 
from occurring [279]. Below the knee the anatomic arrangement, in terms of potential collateral 
flow, is much different. The blood supply to the gastrocnemius muscle is from a single source, 
the sural artery. Within the muscle, the arteries branch much like those of a tree; however, and 
most critically, there are relatively few arterial connections with the gastrocnemius muscle from 
outside sources. In other words, it almost has an isolated blood supply. In contrast, the soleus 
muscle is supplied by multiple side branches that freely communicate up and down the limb with 
other branches that permit inflow in cases of chronic arterial obstruction [289]. These extensive 
intercommunications are usually able to provide adequate levels of blood flow even in the 
presence of extensive chronic arterial occlusion in the arteries below the knee. They are 
particularly important when considering the problem of diabetic arterial disease, in which 
extensive pathology in this area is very common [279]. 
 2.3.7.1.3 Microcirculatory Disturbances   
The components of the microcirculation (arterioles, capillaries, venules, and the 
endothelial cells covering vascular structures) contribute to maintain the internal circulatory, 
coagulative and metabolic homeostasis [110]. The endothelial cells are in the non activated state 
(normal morphology) when the perfusion pressure is normal. In addition, the blood cells are in a 
non secretory, non adherent state [290].  
As a result, the blood vessels are able to deliver the proper amount of blood flow that is 
plentiful in oxygen and substrates for energy production, in order to meet the metabolic 
requirements of the skeletal muscle. The next section will present information regarding two of 
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the microcirculatory disturbances seen in patients with peripheral arterial disease. The topics 
included are: (a) the endothelium and and (b) the blood cells. 
  2.3.7.1.3.1 The Endothelium 
It is interesting to consider that the above-mentioned changes, in large part, aim to 
improve blood flow to tissue, under difficult circumstances. In contrast, a consistent finding in 
the literature is that patients with peripheral arterial disease have impaired endothelial function 
[291-294]. Indeed, Edwards et al., [295] have reported that ischemic conditions promote 
endothelial changes that favor platelet adhesion and subsequently activate the coagulation 
cascade. Furthermore, Thomson et al., [296] revealed the presence of capillary endothelial 
swelling in critical limb ischemia. In addition, studies in patients with peripheral arterial disease 
have reported an increase in adhesion molecules [297] that when interacting with their counter-
receptors expressed by circulating cells, favor the cell–cell adhesion. Raised plasma levels of 
circulating adhesion molecules that further increase with exercise have been reported in patients 
with intermittent claudication [298]. Finally, Boger et al., [299] reported that patients with 
peripheral artery disease present impaired nitric oxide synthesis. These findings suggest that the 
endothelial function is compromised. Clearly, this compensation is difficult to understand if one 
considers that most changes aim to improve the situation. One could speculate that this in fact is 
more a disease related factor rather than a compensation for the atherosclerosis. Certainly, this  
fits with current thinking which strongly suggests that endothelial dysfunction precedes the 
development of atherosclerosis.  
  2.3.7.1.3.2 The Blood Cells  
Erythrocyte mean corpuscular volume is significantly correlated with the angiographic 
score in peripheral artery disease patients [300]. Others also report increases in plasma viscosity 
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with the progression of the atherosclerotic process in patients with peripheral arterial disease and 
these findings correlate with the clinical stages of the disease [301]. Intuitively, this 
compensation makes sense as the body attempts to improve its oxygen carrying capacity in a low 
flow environment. However, this compensation also appears to come with negative 
consequences as the apparent transport of oxygen from the heme to the myoglobin and into the 
cell is compromised.  
In addition, studies in patients with peripheral arterial disease have shown greater 
leukocyte and platelet activation [302,303] that could lead to physical obstruction and/or the 
release of toxic chemicals affecting the microcirculation.  In addition, activated leukocytes and 
platelets may adhere to the endothelium of pre-capillary arterioles and post-capillary venules, 
through the action of adhesion molecules [297]. Activated leukocytes may deliver a variety of 
noxious substances including proteolytic enzymes, oxygen free radicals, and leukotrienes. Then, 
these products by inducing cell membrane peroxidation and endothelial damage, promote 
vascular permeability, plasma leakage and consequent interstitial oedema [302]. The activation 
of platelets produces the release of different products that may promote vasoconstriction and 
fibrin formation and inhibit fibrinolysis [303].  
In addition, increased vascular permeability in patients with peripheral arterial disease 
has been reported by Hickey et al., [304]. Their results showed that in claudicant patients the 
exercise-induced ischemia in the affected limb is accompanied by microalbuminuria. Blood 
viscosity is an important determinant of blood flow, which in turn is determined by hematocrit, 
blood cell deformability, and plasma viscosity. In the normal microcirculation, under high shear 
stress and perfusion pressure, erythrocytes deform easily and thus pass easily through the 
capillaries. In contrast, erythrocytes in patients with peripheral arterial disease deform less 
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rapidly making their passage through the capillaries more difficult [305]. These changes would 
lead to red cell aggregation, increased blood viscosity and reduced blood flow. Clearly more 
work is needed to differentiate which of these observed changes are compensatory and which are 
contributory to the disease progression. 
2.3.7.2 Skeletal Muscle Compensatory Adaptations  
 2.3.7.2.1 Histologic and Biochemical Alterations in Skeletal Muscle 
The reduction in blood flow in patients with peripheral arterial disease progress gradually 
and ultimately leads to severe ischemic disease. As a result peripheral arterial disease patients 
exhibit a variety of structural changes in skeletal muscle consisting of (a) neural modifications, 
specifically denervation, (b) muscle fiber atrophy, and (c) selective loss of type II fibers relative 
to type I fibers [306,307]. The result of these modifications is neuromuscular dysfunction, 
contributing to the clinical course of the disease. For instance, Hedberg et al., [306] have 
reported that peripheral arterial disease patients with critical ischemia have widespread 
destruction of muscle fibers, which are replaced with non-contractile connective tissue. 
 Importantly, the destruction of muscle fibers appears to be, at least, for a period of time 
during the disease progression somewhat selective. In fact, chronic ischemia in peripheral arterial 
disease patients is typically characterized by denervation and a decreased type II fiber area. 
Table 2.10 provides a very simplistic overview of the differences in muscle fibers [283].   
Obviously; the changes are associated with muscle atrophy and a loss of muscle mass that 
lead to functional impairment. In that regard, England et al., [308] have reported that ischemic 
pain associated with peripheral arterial disease leads to lower extremity neuropathy. The 
neuropathy causes partial denervation-reinervation, and it results in decreased muscular strength 
and performance [309].  
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      Table 2.10 Skeletal muscle fiber types  
 
Features Type I Type II 
Color Red White 
Contractility Slow twitch Fast twitch 
Function Postural Fine movement 
Mitochondria density High Low 
Oxidative capacity High Low 
Glycolytic capacity Low High 






These changes are seen in both motor and sensory nerves of peripheral arterial disease 
patients with concurrent diabetic neuropathy, and they are also reported in non-diabetic patients 
[310,311]. Furthermore, Eames and Lange [312] have reported sensory and motor impairment 
weakness in claudicants, which has a detrimental effect on the biomechanics of walking [243]. 
On the other hand, peripheral arterial disease patients with less severe ischemia exhibit more 
diverse skeletal muscle changes. For instance, selective loss of type II fibers [243] to no loss of 
fibers [307], or an increase in the number of type I fibers [313]. In addition, some studies have  
 reported selective loss of type IIb fibers [314]. These changes can lead to greater strength 
deficits in peripheral arterial disease patients due the fact that type II muscle fibers are larger, 
stronger, and faster than type I muscle fibers.  
   Traditionally, the technique in the study of muscle fiber typing involves the examination 
of myofibrillar adenosine triphosphatase activity. This technique allows for the classification of  
muscle fibers in three distinct groups:  (a) slow fibers or type I, highly fatigue resistant, (b) fast 
 fibers or type II, specifically type IIa or intermediate, and (c) fast fibers or type IIb or high 
anaerobic capacity fibers [243,315,316]. Histologic changes in skeletal muscle in unilateral  
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peripheral arterial disease patients were examined by Regensteiner et al., [243]. Their findings 
indicated muscle fiber atrophy and decrease of the type II fiber cross-sectional area. Thus, the 
histologic changes of muscles, especially type II fiber atrophy, may contribute to the reduced 
exercise performance in peripheral arterial disease patients. However, there are other studies that 
report no clear difference in fiber distribution and in diameter between diseased and non-
diseased legs of patients with unilateral peripheral arterial disease [317,318]. One reason for 
these conflicting results may be the heterogeneity of the muscle fiber composition. Furthermore, 
muscle fibers are composed of a series of contractile proteins that have different molecular and 
biochemical characteristics [319].  It means that more than one single myosin heavy chain 
isoform may exist in a single fiber [320].  
 These myosin isoforms determine muscle fiber type and also reflect the functional state 
of the ischemic muscle in peripheral arterial disease patients. The main myosin heavy chain 
isoform of a slow fiber is the myosin heavy chain I, the fast fiber IIb mainly consists of myosin 
heavy chain IIb, and the intermediate (IIa) contains mainly myosin heavy chain IIa. However, 
Jaschinski et al., [321] have reported that in a single fiber different myosin heavy chain isoforms 
exist; (a) a fiber I may be found in myosin heavy chain I and IIa; and (b) a fast fiber IIb may be 
found myosin heavy chain IIa and IIb.  
 In that regard, Steinacker et al., [316] investigated for the first time, the expression of 
myosin heavy chain isoforms in skeletal muscle of peripheral arterial disease patients. They 
findings indicate a relative decrease of myosin heavy chain IIb and increase of myosin heavy 
chain I, followed by a decrease of myosin heavy chain IIa with progressive ischemia (see figure 
2.4). In addition, McGuigan et al., [315] have reported a significant reduction in myosin heavy 
chain I isoforms in peripheral arterial disease patients compared with healthy individuals. The 
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same study using the myofibrillar adenosine triphosphatase activity technique reported a 
significantly reduced percentage of type I fibers and significantly increased percentage of type 
IIa fibers. These investigators concluded that the conversion of type I (oxidative) to type II (non-
oxidative) fibers limits the endurance capacity of peripheral arterial disease patients.  
 
 
  Figure 2.4. MHC isoform distribution between control patients and patients with PAOD   
  with clinical stage II, III, IV. In comparison with control patients, there was no change  
  of MHC isoforms in patients with PAOD II, but there was a significant decrease of  
  MHC IIb in PAOD III and IIa and of IIb in PAOD IV. MHC, Myosin heavy chain;   
  PAOD, Peripheral arterial obstructive disease [316].  
 
 2.3.7.2.2 Capillary Density 
Studies in individuals free of disease indicate that capillary density is directionally 
correlated with the oxidative capacity and endurance of a muscle group [322]. Patients with 
peripheral arterial disease exhibit significant skeletal muscle abnormalities compared with  
healthy controls [323]. Ironically, despite having a reduced aerobic capacity, the skeletal muscle 
capillary density appears to be increased in patients with peripheral arterial disease, and the 
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relative increase in vascular density appears to be proportional to the extent of skeletal muscle 
hypoxia [323,324]. This response could be viewed as a potentially beneficial adaptation and an 
attempt to compensate for the atherosclerotic lesions limiting blood flow upstream.  
 2.3.7.2.3 Metabolic Enzyme Activity  
The literature appears to be quite clear in that patients with peripheral arterial disease up-
regulate skeletal muscle oxidative enzyme activity. It is believed the upregulation of skeletal 
muscle oxidative enzyme activity in peripheral arterial disease patients is an adaptive response to 
the reduced skeletal muscle blood flow [307,325]. Several studies have reported an increase in 
the oxidative enzymes, citrate synthase and cytochrome oxidase in the calf muscles of peripheral 
arterial disease patients [311,313,325]. The upregulation of oxidative enzymes is further 
enhanced in claudicant patients who exercise regularly, suggesting the combination of hypoxia 
and physical activity in stimulating enzyme activity. Interestingly, the histological and 
biochemical features of skeletal muscle of peripheral arterial disease patients are not too 
dissimilar from those seen in athletes [317]. However, studies using electron microscopy have 
identified structural abnormalities in lower limb muscle mitochondria of peripheral arterial 
disease patients [326]. For instance, Kemp et al., [327] reported that peripheral arterial disease 
patients have twice the requirement for adenosine triphosphate than control subjects at the same 
workload. This metabolic imbalance or reduced metabolic efficiency may provide yet another 
glimpse into the mechanisms for the reduced functional ability seen in these patients. It appears 
part of the problem resides with alterations in fat metabolism as evidenced by studies showing an 
accumulation of acylcarnitine in claudicants [328]. The inability to move acylcarnitines across 
the mitochondrial membranes may have significant consequences on overall muscle function 
[329]. Finally, Hands et al., [330] have reported that peripheral arterial disease patients have 
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slower recovery of high-energy phosphate substrate in the muscles which lead to a poorer 
tolerance of exercise and a prolonged recovery time. 
 2.3.7.2.4 Muscle Metabolism  
Muscle contraction depends on a continuous supply of energy. The adenosine 
triphosphate-creatine system supplies energy only for short periods of time. The more efficient 
way to produce adenosine triphosphate is through aerobic synthesis of adenosine triphosphate, 
fueled by glucose and free fatty acids as the major substrates. However, when the oxygen supply 
is limited, the anaerobic system will take command. In doing that, pyruvate is converted to lactic 
acid rather that Acetyl-Coenzyme A. Resting conditions or light intensity activities utilize free 
fatty acids as the main source of energy (β oxidation). If the intensity of the activity increases, 
glycolysis will be activated using glucose as a substrate. Although the oxidation of free fatty 
acids provides more adenosine triphosphate than glucose, the amount of oxygen required for 
fatty acid metabolism is higher.  
In patients with peripheral arterial disease any increase in activity levels would cause an 
inequality between the oxygen supply and the demand. As a result, aerobic generation of 
adenosine triphosphate becomes inadequate, and it forces anaerobic metabolism that increases 
lactic acid production [331]. The ischemic muscle during exercise produces high levels of 
inorganic phosphate as a consequence of a high rate of adenosine triphosphate and 
phosphocreatine breakdown. Hence, the ratio of inorganic phosphates to phosphocreatine 
increases to a greater extent than in the normoperfused muscle. It results in a higher reliance of 
glycolytic metabolism to obtain the energy needed [290]. Kemp et al., [327] using 31P magnetic 
resonance spectroscopy, found an increased accumulation of lactate and depletion of cellular 
adenosine triphosphate during exercise in claudicants compared with normal subjects.  
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The reduced vascular perfusion would be responsible for the reduction of adenosine 
triphosphate synthesis. As a result, both the oxygen delivery (reduced mitochondrial oxidation) 
and the washout of toxic metabolites from the skeletal muscle would be impaired [290]. Patients 
with claudication have been shown to accumulate acetylcarnitine (thus reflecting Acetyl-
Coenzyme A accumulation) and lactate (as a consequence of pyruvate dehydrogenase 
inhibition). Interestingly, Hiatt et al., [332] found that there is an inverse correlation between 
both plasma and muscle levels of acetylcarnitine and subsequent assessments of peak exercise 
performance.  
These findings were corroborated by the same Hiatt in a later study showing that 
peripheral arterial disease patients exhibit an accumulation of lactate and intermediates of 
oxidative metabolism (short-chain acylcarnitines) in skeletal muscle at rest [328]. These results 
strongly suggest that in patients with intermittent claudication, altered carnitine metabolism may 
be associated with the altered muscle energy metabolism. Furthermore, a study by Brevetti [333]  
reported that patients with peripheral arterial disease with mild functional impairment have low 
resting plasma levels of acetylcarnitine that normally increase with exercise, while the most 
affected patients have elevated resting levels of acetylcarnitine and do not form these esters with 
exercise. The plasma concentration of acetylcarnitine depends not only on the rate of formation 
of Acetyl-Coenzyme A but also on the availability of carnitine to remove it from the 
mitochondria pool.  
Therefore, it is possible to assume that in peripheral arterial disease patients with 
moderate to severe claudication, the overutilization of carnitine at rest (as reflect by the elevated 
levels of acetylcarnitine) results in carnitine insufficiency. This condition would prevent to 
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provide sufficient carnitine to meet the increased metabolic demand induced by walking in 
peripheral arterial disease [290]. In fact, these patients after carnitine supplementation showed an 
increase in plasma acetylcarnitine as opposed to the decrease observed before treatment [333].  
 2.3.7.2.5 Oxygen Delivery to the Tissue  
Normally, oxygen passes to the tissue via the capillaries. However, blood entering 
capillaries is only 50% saturated [334], thus implying that one-half of oxygen gathered by the 
lungs exits the circulation prior to arriving to the capillaries. Possible sinks for oxygen exiting 
before the capillaries include oxygen shunting from arterioles to parallel venules, arteriolar-
capillary oxygen diffusional shunting and periarteriolar tissue consumption.  
Those observations were first reported by Duling and Berne [334]; they found that 
significant amounts of oxygen exit the arteriolar network. Intaglietta et al., [335] using the 
phosphorescence decay technology was able to evaluate the longitudinal vessel pO2 gradients (or 
blood oxygen saturation gradients) and the perivascular pO2 tissue gradients that most likely 
determine the rate of oxygen exit from blood vessels. Their results confirm that a major portion 
of blood oxygen is delivered to the tissue by the arterioles.   
In addition, Curtis et al., [336] reported that when endothelium is removed from the dog 
hind limb, oxygen consumption decreases by 34%. In fact, endothelium is capable of metabolic 
activity which can be 100-fold that of other cells [337]. The endothelium is responsible for the 
synthesis and secretion of many vasoactive products (e.g. renin, prostaglandins, collagen, nitric 
oxide, endothelin, and prostacyclin). Moreover, endothelial cells have an active actin/myosin-
based contractile system that also may consume oxygen [338].  
Therefore, the metabolic stress induced by ischemia would result in more oxygen 
consumed by the endothelium and less becomes available to the metabolic requirements of the 
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muscle. Finally, this pathophysiologic mechanism could contribute to the alteration of oxidative 
machinery occurring in the skeletal muscle of patients with peripheral arterial disease. 
2.3.7.3 Summary of Compensatory Adaptations in Peripheral Arterial Disease 
In patients with peripheral arterial disease the vascular compensatory mechanism deals 
more with an initial compensatory dilation and enlargement of the vessel at the site of active 
atherosclerosis. It is due to neurogenic or metabolic relaxation of the smooth muscle surrounding 
the blood vessels. Next, the opening of collateral vessels would try to normalize the blood 
supply. The growth of these collateral vessels follows the principles of both acute (neurogenic) 
and long-term (metabolic) blood flow control. Alterations in skeletal muscle include (a) selective 
loss of type II fibers relative to type I fibers, (b) up-regulation of the oxidative enzyme activity, 
and (c) increased capillary density. However, these changes seem to be proportional to the extent 
of skeletal muscle hypoxia.    
2.3.8 The Role of Exercise in Peripheral Arterial Disease                                                    
 2.3.8.1 The Acute Exercise Response in Peripheral Arterial Disease                         
 Usually, peripheral arterial disease patients with intermittent claudication do not exhibit 
signs or symptoms of their disease at rest. It is not until a physiologic stress, such as exercise, is 
introduced that they develop pain (claudication) due the insufficient blood flow able to reach the 
muscles. Therefore, the purpose of this section is to review the effects of a single bout of 
exercise on patients with peripheral arterial disease. In particular, this review will focus on: (a) 
the vascular responses and (b) the skeletal muscle responses.                                     
  2.3.8.1.1 Vascular Responses to an Acute Bout of Exercise                                
 The change in blood flow upon the transition from rest to exercise in a normal healthy 
individual is regulated by multiple and redundant mechanisms, such as mechanical and/or non- 
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mechanical factors. The major factor that contributes to the initial blood flow change is the 
muscle pump set up by the contracting musculature that moves blood into the veins and away 
from the skeletal muscle. This is followed by a drop in pressure and an actual rapid inflow of 
blood in between contractions. This phenomena is known as exercise hyperemia. The more 
gradual rise in flow appears to be determined by the influence of metabolic and perhaps 
endothelial factors. Interestingly, there are no studies which have examined the flow responses in 
peripheral arterial disease patients. Given the stated changes in the vasculature and muscle mass 
it is hypothesized that the blood flow transition is in part compromised and more than likely 
cannot reach the same height for a given work load secondary to the blockage.                   
 Therefore, it appears that most peripheral arterial disease patients with intermittent 
claudication have relatively normal resting lower limb blood flow, and blood flow could increase 
with exercise [339]. However, as exercise continues, arterial occlusions restrict further increases 
in blood flow, and consequently oxygen delivery reaches a plateau [339]. The primary effect of 
patients with peripheral arterial disease during a single bout of exercise is the development of 
claudication pain in the lower extremity musculature due to the insufficient blood flow.  
 Interestingly, the ankle brachial index is reduced following an exercise session because 
blood flow is shunted into the proximal leg musculature at the expense of the periphery and 
distal areas of the leg [217]. In addition, Bauer et al., [340] have reported that the oxygen 
consumption (VO2) kinetics at the onset of exercise are markedly slowed in patients with 
peripheral arterial disease compared with control subjects. These investigators concluded that the 
impaired VO2 kinetic responses in peripheral arterial disease patients appeared to be related to 
the presence of vascular disease. Finally, the same investigators stated that further research is 
needed to assess whether peripheral flow limitations or changes in the regulation of skeletal 
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muscle oxidative function, or both, are responsible for the observed response in patients with 
peripheral arterial disease.                                                                                                                         
  2.3.8.1.2 Skeletal Muscle Responses to an Acute Bout of Exercise           
 Peripheral arterial disease leads to insufficient blood supply to the involved muscle, 
which is especially aggravated during exercise, inducing an imbalance between supply and 
demand to active muscles. Hemodynamic measures are poor predictors of symptom-limited 
capacity despite the major role of decreased arterial blood flow in limiting exercise performance 
[341]. Therefore, it indicates that alterations in skeletal muscle fibers may play an important role 
in exercise capacity among patients with peripheral arterial disease. Next, this section will 
review the major modification in skeletal muscle metabolism. Previous studies have shown that 
peripheral arterial disease have alterations in the regulation of oxidative adenosine triphosphate  
generation, abnormalities of electron transport chain enzyme activities, and an accumulation of  
short-chain acylcarnitines in affected skeletal muscle [328,342].                                                
 The inherent delay to increase muscle oxidative metabolism in the face of increasing 
adenosine triphosphate requirements has been termed “metabolic inertia,” and has been 
hypothesized to be an important physiologic characteristic of the exercise response [343,344]. 
Indeed, it has been reported that contrary to the up-regulation of oxidative enzymes seen in 
patients with peripheral arterial disease, these enzymes exhibit a low activity due to structural 
abnormalities [345]. Thus, these modifications would limit the exercise tolerance in peripheral 
arterial disease patients.                                                                                                
  2.3.8.1.3 Summary of the Acute Exercise Response in Peripheral Arterial Disease 
 Peripheral arterial disease patients showed interplay between the metabolic and 
hemodynamic factors that may contribute to the exercise impairment. The exercise performance 
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of peripheral arterial disease is reduced because of the onset of claudication leg pain. Impaired 
endothelial function is one mechanism that plays a role in limiting exercise capacity in patients 
with peripheral arterial disease. The increase in capillary density among patients with peripheral 
arterial disease may follow the metabolic hypothesis by Adair et al., [346] who suggest that the 
blood vascular system adapts its structure to meet the maximum oxygen needs of the tissue cells 
rather that the average tissue requirements. Muscle performance is compromised in patients with 
peripheral arterial disease because of alterations in fiber type composition that limits the 
endurance capacity of the muscle. The hypothesized mitochondrial dysfunction may result in less 
efficient use of the extracted oxygen (less ATP per oxygen) and an accumulation of 
intermediates that further disrupt metabolism. This means oxidative ‘capacity’ may be preserved 
while mitochondria function under the non-optimal conditions resulting from the functional 
abnormality.  
 2.3.8.2 The Response to Exercise Training in Peripheral Arterial Disease                      
 Many prospective studies have demonstrated the benefits of exercise training in 
peripheral arterial disease patients with intermittent claudication. The first randomized, 
controlled trial of exercise training in persons with intermittent claudication demonstrated a 
marked improvement in treadmill walking ability [347]. A meta-analyses [348] that examined 
both nonrandomized and randomized trials showed that exercise training improved pain-free 
walking time by an average of 180% and improved maximal walking time by an average of 
120%.  
 Furthermore, a meta-analyses from the Cochrane Collaboration [349] that considered 
only randomized, controlled trials concluded that exercise improved maximal walking distance 
time by an average of 150%. Many trials have demonstrated the efficacy of walking 
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rehabilitation compared to placebo, those outcomes reported an increase in pain-free and 
maximal treadmill walking duration [347,350,351]. In addition, the improvement in walking 
ability results in improvement in routine daily activities [352]. Regensteiner et al., [353] found 
an improved capacity to perform routine daily activities after exercise training. Exercise training 
has been shown to significantly improve (a) the onset of leg discomfort, or initial claudication 
distance, and (b) the point at which the pain becomes unbearable, forcing the patient to stop 
walking, or absolute claudication distance [354,355].                                                                               
  Patients participating in a supervised, structured exercise program had a 180% increase 
in initial claudication distance, compared with a 40% increase in control groups [348]. On the 
other hand, unsupervised exercise rehabilitation programs, often referred to as home programs, 
have been carried out in addition to supervised ones. The majority of those called “home 
programs”, have produced a more modest benefit or even have had a lack of benefit compared to 
a supervised program. A recent meta-analysis by Degischer et al., [356] has reported a lack of 
significant benefit from these programs. However, Wullink et al., [357] have suggested that a 
home program with structured coaching might lead to exercise improvement. These findings 
suggest that exercise training programs have a clinically important impact on functional capacity 
among patients with peripheral arterial disease. Therefore, exercise training is one of the most 
effective interventions available for the treatment of claudication as a result of peripheral arterial 
disease. Despite its demonstrated effectiveness, supervised exercise rehabilitation has several 
limitations, most notably the lack of available programs.  
 Recently, the Centers for Medicare and Medicaid Services have established a current 
procedural terminology code for exercise rehabilitation in patients with peripheral arterial 
disease (CPT 93668) [358]. Finally, despite numerous studies demonstrating the benefits of a 
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supervised exercise program for treatment of claudication [359], there is a paucity of data on the 
durability of results. Menard et al., [360] showed that continuation of an exercise program either 
supervised or at home, is necessary for maintenance of the positive effects in the treatment of 
intermittent claudication. In addition, patients who continue to exercise maintain a higher health-
related quality of life and greater daily functional status than do those who discontinue training.  
  2.3.8.2.1 Vascular Responses to Exercise Training in Peripheral Arterial Disease  
    2.3.8.2.1.1 Blood Flow                                                                      
 Evidence from the literature suggests that an increase in the blood flow to the lower 
extremity is uncommon [325,350,361-363]. The inability to increase lower limb blood leads to 
exercise induced pain because the muscle’s metabolic demands exceed the body’s capacity to 
deliver the needed energy substrate. It has been suggested that exercise in patients with 
peripheral arterial disease improves maximal walking distance due to an absolute increase in 
blood flow, possibly secondary to the growth of a collateral circulation. Studies on dogs [364] 
with ligated femoral arteries have shown an increase in blood flow to the lower limbs after the 
training intervention. However, many studies have shown that exercise training in patients with 
intermittent claudication does not significantly improve leg blood flow [339,350,365,366].   
Furthermore, a study by Gardner and Poehlman [348] found that the increase in lower limb blood 
flow was small while exercise tolerance increased by over 100%. Tan et al., [367] reported that 
exercise training improved exercise tolerance significantly without any increase in femoral blood 
flow.  
 Finally, an increase in collateral vessel formation in relation to the leg muscle has been a 
postulated mechanism for improvement in intermittent claudication symptoms after exercise. 
Although, animal models of occlusive arterial disease [368-370] have shown that exercise 
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training may also cause redistribution of blood flow from inactive to active muscles, that 
response has not been evaluated widely in humans. One study showed that maximal calf blood 
flow increased modestly with exercise, but this small improvement was not related with the 
improvement in exercise intolerance [350]. Other studies have also varied results in terms of 
whether leg blood flow increased or not and whether any increase observed was correlated to 
improved walking ability resulting from exercise training [325,366].  
 In addition, the role of angiogenesis in improving walking ability after exercise 
rehabilitation has not been well investigated in patients with peripheral arterial disease. The 
mechanisms underlying endogenous angiogenesis are complex, possible pro-angiogenic stimuli 
include reductions in oxygen tension or related metabolic alterations in the muscle, and increased 
blood flow and muscle contraction [371]. In that regard, in healthy subjects, a single session of 
exercise increased vascular endothelial growth factor mRNA expression in calf muscle [371].  
However, that response has not been studied in patients with peripheral arterial disease. In 
addition, the finding of increased vascular endothelial growth factor mRNA expression during a 
bout of exercise suggests that vascular endothelial growth factor may be related to angiogenesis 
[372]. Furthermore, that increase was related in a dose-dependent fashion to the degree of 
metabolic stress [372].  
 Exercise training may be associated with transient hypoxia in the lower extremity which 
would up-regulate vascular endothelial growth factor mRNA protein expression potentially 
enhancing endogenous angiogenesis. In fact, Gustafsson et al., [373] have reported similar 
finding for patients with heart failure. However, content of basic fibroblast growth factor, 
another important angiogenic growth factor, does not seem to be altered in response to muscle 
activity in hypoxic skeletal muscle [374,375]. In conclusion, the current evidence does not 
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support the hypothesis that an increase in blood flow is a major mechanism to improve exercise 
tolerance in patients with peripheral arterial disease.  
 Therefore, other mechanisms must play a role in the substantial improvements in function 
and symptoms that occur in these patients when they receive exercise training. Therefore, it 
would appear that there is not sufficient evidence to suggest that muscle blood flow is positively 
affected.                                                
   2.3.8.2.1.2 Vascular Endothelial Function                                                              
 Patients with peripheral arterial disease have impaired endothelial-dependent vasodilation 
[292]. Indeed, Brendle et al., [376] found that endothelial-dependent vasodilation, ambulatory 
function, and calf blood flow significantly improved after a 6 month exercise rehabilitation 
program. Furthermore, arterial flow-dependent dilation is mediated by the endothelial release of 
nitric oxide, which is increased with exercise training and may improve walking ability in 
patients with intermittent claudication [377,378]. Therefore, it would appear that there is not 
sufficient evidence to suggest that endothelial function is positively affected with training.  
   2.3.8.2.1.3 Blood Viscosity                                                                 
 Patients with peripheral arterial disease have a high incidence of abnormal blood 
rheology [379]. The study by Pararajasingam et al., [379] showed that peripheral arterial disease 
had a plasma viscosity in excess of the upper limit of normal (1.72). Exercise training in normal 
subjects leads to a reduction in plasma viscosity [380] and a decrease in packed cell volume 
[381]. The decrease in packed cell volume could lead to a reduction in blood viscosity and 
improvement in blood flow. Studies in peripheral arterial disease patients have reported no 
significant changes in the blood rheology after training [367,382]. Therefore, it would appear 
that there is not sufficient evidence to suggest that blood viscosity is positively affected.  
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  2.3.8.2.2 Skeletal Muscle Responses to Exercise Training in Peripheral Arterial  
  Disease  
 
    2.3.8.2.2.1 Skeletal Muscle Metabolism and Oxygen Extraction      
 Elevated plasma acylcarnitine levels at rest have been associated with the functional 
impairment in patients with peripheral arterial disease [332]. Additionally, exercise to 
claudication pain has been associated with an increase in the plasma concentration of 
acylcarnitines, which may reflect the disordered metabolic state of ischemic muscle [383]. 
Muscle oxidative metabolism in patients with peripheral arterial disease favors the accumulation 
of acylcarnitines. A controlled, randomized trial conducted by Hiatt et al., [350] reported that a 
12-week exercise training program for patients with peripheral arterial disease increased peak 
exercise performance in all treated subjects, delayed the onset and progression of claudication 
pain during exercise, and improved community-based walking ability.                                          
 These investigators also reported that the improvement in performance was correlated 
with a change in carnitine metabolism (an index of cellular metabolism) and not to a change in 
blood flow. In addition, the same investigators reported that after 12 weeks of training, there 
were further increases in exercise performance determined from the training sessions and from 
treadmill testing. At this point in time, treated subjects had an increase in peak oxygen 
consumption possibly reflecting either an increase in muscle oxygen delivery or an improvement 
in muscle oxidative metabolism [350]. The same Hiatt et al., [311] reported that 12 weeks of 
treadmill training increased peak exercise performance in peripheral arterial disease patients. 
Although this study did not find the "classic" mitochondrial training response (increase in citrate 
synthase activity), the results confirm the relationship between skeletal muscle acylcarnitine 
content and function in peripheral arterial disease, demonstrating that the response to treadmill 
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training was associated with parallel improvements in intermediary metabolism. In addition, 
studies have been reported that exercise training in patients with peripheral arterial disease leads 
to lower lactic acid concentration than was recorded before training [351,384,385]. Many studies 
have reported an improvement in oxygen extraction in patients with peripheral arterial disease 
[311,347,350].                                                                                                                       
 Exercise training is associated with an increase in muscle mitochondrial content [386], 
and the increase in mitochondrial content correlates with the increase in oxidative exercise 
capacity [387]. On the other hand, detraining or sedentary behaviors are associated with a 
decrease in muscle mitochondrial content [388]. Peripheral arterial disease leads to a limitation 
in physical activity, and an increasingly sedentary lifestyle. This level of physical activity might 
be considered analogous to detraining, and thus would be predicted to be associated with a 
decrease in mitochondrial enzyme activities. However, earliest observations have reported that 
the expression and activity of several mitochondrial enzymes are increased in skeletal muscle 
from limbs in patients with peripheral arterial disease [389]. Furthermore, the same findings have 
been reported in recent studies that showed an increased mitochondrial content in the muscle of 
patients with peripheral arterial disease [307,311,325]. This increased mitochondrial expression 
appears to be a direct consequence of, and is proportionate to, the severity of the occlusive 
disease. For instance, Jansson et al., [307] reported that bilateral gastrocnemius biopsies from 
patients with peripheral arterial disease primarily in one leg demonstrate increased enzyme 
activities in the limb with significant hemodynamic changes when compared with the less-
affected limb.  
 One could assume that the increased mitochondrial expression could be understood in the 
context of compensation for impaired oxygen delivery [307]; it also suggested that the metabolic 
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signals leading to this enhanced expression may represent important factors in peripheral arterial 
disease pathophysiology.                                                                                                       
 Although peripheral arterial disease is associated with increased mitochondrial content, 
the regulation of mitochondrial enzyme activity may also differ from that in control subjects. In 
fact, exercise training is a strong stimulus for mitochondrial proliferation in normal subjects. 
However, exercise training in patients with peripheral arterial disease has not been uniformly 
associated with enhanced mitochondrial activity. Indeed, some studies have documented 
increased mitochondrial enzyme activities with training in peripheral arterial disease [325,363] 
with others showing no increase despite achieving a systemic training response [311].                
 This suggests that the regulation of mitochondrial expression in peripheral arterial disease 
may be under a different series of control factors compared with normal subjects. Despite the 
limitation in oxygen delivery, changes intrinsic to the skeletal muscle might also contribute to 
metabolic dysfunction. These findings support the concept that patients with peripheral arterial 
disease develop a mitochondrial myopathy [390]. Finally, mitochondria in chronically ischemic 
muscle have abnormal ultrastructure [391], extensively damaged DNA [392], altered expression 
and activities of enzymes, and abnormally high intermediates of oxidative metabolism [273,332]. 
   2.3.8.2.2.2 Skeletal Muscle Enzymatic Changes                                              
 Using muscle biopsies, before and after training, allowed the study of possible enzymatic 
changes in peripheral arterial disease. In that regard, Lundgren et al., [393] have reported 
significant increases in the levels of oxidative enzymes such as cytochrome oxidase and succinic 
oxidase, with a very small rise in citrate synthase. The same study found that patients with a low 
level of cytochrome oxidase (compared with normal) before training have a markedly improved 
level on completion of an exercise [393].  
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 Perhaps, the low enzyme activity before training may result from reduced physical 
activity, muscle fiber depletion or mitochondrial damage secondary to ischemia. These findings 
would suggest that exercise training may reverse the low oxidative capacity of the muscle in 
peripheral arterial disease patients.                                       
  2.3.8.2.3 Summary of the Response to Exercise Training in Peripheral Arterial  
  Disease  
 
 Although there is little doubt that an exercise program is an invaluable first line of 
treatment for patients with peripheral arterial disease, the mechanisms of improvement in 
claudication symptoms with exercise are not well understood. The physiological, metabolic, and 
mechanical alteration produced by the exercise intervention presumably stimulates an adaptive 
response that may reduce claudication symptoms.  
 Some of the proposed mechanisms for an increase in exercise tolerance include: increase 
in leg blood flow, more favorable distribution of blood flow, improved hemorheological and 
fibrinolytic properties of blood (e.g. reduced viscosity), greater reliance upon aerobic metabolism 
because of a higher concentration of oxidative enzymes, less reliance upon anaerobic 
metabolism, an improvement in the efficiency of walking economy and oxygen uptake kinetics, 
increased free-living daily energy expenditure.   
 One set of mechanisms that is currently receiving attention is the role of blood flow and 
associated factors. There is the possibility that angiogenesis, adaptations in peripheral blood flow 
or changes in blood flow distribution may be a cause of improvement in walking after exercise 
rehabilitation [371,372]. The role of angiogenesis in improving walking ability after exercise 
rehabilitation has not been well investigated in patients with peripheral arterial disease and 
provides an exciting possibility. Although animal models of occlusive arterial disease have 
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shown that exercise training enhances collateral-dependent blood flow to the hind-limb muscles 
[369], studies of that nature are limited in humans.                                                                                                                                      
2.4 Protection vs. Optimization                                                                                                 
 The conditions so far, heart failure and peripheral arterial disease, have a common 
underlying problem of reduced muscle blood flow and subsequent exercise intolerance. 
However, the manner in which the body responds to the reduced blood flow is remarkably 
different and warrants careful consideration. This review has outlined in great detail the different 
physiological and morphological compensatory adaptations for both conditions. It is very 
important that we understand these compensatory adaptations properly in order to provide the 
most effective exercise prescription and avoid just prescribing a generic recommendation for 
exercise that cannot be as effective.                                                                                        
 The main purpose of this next section is to compare heart failure and peripheral arterial 
disease in regard to the different pathophysiologic pathways to a common problem, the reduction 
of blood flow to skeletal muscle. In doing so, this section of this review includes: (a) differential 
adaptation to reduced blood flow, (b) indication for protection and optimization, (c) the 
underlying mechanisms, and (d) the implication of an exercise program. 
2.4.1 Differential Adaptation to Reduced Blood Flow                                                                       
 In the early stages of both diseases, the majority of patients are able to still perform 
normal daily activities. However, the symptoms and signs are more evident when these patients 
are exposed to stressful conditions, such as physical activity. Heart failure, as defined previously, 
is a syndrome in which cardiac output is insufficient to meet metabolic demands. Although the 
natural history of heart failure is punctuated by occasional episodes of acute decompensation 
with overt systemic volume overload and pulmonary edema, the primary chronic symptoms in 
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patients with heart failure are exertional fatigue and dyspnea. These symptoms are the primary 
determinants of their health-related quality of life. Heart failure is characterized by a series of 
compensatory mechanisms designed to maintain cardiac output and arterial pressure at a level 
compatible with life.  
The cardiac compensatory changes include (a) ventricular dilation to stretch the 
sarcomeres (fast adaptation); (b) ventricular hypertrophy (slow adaptation) and aim to preserve 
cardiac output. The circulatory changes include (a) autonomic nervous system activation (fast 
adaptation); (b) humoral activation (intermediate to slow adaptation); (c) impaired vascular 
responsiveness (slow adaptation), and aim to maintain blood pressure. Alterations in skeletal 
muscle include (a) skeletal muscle atrophy (slow adaptation) and (b) impaired oxidative 
metabolism (slow adaptation). Although speculative, it is thought that those mechanisms with an 
intermediate to long-time constant eventually contribute to the severe clinical manifestations.  
In contrast, peripheral arterial disease results from atherosclerotic occlusion that impairs 
perfusion to the lower extremity. The two major clinical presentations of peripheral arterial 
disease are intermittent claudication and critical limb ischemia. Normally, in patients with 
intermittent claudication, arterial occlusive disease is manifested by insufficient blood flow 
during exercise. On the other hand, in patients with critical limb ischemia, blood flow is 
inadequate to meet the resting demands of the limb. Furthermore, peripheral arterial disease is 
characterized by a series of compensatory mechanisms designed to increase the peripheral blood 
flow. They include an initial compensatory dilation and enlargement of the vessel at the site of 
active atherosclerosis. These changes are thought to be due to neurogenic or metabolic relaxation 
of smooth muscle surrounding the blood vessels. Next, the opening of collateral vessels would 
try to normalize the blood supply. The growth of these collateral vessels follows the principles of 
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both acute (neurogenic) and long-term (metabolic) blood flow control. Alterations in skeletal 
muscle include: (a) selective loss of type II fibers relative to type I fibers, (b) up-regulation of the 
oxidative enzyme activity, and (c) increased capillary density. However, these changes seem to 
be proportional to the extent of skeletal muscle hypoxia.                                                            
2.4.2 Indication for Protection and Optimization                                                                             
 In terms of the heart failure condition, one can argue that the reduction in physical 
performance secondary to the compensatory changes is an effort to protect the organism from 
putting too much stress on a weakening organ. In other words, if the heart is failing, the body 
does not want to add an additional stress to cause the heart to fail even more. Thus, exercise 
intolerance in heart failure is a protective mechanism. Removal of these compensatory changes 
could therefore be disastrous. Therefore, the patient is dealing with a double-edged sword. By 
not being active the condition gradually worsens, by being potentially too active the patient will 
cause further harm. In contrast, patients with peripheral arterial disease also aim to protect 
themselves, but do so by optimizing blood flow and oxygen transport, in an effort to maintain 
functionality. However, in peripheral arterial disease exercise intolerance is also a protective 
mechanism, as the claudication pain with exercise is a warning signal that the tissue is 
underperfused and at risk for damage and deterioration.  
 Therefore, two interesting questions come to mind that are relevant to this review and my 
focus area. First, how does a muscle cell recognize that reduced blood flow is a consequence of a 
failing heart or a femoral lesion? Second, what are the clinical implications of these differential 
compensations, and how can this be addressed by the exercise physiologist?  
These are clearly challenging questions. In regards to the first, there certainly must be a 
series of mechanisms that need to be identified to help understand the phenomena. In addition, 
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there clearly must be interplay between organ systems to orchestrate such compensations, 
thereby re-establishing the importance of the integrative physiologist. There are probably many 
candidates that may help understand the compensations for heart failure. These include (a) the 
neurohormonal system and (b) an altered balance between catabolism and anabolism. Without a 
doubt the neuroendocrine milieu in heart failure is significantly altered, and in most cases 
hyperactive in comparison to controls.                                                                                             
 In heart failure, the impaired contraction and/or relaxation of the heart and disturbance of 
central hemodynamics activate compensatory mechanisms, including the neuroendocrine 
reaction, also called the neurohumoral response, which creates the self-perpetuating vicious 
circle of heart failure. The low blood pressure reflexly stimulates the adrenergic and renin-
angiotensin-aldosterone systems, with increased peripheral vascular resistance and afterload. 
Then, aldosterone excess promotes fluid retention, peripheral congestion and edema so that both 
the preload and afterload also increase. Among these neuroendocrine responses, the ergoreflex 
response is quite important in heart failure. In fact, these ergoreceptors, small myelinated and 
unmyelinated afferents of the skeletal muscle (group III and group IV afferents), play the role of 
a feedback control mechanism to maintain the homeostasis between muscle work and energy 
supply to perform it. Stimulated by the metabolic state of the muscle, the ergoreceptors monitor 
the effectiveness of the blood flow, and adjust the cardiocirculatory, ventilatory, and autonomic 
responses to meet the increased metabolic needs of the contracting muscle. In addition, it has 
been reported an enhanced activity of these receptors, which contribute to the excessive 
neuroendocrine response [84,92,142]. Some of the possible metabolic products of a discrepancy 
between blood flow and metabolism in the contracting muscle that have been shown to activate 
the muscle afferents are potassium [394], a decrease in pH [395], prostaglandins [396], and 
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blood flow itself [397]. This information is clear evidence of the role of the ergoreceptors as the 
muscle cell that is able to recognize the reduction of blood flow as result of a failing heart.                                                                                                       
 In contrast, these neuroendocrine changes are typically not observed in peripheral arterial 
disease. The main physiological cause for the manifestations of peripheral arterial disease is 
linked to the insufficient oxygen supply secondary to reduced blood flow. It seems that the 
candidate is the skeletal muscle itself. Many studies have reported that peripheral arterial disease 
is associated with a skeletal muscle metabolic myopathy [325,398]. In fact, patients with 
peripheral arterial disease with severe ischemia had the most defective oxidative function [399]. 
In addition, the combination of factors related to intensity and frequency of “ischemic insult,” 
and possibly the ischemia reperfusion associated with it, may be responsible for defective 
mitochondria [400]. The mitochondrial dysfunction may have two major negative consequences 
in patients with peripheral arterial disease; (a) peripheral arterial disease mitochondria do not 
have the capacity to produce as much adenosine triphosphate as normal skeletal muscle 
mitochondria do, (b) dysfunctional mitochondria are a source of abnormally high levels of 
reactive oxygen species, which may be independently injurious to the mechanisms that sustain 
normal cellular structure and function. The end result of this process is a significant decrease in 
energy production and a potentially increased level of destructive oxygen radicals in the skeletal 
myocytes of patients with peripheral arterial disease [401]. This evidence would suggest that 
independent of where the reduced blood flow is coming from, the major problem is the defective 
mitochondrial function as a pathophysiologic component of peripheral arterial disease.  
The next section will try to address the second question: what are the clinical implications 
of these differential compensations, and how can this be addressed by the exercise physiologist? 
In heart failure, these compensations are present in every step of the oxygen transport system, 
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from the center (the heart, lung, central neural control) to the periphery (circulation, 
neurohumoral status, reflexes, autonomic nervous system, and muscle metabolism). Therefore, 
the complete system is under permanent stress due to the compensatory responses that are trying 
to maintain function in these patients. As an exercise physiologist, it is important to have a better 
understanding of these modifications in order to provide the best and appropriate exercise 
program without producing further cardiovascular stress in these patients.     
 In contrast, in peripheral arterial disease, the greater compensations are in the periphery. 
These compensations are trying to optimize blood flow and oxygen transport in order to maintain 
and preserve function in these patients. The role of the exercise physiologist is also very 
important in patients with peripheral arterial disease. It is necessary to know these modifications 
in order to recognize how these patients will response to the different exercise activities. In 
summary, it is very important that we understand these compensatory adaptations in heart failure 
and peripheral arterial disease, to provide the best recommendation for exercise that fit the 
condition of these individuals.                                                                                                     
2.4.3 Underlying Signals and Mechanisms                                                                                   
 This section will attempt a discussion to further understand the underlying signals and 
mechanisms contributing to, and differentiating compensations between the disease states. The 
section will also attempt to present information regarding the underlying mechanisms of exercise 
intolerance in heart failure and peripheral arterial disease.                                                        
 Heart failure is characterized by general muscular weakness, muscle atrophy, and 
exercise intolerance that lead to reductions in functional capacity, ability to perform activities of 
daily living, and health-related quality of life [402]. The cardinal symptoms limiting exercise 
capacity in patients with heart failure are fatigue and/or dyspnea. The severity of exercise 
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intolerance can be quantified by a variety of methods, semi-quantitative assessments, such as 
interview (New York Heart Association classification) and surveys (Minnesota Living with 
Heart Failure or Kansas City Cardiomyopathy questionnaires), and quantitative methods, 
including timed walking tests (6-minute walk distance) and graded exercise treadmill or bicycle 
exercise tests. However, the cardiopulmonary exercise testing on a motorized treadmill or a 
bicycle ergometer provides the most accurate and reliable assessment of exercise tolerance [22]. 
 Normally, heart failure patients exhibit reduced peak exercise oxygen consumption when 
compared to normal individuals. Heart failure causes exercise-limiting changes in every step of 
the oxygen transport system, from the center (the heart, lung, central neural control) to the 
periphery (circulation, neurohumoral status, reflexes, autonomic nervous systems, and muscle 
metabolism). The assessment of peak oxygen consumption gives insight into the 
pathophysiology of exercise intolerance. Exercise intolerance will be closely related to one or 
both of the parameters that influence peak oxygen consumption (i.e. cardiac output and 
arteriovenous oxygen (a-vO2) difference). Indeed, it has been shown that fatigue arises from the 
impaired cardiac pumping capacity delivering inadequate amounts of oxygen, leading to a 
buildup of products of anaerobic metabolism within the exercising muscle [142]. The association 
of heart failure and muscular function might propose that a reduction of blood flow to exercising 
skeletal muscle would cause a demand-perfusion mismatch, leading to the symptoms and 
reduced exercise capacity. In fact, patients with severe heart failure distribute only approximately 
50% to 60% of total cardiac output to the exercising skeletal muscles, compared with 
approximately 90% of total cardiac output in healthy individuals [151].                              
 However, in patients with more established heart failure, the major determinants of 
diminished work capacity appear to be reduced skeletal muscle perfusion during exercise and 
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alteration in skeletal muscle histology and biochemistry. In these patients, reduced exercise 
capacity cannot be explained by clinical measures of heart failure (e.g. left ventricular ejection 
fraction) [173]. In fact, improvement of cardiac output with an infusion of dobutamine improves 
the femoral vein flow of patients with heart failure, but does not alter muscle performance [403]. 
These results suggest that nutrient delivery to skeletal muscle may not simply equate to total 
blood flow, and abnormal nutrient delivery may be caused by maldistribution of blood during 
exercise. Muscle metabolism and contractile performance correlate with the extent of nutritive 
flow and inversely with non-nutritive flow [404]. In addition, alterations in the regulation of 
vascular activity by the sympathetic nervous system and increased noradrenaline may contribute 
to abnormal nutritive delivery [142]. Therefore, the problem appears to reside in the periphery. 
Indeed, the problem may be secondary to the inability to shunt blood to the working muscle, to 
distribute the blood within muscle, or to utilize the available oxygen. A recently proposed 
hypothesis argues that peripheral skeletal muscle is the source of the signals which disrupt 
normal patterns of cardiorespiratory control [141]. This hypothesis is known as the muscle 
hypothesis.                                                                                                                                       
 In patients with heart failure the neurohormonal activation and the altered balance 
between catabolism and anabolism (in favor of catabolism) contribute to disease progression and 
the transition from non-wasted heart failure to cardiac cachexia [309]. In addition, the ergoreflex 
(a peripheral reflex originating in skeletal muscle sensitive to products of muscle work) is 
overactive in heart failure patients and contributes significantly to impaired exercise tolerance 
[405]. Indeed, a clear association exists between symptom severity, New York Heart Association 
functional class, muscle wasting, [309] and ergoreflex overactivity [406]. In addition, a recent 
study by Piepoli et al., [152] has reported: (a) a significant association between peripheral muscle 
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wasting and enhanced muscle reflex, (b) a strong relationship between more advanced cardiac 
cachexia and muscle reflex overactivity, which is consistent with the concept that syndrome 
progression is related to peripheral maladaptive changes in the muscles, and (c) the ergoreflex 
assessment in 1 limb (arm) is associated with lean tissue loss measured in a different limb (leg), 
consistent with a systemic activation of the muscle reflex system in heart failure patients. These 
authors concluded that the downward spiral of dysregulation in exercising skeletal muscle 
suggested by the muscle hypothesis is similar to the larger picture of other vicious cycles in heart 
failure in which the physiological responses initially appear adaptive but turn maladaptive over 
time.                                                                 
 In contrast, patients with peripheral arterial disease suffer exercise-induced limb pain, or 
claudication. Indeed, claudication is associated with significant functional disability and 
impairment of quality of life. Claudication typically limits maximal walking capacity to 
approximately 50% of that in age-matched controls [332]. As a result peripheral arterial disease 
patients face inability to perform a variety of occupational and recreational physical activities. 
Despite the clear role of decreased arterial flow in claudication, hemodynamic limitations in the 
limb are poor predictors of the degree of claudication-associated impairment [331,341]. 
Furthermore, invasive revascularization does not completely normalize exercise performance 
[407], and interventions such as exercise rehabilitation (which do not alter hemodynamics) have 
established efficacy [350]. Therefore, one could suggest that additional factors distal to the 
arterial obstruction may contribute to the pathophysiologic pathway seen in patients with 
peripheral arterial disease.                                                                                                 
 Many investigators have reported evidence that peripheral arterial disease is associated 
with a skeletal muscle metabolic myopathy [325,326,342,408-410]. Their findings suggest that 
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in addition to reduced oxygen supply, suboptimal energy production from defective 
mitochondria may be a factor in peripheral arterial disease pathogenesis. Over the last decade a 
number of studies have documented that mitochondria in chronically ischemic muscle have 
abnormal ultrastructure [326], damaged DNA [411], altered enzyme expression and activity, and 
abnormally high intermediates of oxidative metabolism [325,342]. These studies evaluated the 
mitochondria characteristics using fixed or frozen muscle samples.  Other laboratories have used 
phosphorus 31 magnetic resonance spectroscopy [398,409,412] to study the bioenergetics of 
chronically ischemic skeletal muscle during various types of exercise. These in vivo studies of 
mitochondrial function demonstrate an intrinsic defect in mitochondrial respiration, similar to 
that in the mitochondrial myopathies [323,413]. In summary, the skeletal muscle abnormalities 
include: (a) alterations in mitochondrial expression, (b) accumulation of metabolic intermediates, 
(c) altered control of mitochondrial respiration, (d) enhanced oxidative stress, and (e) somatic 
mitochondrial DNA mutations [319].                                                                                          
2.4.4 The Implication of an Exercise Program                                                                                  
 Patients with heart failure have poor clinical status and impaired exercise capacity due 
both to cardiac limitations (significant left ventricular impairment) and to peripheral 
maladaptations of the skeletal musculature. The latter include the reduction of peripheral blood 
flow and impaired perfusion as well as deficiencies in skeletal muscle function, morphology and 
metabolism. These skeletal muscle disturbances increase cardiovascular stress, deteriorate 
symptoms and reduce further exercise capacity [156,414]. Since the late 1970s, several studies 
have reported that exercise training can induce favorable physiological adaptations and improve 
symptoms, clinical outcome and quality of life [70,195,415,416]. The majority of these studies 
were based on aerobic exercise, which was traditionally the main exercise mode in rehabilitation 
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programs. Recently, it has been reported that muscle strength [417] was a better predictor of 
long-term survival than workload or peak oxygen consumption (VO2peak) in patients with severe 
congestive heart failure, indicating the importance of maintaining a normal skeletal muscle mass 
in order to improve the outcome of these patients. Therefore, resistance training programs would 
allow training the peripheral muscles effectively without producing great cardiovascular stress. 
In that regard, dynamic resistance training, based on the principles of interval training, alone 
[200-202,418] or in combination with aerobic exercise [203-205] is beneficial and counteracts 
the negative peripheral side effects seen in patients with heart failure.                                                    
 In contrast, peripheral arterial disease is an obstructive condition where the flow of blood 
through peripheral arteries is impeded. During periods of increased oxygen demand (e.g. 
exercise), peripheral limb ischemia occurs, resulting in the sensation of muscle pain termed 
claudication. As a result of claudication, subjects’ ability to exercise is greatly reduced affecting 
their quality of life [252,419]. Many treatment options for patients with peripheral arterial 
disease exist; however, exercise training is an effective and low-cost means of improving 
functional ability and quality of life. Recently, a Cochrane Review supported the role exercise 
training has in the symptoms of peripheral arterial disease [349], specially improving walking 
ability in these patients. In addition, Gardner and Poehlman [348] published a meta-analysis of 
training studies conducted in patients with peripheral arterial disease. Their recommendations 
appear to have formed the basis of exercise prescription for patients with peripheral arterial 
disease. These investigators concluded that the most effective training program included training 
sessions > 30 minutes in duration, at least three times a week, over a period of 27 weeks or more 
[348]. In regard to the intensity they stated that the program must include training to near 
maximal pain levels. In addition, few research studies have compared the use of different 
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training modes in improving walking ability in patients with peripheral arterial disease. The use 
of resistance [351,353], stair-climbing [420], pole-striding [421] and less specific modes of 
training including flexibility [422] and gymnastics [423] have been complemented with, or in 
place of, treadmill walking in an attempt to  improve walking ability in patients with peripheral 
arterial disease. The effectiveness of each type of training appears to vary; however, few 
statistical comparisons analyzing the effectiveness of walking training to other training modes 
have been made. However, the use of different modes of exercise training has become an 
important research topic. Indeed, some elderly people are not able to, or are not comfortable 
with, exercising on treadmills [424]. In addition, the use of training modes other than walking 
could improve the adherence of subjects to training programs by removing the discomfort of 
claudication during exercise.          
 2.5 Conclusion                                                                                                                                              
 In conclusion, in both diseases, heart failure and peripheral arterial disease, which 
essentially have a common underlying problem of reduced muscle blood flow and subsequent 
exercise intolerance, the manner in which individuals respond, adapt, and compensate to the 
disease is highly variable. This review was intended to outline how the different physiologic 
systems attempt to compensate for the problems incurred by the pathophysiologic pathway of 
heart failure and peripheral arterial disease. These “compensatory changes” are critical to 
understand as they to a large degree contribute to the clinical course of patients afflicted by these 
two diseases. Finally, this is critical as we need to move from generic exercise programs to 
individualized targeted treatment plans that may be more effective in their delivery, and 
subsequently help to maintain and preserve functional ability in these patients. 
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Chapter 3                                                                                                                                   
High and Low Volume Resistance Training and Vascular Function 
3.1 Introduction                                                                                                                     
 The addition of resistance training guidelines to the 1998 American College of Sports 
Medicine (ACSM) position stand was the result of overwhelming evidence of the health and 
functional benefits associated with this type of training [425]. Resistance training not only 
impacts strength and endurance, but also contributes to the maintenance of functional ability, 
prevents osteoporosis, sarcopenia and disabilities [425-427]. Resistance training also reduces 
cardiovascular risk factors [426]. The mechanisms through which resistance training reduces 
cardiovascular disease risk are currently not clear. One hypothesis is that resistance training 
improves vascular function. Data from our laboratory and others show regional vascular 
adaptations when a localized training stimulus is used [5,428,429]. Importantly, these 
adaptations occur within 4 weeks of training.                                                                               
 Few studies have examined the effects of whole-body resistance training on vascular 
function. Those that have studied this issue reveal mixed results. For example, Rakobowchuk et 
al., [430] reported peripheral arterial remodeling following intense resistance training. However, 
they did not find changes in the reactivity of the artery. Maiorana et al., [431] did not find any 
vascular modifications following resistance/aerobic training. In contrast, Green et al., [432] 
reported improvements in nitric oxide-mediated vascular function, following 8 weeks of 
resistance/aerobic training in patients at risk for and with coronary artery disease. Those findings 
were further confirmed in type II diabetics [433]. One study reported a decrease in vascular 
function following high-intensity resistance training [434]. The reasons for the mixed results are 
probably multifactorial and include: training duration, intensity, volume, and specificity. We 
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hypothesized that vascular function would be modified following short-term, whole-body circuit 
weight training (CWT) and that the improvements would be greater in individuals performing 
high volume compared to low volume training.  
 Consequently, the aim was to examine the influence of two volumes of CWT on reactive 
hyperemic blood flow (RHBF), venous capacitance (VC) and outflow (VO) in younger 
individuals.  
3.2 Methods                                                                                                                                 
3.2.1 Subjects and Experimental Protocol                                                                               
 Thirty-five individuals were recruited. The majority of participants were untrained and/or 
novices to weight lifting. Those with disease were excluded. Following explanation of the 
details, participants signed an informed consent approved by the Institutional Review Board of 
the host institution. The study was a prospective, randomized trial, consisting of 5 weeks of 
CWT. The experimental procedures consisted of two separate visits performed before and after 
training.                                                                                                                                                
3.2.2 Experimental Procedures                                                                                                 
 3.2.2.1 Visit 1: Strength Measures                                                                                        
 Handgrip strength was examined in the non-dominant arm, using a dynamometer (model 
78010, Lafayette Instruments; Lafayette, IN) and determined from the average of 3 maximum 
voluntary contractions (MVC). A one repetition maximum (1RM) was used to determine knee 
extension and bench press strength, using standard nautilus equipment. To eliminate inter-
observer variability the same investigator performed these procedures before and after training. 
Prior to the measures participants were familiarized with the procedures and instructed on the 
correct techniques.                                                                                                                      
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 3.2.2.2 Visit 2: Vascular Function                                                                                    
 Participants were refrained from food, alcohol or caffeine for 12 h, and rigorous physical 
activity for 24 h before the procedures. Prior to the measures, blood pressure cuffs were 
positioned around the non-dominant upper arm and wrist, and a mercury-filled strain gauge 
placed around the forearm 10 cm distal to the olecranon process. The strain gauge was connected 
to a plethysmograph (EC-5R system, Hokanson; Bellevue,WA, USA). The forearm was 
extended and slightly supinated and supported by a foam block. Following the set-up the 
participant was allowed to rest for 15 min. The technique is noninvasive, and based on the 
assumption that alterations of pressures in strategically placed cuffs allows for examination of 
the rate of change in limb volume thought to reflect vascular function [435].   
 Resting forearm blood flow was obtained as follows: First, hand circulation was occluded 
for 1 minute by inflating the cuff at the wrist to 240mmHg. Forearm blood in-flow was obtained 
using a venous occluding pressure of 7 mmHg below diastolic blood pressure [4]. Forearm VC 
and VO were measured after an additional 5 min of venous occlusion. Then, RHBF was 
examined after 5 min of forearm arterial occlusion achieved by inflating the upper arm cuff to 
240mmHg [4]. Vascular indices were then determined as described above. Throughout the 
experiment heart rate and blood pressure were obtained.                                                                                                      
 Data analysis was performed as follows: Resting blood flow was recorded at a paper 
speed of 5 mm/sec and values were derived from the slope drawn at a best-fit tangent. 
Calculations were made as a function of 60 sec divided by the horizontal distance (mm) needed 
for the slope to rise vertically from baseline to the top of the recording paper and multiplied by 
the full chart range. Forearm VC was calculated as the vertical distance (mm) representing the 
change in volume graph following 5 min of venous filling [436]. Forearm VO was derived from 
121 
 
a tangent line representing the vertical drop in the volume-graph from the excursion line and 
drawn at 0.5 second and 2 sec following the release of the venous occlusion pressure [436,437]. 
Forearm RHBF was recorded at a paper speed of 25 mm/sec.  
 Analyses were performed using a slope drawn at a best-fit tangent to the curves of the 
first 3 pulse flows post cuff release. The RHBF was then calculated from 60 sec multiplied by 
the paper speed (25 mm/sec) divided by the horizontal distance (mm) needed for the volume 
slope to increase by 20 mm vertically [4]. All vascular indices are expressed in ml · 100 ml 
tissue-1 · min-1. Previous work from our laboratory indicated adequate stability and 
reproducibility of this technique [4].                                         
 3.2.2.3 Training Intervention                                                                                             
 The CWT was performed in 1 hr sessions, 3 days/wk for 5 wks, consisting of 8 stations. 
The high volume group was encouraged to complete 3 sets/station, while the low volume group 
performed 1 set/station. For each station, participants performed 2 or 3 exercises, using sets of 8 
to 12 reps performed to voluntary muscular fatigue.  
 Initial intensity was set at 60% of 1RM or as tolerated. After each station, passive static 
stretches were performed. Training load was increased by 5-10% for the next session when 
participants were able to perform 12 reps. Training load, number of reps, and ratings of 
perceived exertion (Borg scale) were recorded, to document the tolerance and progression of 
training.  
 The circuit included: Station 1: biceps curl, triceps extension, and punch-outs; Station 2: 
knee flexion, knee extension, and calf raises; Station 3: pull backs, pull over; Station 4: squats, 
and step lunges; Station 5: bench and military press; Station 6: row, and pull down; Station 7:  
pull and jerk, and sit-ups; and Station 8: Back extension: McKenzie exercises [438].                                                                                                            
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 3.2.3 Statistical Analysis     
             Statistical analyses were performed using SPSS (11.0). Group values are expressed as 
mean ± SD. Pre-training group differences were examined using independent t-tests. Differences 
in training volume across the 5 wks were examined using a 2 (high and low volume) * 5 (wks of 
training) analysis of variance with repeated measures. The influence of training on vascular 
function and strength was examined using two separate multivariate analyses (MANOVA). 
Alpha was set a priori at 0.05.                                                                                                         
3.3 Results                                                                                                                                   
3.3.1 Participant Characteristics and Intervention Results                                                            
 The average age of the participants was 22±1.89yrs. Weight, height, BMI, resting systolic 
and diastolic blood pressure, and resting heart rate were not statistically different between 
groups. The participants’ characteristics are presented in Table 3.1.  
       Table 3.1 Participants characteristics 
 
 Group Mean SD 
Age (years) Low Volume 21 1.84 
 High Volume 22 1.85 
Weight (kg) Low Volume 74 14.39 
 High Volume 85 28.45 
Height (cm) Low Volume 168 9.64 
 High Volume 173 9.38 
BMI (kg/m2) Low Volume 26.2 4.44 
 High Volume 27.9 7.00 
Rest SBP (mmHg) Low Volume 118 10.31 
 High Volume 120 9.48 
Rest DBP (mmHg) Low Volume 65 9.04 
 High Volume 65 9.86 
HR rest (bpm) Low Volume 61 11.49 
 High Volume 65 7.07 
   BMI, body mass index; Rest SBP, resting systolic blood pressure; Rest DBP,              




One participant from the low volume group did not finish the training due to lack of 
compliance. No injuries or significant problems were reported. The progression and volume of 
training are presented in Figure 3.1. Over the 5 wks of CWT the high volume group increased 
the training volume by 62%, from 3219 (Wk 1) to 5236 lbs (Wk 5). The low volume group 
increased the training volume by 68%, from 2707 (Wk 1) to 3997 lbs (Wk 5).  
       Table 3.2 Changes in strength measures (pre and post) in both groups 
 
 Group Test Mean SD 
Handgrip (kg) Low volume Pre 22.39 9.80 
  Post 25.4* 10.76 
 High volume Pre 28.02 12.98 
  Post 33.37* 14.01 
Bench press (kg) Low volume Pre 56 35.97 
  Post 70.91* 38.41 
 High volume Pre 60.93 32.62 
  Post 71.97* 37.42 
Knee extension (kg) Low volume Pre 79.38 31.56 
  Post 112.44* 36.46 
 High volume Pre 94.04 34.35 
  Post 123.53* 36.21 
                   Pre, pre-training measures; Post, post-training measures; *p<0.05 vs. Pre 
3.3.1.1 Visit 1: Strength Measures                                                                                    
 The MANOVA revealed significant increases in all strength measures. However, no 
significant differences in strength gains were observed between the groups. The strength 
measures are presented in Table 3.2. The mean absolute and percent change in strength for 
handgrip strength was 3.89±4.57 kg (+15.59%), knee extension 30.62±12.52 kg (+ 35.31%), and 
bench press 12.4±8.81 kg (+21.03%). 
3.3.1.2 Visit 2: Vascular Function                                                                                
 Results for forearm vascular measures are presented in Table 3.3. The MANOVA 
revealed no significant changes in forearm RHBF, VC and VO.  
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3.4 Discussion                                                                                                                               
            The aim was to examine the influence of different volumes of CWT on forearm vascular  
Function including RHBF, VC and VO among young individuals. Our findings indicate 
significant and similar increases in strength for both groups. In contrast, group averages for 
vascular function did not change following five weeks of CWT. Overall changes in strength for 
this study averaged 24%. These improvements are consistent with previous studies. In fact, the 
2002 ACSM [439] position statement on progression models in resistance training indicate that 
muscular strength increases approx. 40% in untrained and 20% in moderately trained individuals 
over periods ranging from 4 wks to 2 yrs. The initial gains in strength are believed to be due to 
neural changes [439]. These adaptations include: improvements in muscle activation and 
coordination, enhanced muscle fiber recruitment, and improved muscle contraction synergism 
[440,441]. It is not until ~6 wks into training that muscle hypertrophy becomes obvious and 
contributes to the strength gains [442]. This study was not designed to measure muscle mass or 
size, but, forearm circumference did not change. 
 The average values for the vascular measures were similar to those found in previous 
studies [4,5], and similar to a low fitness group studied in our laboratory [4]. In addition, the 
forearm RHBF values are in agreement with others [429,443]. It was hypothesized that vascular 
function would be modified following CWT and that the improvements would be greater in 
individuals performing higher volume training. It is important to understand the rationale for the 
hypothesis. First, the selection of the training duration stems from studies conducted in our 
laboratory and by others indicating short-term handgrip exercise training results in improved 
vascular function [5,428]. For example, Alomari et al., [5] reported a unilateral improvement in 
vasodilatory responsiveness after 4 wks of handgrip training. The training protocol consisted of 
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20 min/session performed 5 days/wk at 60% of MVC. After training, RHBF improved by ~21% 
[5]. Studies conducted by others report similar increases (~ 20% to 30%) in RHBF following 
short-term localized forearm training [429,443]. Given these findings we hypothesized that 
whole-body CWT for 5 wks would be a sufficient stimulus to induce vascular changes. 
        Table 3.3 Results for the pre and the post forearm blood flow measures 
 
 Group Test Mean SD 
Rest BF Low volume Pre 2.45 0.75 
(ml/100ml/min)  Post 2.76 0.86 
 High volume Pre 3.14 0.99 
  Post 3.15 0.83 
Rest VC Low volume Pre 3.11 0.67 
(%)  Post 3.48 0.81 
 High volume Pre 3.21 0.95 
  Post 3.34 0.87 
Rest VO Low volume Pre 38.92 7.82 
(ml/100ml/min)  Post 40.78 7.94 
 High volume Pre 36.83 11.26 
  Post 39.29 9.82 
RHBF Low volume Pre 20.69 6.50 
(ml/100ml/min)  Post 21.67 4.76 
 High volume Pre 23.05 5.95 
  Post 22.71 5.24 
         Rest BF, resting blood flow; Rest VC, resting venous capacitance; Rest VO,                 
         resting venous outflow; RHBF, reactive hyperemia blood flow. 
 
 Second, the issue of volume of training stems from the lack of predictability in the 
vascular responses among the available studies. For example, Rakobowchuk et al., [430] noted 
an increase in mean brachial artery diameter following intense whole body resistance training. 
Their participants completed 60 sessions (2/3 sets of 10-12 repetitions, and finished with 4-6 reps 
with loads exceeding 90% of 1 RM) conducted 5 days/wk for 12 wks. In addition, they reported 
an increase in RHBF thought to be the result of increased capillarization. However, they did not 
find changes in the reactivity of the peripheral artery. Maiorana et al., [431] did not find any 
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vascular modifications following 8 wks of resistance/aerobic training in middle-age men. Their 
training consisted of aerobic activities (70 to 85% of peak heart rate) and 7 strength training 
exercises (55 to 65% of MVC), designed to minimize the involvement of the arms. Training was 
conducted 3 days/wk. Finally, Bond et al., [434] reported a decrease in leg RHBF following 4 
wks of training consisting of 6 sets*15 MVC’s of the calf, 4 days/wk. The authors attributed the 
decrease in peripheral hemodynamics to an increase in calf volume. Clearly the lack of 
predictability in the vascular responses between studies could, in part, be a consequence of 












































     Figure 3.1. Average volume of weight lifted (lbs) across the training weeks. Values   
                are mean + SD. * = p < 0.05 as compared to Week 1; † = p < 0.05 as compared to the  
                low volume group. 
 
The present study is the first to examine the influence of different training volumes on 
vascular function. As shown in figure 3.1, the training volume increased significantly, with both  
groups noting a 60% change. In addition, the training volume was approx. 25% greater for the  
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high volume group from wk 1 through 5. Despite the evidence in training progression and 
difference in volume, no group changes were apparent for any of the vascular measures under 
study. Thus, the stated hypothesis was rejected. Several factors may have contributed to the 
present findings. These factors will be discussed briefly.  
 The first factor may be the training stimulus and localization. Our previous handgrip 
studies [5,6] included protocols that were quite intensive (20 min sessions, 4 or 5 days/wk) and 
very specific to a region. The current study may not have been able to achieve the specificity or 
localization needed to trigger vascular adaptations.                                                                                                                                      
 A second factor concerns the length of training. Despite our previous work and 
expectations, the relative short period of training may not have been enough to promote changes 
in muscle mass and/or capillarity density in the region of interest. Arguably, vascular adaptations 
may not occur until there is evidence of a change in muscle mass. In fact, changes in the cross-
sectional area of muscle appear to contribute to an increase in capillary density [442]. Perhaps, 
the length of training was not enough to allow the structural changes that accompany muscle 
hypertrophy to occur. Moreover, Rakobowchuk et al., [430] noted peripheral arterial remodeling 
at 6 wks into training. Thus, the present study may have been on the verge of peripheral changes, 
but fell short.                                                                                                                                    
 A third factor may be the population under study. The participants were healthy students 
without overt disease. Generally, improved vascular function following training is observed in 
individuals who have reduced vascular function prior to training. For example, Green et al., 
[432] reported that an 8 wk resistance/aerobic training improved endothelium-dependent nitric 
oxide-mediated vascular function in both conduit and resistance vessels in patients at risk for and  
with coronary artery disease. Those findings were further confirmed in type II diabetics [433] 
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and patients with heart failure [204]. Interestingly, in this study those individuals with RHBF’s 
below the 50th percentile (i.e. <23 ml/100ml/min, n=19) before training had a 17% greater RHBF 
response after training (Pre: 17.41±4.03; Post: 20.30±4.55 ml/100ml/min, p=0.006), independent 
of group assignment. Similarly, those with the lowest values for VO (i.e. <39.5 ml/100ml/min, 
n=17) also had significant improvements after training (Pre: 30.58±6.46; Post: 36.11±8.38 
ml/100ml/min, p=0.013). We are cautious in the interpretation of these findings due to: (1) 
paired t-tests were used for these sub analyses, (2) there was no control group, as this was not the 
focus of the study, and (3) there were no associations between the observed strength gains and 
vascular changes. Despite this, the improvements in this sub-group are not too dissimilar from 
previous reports [5,429]. Thus, it appears individuals with evidence of low vascular function may 
respond favorably to CWT.                                                                                                                         
3.4.1 Conclusion                                                                                                                              
 In conclusion, short term CWT using high and low volume training resulted in 
significant, yet, similar increases in strength. In contrast, group averages for vascular function 
did not change following CWT. Interestingly; those with the lowest pre-training vascular 




Chapter 4  




Peripheral neuropathies are a wide range of diseases affecting the peripheral nerves. 
According to the 108th Congress report, 20 million Americans suffer from the disease [7]. In fact, 
peripheral neuropathy affects more people than several other well-publicized pathologies, 
including diabetes mellitus (17-18 million), coronary heart disease (13.2 million), and asthma 
(15 million) [444]. The prevalence of peripheral neuropathy increases significantly in the older 
adult population and nearly one-third of all diabetics suffer from this condition [7].                    
 Irrespective of the etiology, it appears that pathological changes associated with the 
disease are in many cases consistent with ischemia, secondary to vascular insufficiencies [8]. In 
fact, the literature has clearly established that chronic ischemia contributes to demyelination or 
axonal degeneration [445], which consequently, gives rise to a variety of symptoms including 
reduced or altered sensation, pain, muscle weakness, and chronic fatigue. The progression of 
peripheral neuropathy, generally, follows a distal to proximal pattern, with symptoms usually 
beginning in the toes before the fingers. Eventually, patients with peripheral neuropathy develop 
gait abnormalities and subsequent decrements in balance [446]. As a result, a large number of 
individuals with peripheral neuropathy suffer from a reduction in daily physical activity and 
reduced quality of life [447].                                                                                              
 Importantly, in a recent 2-year follow-up on individuals with lower-extremity peripheral 
arterial disease (PAD), baseline leg symptoms and ankle brachial index (ABI) were strong 
predictors of the degree of functional decline [219]. Moreover, PAD patients reportedly have 
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worse nerve conduction velocity in the legs, considered a clinical marker of peripheral 
neuropathy, than individuals without PAD [243], suggesting a link between vascular deficiencies 
and neural function. Thus, it appears that vascular impairments contribute to the functional 
decline in patients with PAD. Ultimately, it is thought that functional decline leads to loss of 
independence and disability [448].                                                                                             
 Interestingly, despite evidence of functional deterioration and increased risk of falls in 
patients with peripheral neuropathy [449,450], and studies reporting nerve damage in patients 
with chronic ischemia [445], few studies have examined the link between vascular and motor 
function in peripheral neuropathy patients. In one such study, patients with PAD coupled with 
diabetes exhibited greater lower extremity dysfunction compared to PAD patients without 
diabetes. The apparent differences were, at least, in part secondary to poorer neuropathy scores 
[256]. Given the association between physical function and independence, understanding those 
factors that may contribute to a loss of functional ability and mobility in individuals with 
peripheral neuropathy is critical.  
Therefore, the purpose of the present investigation was to examine the relationship 
between measures of vascular (both arterial and venous) and physical function (mobility and 
lower extremity strength) in individuals with peripheral neuropathy. It was hypothesized that 
individuals with evidence of greater vascular function also would exhibit greater physical 
function among this population.                                                                                                    
4.2 Methods                                                                                                                                             
4.2.1 Participants                                                                                                                   
 Individuals with peripheral neuropathy were recruited from the greater Baton Rouge 
metropolitan area. The participants were referred to us with the diagnosis of peripheral 
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neuropathy by their respective physicians. No distinction was made for the types of peripheral 
neuropathy. The inclusion criteria for the study was (a) ability to maintain an upright posture for 
at least one minute voluntarily; (b) ability to walk at least 20 yards independently; (c) willingness 
to participate in the study; and (d) a diagnoses of bilateral peripheral neuropathy. Individuals 
were excluded from participation if there was (a) a history or evidence of central nervous system 
dysfunction; (b) musculoskeletal deformity which could influence gait and balance; (c) a history 
or evidence of vestibular dysfunction; (d) a history of angina; (e) evidence of plantar ulcer; (f) 
unstable disease (e.g. uncontrolled diabetes mellitus, Arthritis, coronary artery disease, etc.); and 
cognitive impairment defined as a score of less than 25 on the mini-mental state exam [451]. 
Following explanation of all the details of the study, each participant signed an informed consent 
approved by the Institutional Review Board.                                                                                        
4.2.2 Measurements                                                                                                             
 4.2.2.1 Peripheral Sensory Testing                                                                                                     
 Plantar cutaneous pressure sensitivity was assessed using the 5.07 gauge Semmes-
Weinstein monofilament (North Coast Medical, Inc). The monofilament exerts 10 g of force at 
the tip upon buckling and has been used in both clinical and research settings. While there is no 
widespread consensus as to the optimal protocol, reduced sensitivity as measured by this 
monofilament has been correlated to common symptoms of peripheral neuropathy [452].  
The fiber was applied to 5 sites on the plantar surface (i.e. the great and fifth toes, the 
first and fifth metatarsal, and the heel). The fiber was applied for 1.5 s and pushed to an angle of 
90o. The order of the test sites was randomized to help prevent anticipation of the test by the 
participant. The participant indicated when he or she felt the fiber. If the participant exhibited 
any sign of foot ulcers, the testing sites were moved to the perimeter of the ulcer. All testing was 
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performed by the same technician. Data was recorded as a “0” for no sensation, or a “1” if the 
monofilament was sensed.                                                                                                                                  
 4.2.2.2 Vascular Assessment                                                                                                       
 Vascular function of the lower leg was assessed using strain gauge plethysmography at 
rest and after 5 min of arterial occlusion. Specific measures included resting arterial inflow (AI), 
vascular capacitance and conductance, venous outflow volume and half time (VOt1/2), and 
reactive hyperemic blood flow (RHBF).                                                                                      
 Prior to the vascular assessments participants were instructed to refrain from food, 
alcohol or caffeine for 12 h, and rigorous physical activity for 24 h. Upon arrival to the vascular 
laboratory, the participants were placed on an examination table and segmental pressure cuffs 
were positioned around the lower thigh and ankle [453]. In addition, a blood pressure cuff was 
positioned in the standard position around the upper arm to obtain blood pressure measures 
continuously. The data was collected using an automatic blood pressure device (Datascope 
Accutorr 4, Datascope Corp. Paramus, NJ).  
Subsequently a mercury-filled strain gauge was positioned around the widest girth of the 
lower leg. The position was marked and kept constant throughout the experiments. The strain 
gauge was connected to a plethysmograph (EC-5R system, Hokanson; Bellevue,WA). The leg 
was extended and slightly supinated and supported at least 10 cm above the level of the heart by 
foam blocks, but ensuring the strain gauge was not impeded, in order to provide the most 
comfortable arrangement for the participant. Following the set-up procedures, participants were 
allowed to rest for 25 minutes. Resting in-flow was measured in triplicate as follows. First, foot 
circulation was occluded for 1 minute prior to the assessment by inflating the cuff at the ankle to 
240mmHg. Then, the segmental pressure cuff on the thigh was inflated to 7 mmHg below 
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diastolic blood pressure, measured at the arm. Arterial in-flow was then recorded three times for 
10 seconds with 10 seconds between each recording. Following an additional 2 minutes of 
maintaining the segmental thigh cuff at the previous determined pressure, venous capacitance 
was obtained. Subsequently, venous outflow was measured after release of the thigh pressure 
cuff for 20 seconds.                                                                                                                                      
 Patients were then given another 5 minutes of rest prior to initiating the hyperemic test. 
Following this rest period the thigh cuff was inflated to at least 60mmHg above systolic blood 
pressure for 5 minutes. In the fourth minute foot circulation was again occluded for 1 minute by 
inflating the cuff at the ankle to 240mmHg. Upon release of the thigh pressure cuff to a pressure 
equal to 7 mmHg below diastolic blood pressure, reactive hyperemic blood flow was measured 
in triplicate for 10 seconds, with 10 seconds between each measure.                                            
 Data were analyzed using a customized computer program (Matlab; Mathworks, Natick, 
MA, U.S.A.). Resting arterial in-flow was calculated from the entire slope, 10 seconds in length, 
of the volume change over an interval of 10 seconds and the mean of three consecutive 
measurements was used to determine the average arterial in-flow. Recordings with significant 
movement artifact were excluded. Resting vascular resistance was calculated as mean arterial 
pressure / average in-flow. Resting vascular conductance was the reciprocal of vascular 
resistance or average in-flow / mean arterial pressure. For both assessments, vascular resistance 
and conductance, a blood pressure measure taken at that point was used for the analysis. Venous 
capacitance was determined through visual inspection of the position of the recording needle on 
the plethysmograph. Using a standard scale developed by the manufacturer an overlay is placed 
over the recording paper. The distance from the base of the graph to the position of the mark at 
the end of 2 minutes represents the relative venous capacitance.                               
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 Reactive hyperemic blood flow was calculated from the slope of the volume change over 
each 10 seconds interval. This allows for the determination of peak and the average reactive 
blood flow response across the three measurements. In order to assess the timing characteristics 
of the venous outflow, venous outflow data were fitted to an exponential curve using the least 
mean square optimization method and processed by using Solver plug-in within the Microsoft 
Excel environment. The Venous outflow half time (VOt1/2) were calculated based on the time 
constant of the simulated exponential curve of each testing session.                          
 4.2.2.3 Physical Function Assessment                                                                               
 On a separate day, participants were evaluated in a series of tests for functional capacity, 
mobility, and lower extremity strength. At least five minutes of rest was provided in between 
each test, while at least two minutes of rest was provided between trials of applicable tests. The 
reliability of the functional testing protocol in this study has been reported elsewhere, and was 
found to be high for patients with peripheral neuropathy. The protocol used is outlined below.   
 The Six-Minute Walk test was administered using a standardized protocol outlined by the 
American Thoracic Society [73]. Briefly, cones were placed 30m apart along a well-lit indoor 
hallway. Participants walked as far as possible in 6-min by walking back and forth around the 
cones. The distance covered was recorded to the nearest meter. Specific pre- and within-test 
participant instructions can be found in the American Thoracic Society statement [73]. 
Maximum walking distance traveled in 6 minutes (6MWD), to the nearest meter, was recorded 
and used for analysis.                                                                                                                       
 In order to examine balance and coordination a timed up- and-go test (TUG) was 
implemented, using a previously established protocol [454]. The TUG-test is a useful test in 
detecting mobility impairment [455]. Briefly, a firm chair with arm rests was placed in the 
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middle of a well-lit, indoor hallway. In front of the chair, a distance of 3 m was marked on the 
floor and a large cone was placed on the opposite end from the chair. The test began with the 
participant seated with their back against the chair, arms in lap, and feet just behind the distance-
marker on the floor. Instructions were to stand up using the arm rests if needed, walk safely to 
and around the cone, walk back to the chair, and sit all the way back in the chair as fast as 
possible. The timer was started on the work “go,” and stopped when the participant’s back 
touched the back of the chair. The average time to complete each of 2 separate trials was 
recorded and used for analysis.                                                                                                  
 Isokinetic knee extensor peak torque and knee flexor peak torque were measured with the 
Biodex isokinetic dynamometer (Biodex Medical, Shirley, New York). Participants sat in the 
Biodex chair with the back rest fixed at 85 degress. Subjects were secured using pelvic and torso 
straps to minimize extraneous body movements that may influence testing performance. To 
further minimize such effects, participants were instructed to hold the Biodex handgrips during 
the procedure. The lateral femoral epicondyle was used as the reference point for matching the 
axis of rotation of the knee joint with that of the dynamometer resistance adapter. The lower limb 
was attached to the resistance adaptor to allow full knee extension and flexion to approximately 
100 degrees.                                                                                                                                     
 A warm-up procedure consisting of five isokinetic knee extension and flexion 
movements at 60 o/s was initially completed. A 10s rest period was given in between each trial. 
Participants were instructed to kick and pull their leg lightly during the first trial, and increase 
the amount of produced force with each trial so as to generate at or near maximal force during 
the fifth trial. Following a 3-min rest period, the maximal strength test was completed. 
Participants repeated warm-up procedures (5 trials, 10s rest between trials), only with specific 
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instructions to “push/pull your lower limb as hard as you can, remembering to breathe out 
normally during the trial.” During all maximal trials, verbal encouragement and concurrent 
visual feedback from a computer monitor were provided to facilitate maximal values. Peak knee 
extension (KE) and knee flexion (KF) torque (N·m) were recorded for each trial. Values from the 
three best trials for each movement were averaged and used for analysis.                                          
4.2.3 Statistical Analyses                                                                                                                  
 Statistical analyses were performed using SPSS for Windows (version 11.0).  Data are 
presented as means and SD. To examine the associations between age, measures of vascular and 
physical function, Pearson product moment correlation coefficients were calculated. 
Associations between the monofilament scores and various measures were examined using a 
Spearman rank correlation. To further appreciate the influence of the vascular indices on motor 
function, analyses of variance were used to compare participants classified according to tertiles 
on the performance scores, or in the case of the six minute walk test the clinically relevant score 
of 400m. Finally, potential differences in vascular and motor function based on certain groupings 
(e.g. etiology, gender, duration of disease) were determined using analyses of variance or 
independent t-tests. Significance was tested at the 95% confidence level (p≤0.05).                      
4.3 Results                                                                                                                                                                 
4.3.1 Participant Characteristics                                                                                                                                                       
 A total of 59 individuals with peripheral neuropathy participated in all aspects of this 
study. Participant characteristics are presented in Table 4.1. Forty-one percent of the participants 
were women, and 59% men. Seventy percent of the participants were over the age of 65.  
The oldest participant tested was 87years old, and the youngest was 39 years old. The  
duration of the diagnosis ranged from 6 months to 20 years, with ~60% of the participants 
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suffering from peripheral neuropathy less than 5 years. The etiology of peripheral neuropathy 
was idiopathic in approximately 56% of the subjects. Thirty-one percent had Type II Diabetes 
Mellitus, 7% of patients suffered from chronic low back pain, and 5% of patients with 
neuropathy were cancer survivors. Thirty percent of the patients had a BMI greater than 30kg·m-
2, and 40% had stage I hypertension on the basis of systolic blood pressure (SBP > 130mmHg). 
   Table 4.1 Participant characteristics 
 
 Minimum Maximum Mean SD 
Age (yr) 39 87 69 12 
Disease duration (yr) .5 20.0 5.50 4.24 
Height (m) 1.50 1.96 1.70 0.10 
Weight (kg) 43.64 150.00 83.96 21.78 
BMI(kg·m-2) 16.43 47.94 28.78 6.29 
Systolic Blood Pressure (mmHg) 95 175 130 17 
Diastolic Blood Pressure (mmHg) 52 95 72 11 
Resting Heart Rate (bpm) 42 116 71 12 
Pulse Pressure (mmHg) 









          m = meters; kg = kilograms; bpm = beats per minute 
 
4.3.2 Peripheral Sensory Test                                                                                                             
 The majority of patients reported partial sensation on the peripheral sensory tests. Ten 
percent of patients reported no sensation at any of the sites tested, and only 5% of participants 
reported no diminished sensation at any of the sites. The sites that yielded the greatest sensitivity 
were the big toe and fifth toe (~64% of participants reported sensing the monofilament). The site 
of the heel yielded the lowest sensitivity, with ~16% of patients sensing the monofilament. The 
duration of disease was significantly associated with the sum of the scores on the peripheral 
sensory test (r=-0.48, p=0.002).  
 No significant relationships were found between the reactive hyperemic responses or 
VOt1/2 and the sum of the sensory test scores. However, there were significant associations 
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between vascular conductance (r=0.44, p=0.01), the TUG (r= -0.37, p=0.03) and the sum of the 
sensory tests.                                                                                    
4.3.3 Vascular Assessment                                                                                                           
 The average values for the blood flow indices at rest and following occlusion are 
presented in Table 4.2. The average resting inflow was 2.48±1.17 mL·100mL-1 ·min-1. Post 
occlusion reactive hyperemia values significantly decreased (p=0.0001) with each measure from 
a peak hyperemic response of 26.93±13.44 mL·100mL-1 ·min-1, immediately after cuff release, to 
17.23±8.58 mL·100mL-1 ·min-1 at the second and 13.72±7.59 mL·100mL-1 ·min-1 at the third time 
point.  
 Group comparisons based on etiology, gender, or disease duration did not reveal 
significant differences in any of the blood flow indices, even when the diabetic patients were 
compared to all others. In addition, there were no correlations between age and any of the inflow 
measures. In contrast there was a significant association between age and VOt1/2 (r=0.31, 
p=0.02). Finally, Table 4.3 reveals several significant associations between RHBF, venous 
volume, VOt1/2 and vascular conductance.                                                                                        
4.3.4 Physical Function Assessment                                                                                             
 The average scores for the physical function tests are shown in Table 4.4. No differences 
in performances scores were noted for the different etiologies and disease duration. Men were 
significantly stronger for KE (Men: 141±73; Women: 80±20 N·m, p=0.001) and KF (Men: 
70±30; Women: 39±10 N·m, p=0.001), but no differences were noted for the 6MWD and TUG. 
 In addition, there were significant associations between age and each of the functional 
scores (Age vs. 6MWD: r= -0.34, p=0.01; Age vs. TUG: r= 0.33, p=0.01; Age vs. KE: r= 0.51, 
p=0.001; and Age vs. KF: r= 0.50, p=0.001). Finally, Table 4.3 shows several associations 
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between the performance scores. A particular strong association was noted between 6MWD and 
TUG (r=0.79, p=0.001), whereas there were no significant relationships between TUG and 
measures of leg strength. 
 Table 4.2 Blood flow indices at rest and following occlusion 
 
 Minimum Maximum Mean SD 
Arterial Resting Inflow (mL·100mL-1 ·min-1) 0.96 6.29 2.48 1.17 
Vascular Resistance (AU) 13.46 109.85 45.43 22.01 
Venous Capacitance (mL·100mL-1 ·min-1) 0.00 4.00 1.57 0.90 
Venous Volume (mL·100mL-1 ·min-1)  8.00 58.00 31.26 12.37 
VO t1/2 (s) 0.60 3.25 1.31 0.51 
RHBF Peak (mL·100mL-1 ·min-1) 8.46 73.62 26.93 13.44 
RHBF Average (mL·100mL-1 ·min-1) 










  AU = arbitrary units of resistance; VO t1/2 = venous outflow halftime; s = seconds;    
  RHBF = reactive hyperemia blood flow 
 
4.3.5 Associations between Vascular and Physical Function                                                             
 The associations between the vascular indices and physical function are presented in 
Table 4.3. In particular the associations between peak RHBF responses and the TUG (Peak 
RHBF= 37.88 - 1*TUG; r=-0.31, p=0.024) and the 6MWD (Peak RHBF= 8.65 + 0.05*6MWD; 
r=0.37, p=0.007) are of interest. Specifically, as shown in Figure 4.1 individuals in the top 
tertiles of the TUG had significantly higher peak RHBF responses compared to the lowest tertile 
[≤9.02s, RHBF: 30.97±12.56 mL·100mL-1 ·min-1; 9.02-10.88s, RHBF: 28.88±15.99 mL·100mL-1 
·min-1; >10.88s, RHBF: 19.88±8.10 mL·100mL-1 ·min-1 , p=0.04].  
 Those with a 6MWD score <400m had lower RHBF compared to those who walked 
>400m (see Figure 4.2) [<400m, RHBF: 23.47±10.52 mL·100mL-1 ·min-1; >400m, RHBF: 
30.65±15.05 mL·100mL-1 ·min-1, p=0.05]. In addition, peak vascular conductance was also 
significantly related to the TUG (Peak Vascular Conductance = 0.50 – 0.02*TUG; r=-0.38, 
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p=0.007) and 6MWD (Peak Vascular Conductance = 0.50 + 0.001*6MWD; r=0.44, p=0.001), 
showing similar differentials based on the tertiles and 400m threshold as for the peak RHBF 
response (see Figure 4.3 and 4.4). Finally, a significant association between VOt1/2 and KF 
(VOt1/2 = 1.67 - 0.01*KF; r=-0.37, p=0.01) and KE (VOt1/2 = 1.67 - 0.01*KF; r=-0.37, p=0.01) 
was observed, with those in the top tertile exhibiting faster VOt1/2 (see Figure 4.5) [>77N·m, 
VOt1/2: 1.01±0.31s; 36-77N·m, VOt1/2: 1.54±0.64s; <36N·m, VOt1/2: 1.38±0.40s, p=0.004].  
 Table 4.4 Physical function scores 
 
 Minimum Maximum Mean SD 
6MWD (m) 98 570 373 106 











 6MWD = 6 minutes maximal walking distance; m = meters; s = seconds;                         
 KE = knee extension; N·m = newton-meter; KF = knee flexion 
 
4.4 Discussion                                                                                                                          
 The purpose of the present investigation was to examine the relationship between 
measures of lower leg vascular and physical function in individuals with peripheral neuropathy. 
The present data, indeed, support a link between measures of vascular and physical function in 
individuals with peripheral neuropathy. Specifically, individuals in the lowest tertile of the TUG 
and those with a 6MWD score <400m had significantly lower peak RHBF responses and peak 
vascular conductance compared to the other groups.  
 In addition, individuals in the top tertile of KE and KF exhibited faster VOt1/2 than the 
other tertiles. These findings fit “The Disablement Pathway” and suggest that lower motor 
function may, in part, be a consequence of deterioration of peripheral vascular function in 
individuals with peripheral neuropathy.                                       
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  4.4.1 Vascular Assessment                                                                                                                   
 The use of venous occlusion plethysmography is a powerful tool to study limb blood flow 
in humans. In general, the study of blood flow responses following occlusion indicates that  
younger, fitter, and healthier individuals exhibit greater flow responses, suggesting better 
vascular function.  
 
   Figure 4.1. Association between peak reactive hyperemia blood flow (peak RHBF)   
   responses and the timed up and go (TUG) tertiles.* indicates significant difference from  
   other tertiles (p=0.01) 
 
To that extent, peak RHBF responses in the present study were ~17% lower than values reported 
for a group of healthy individuals in the same age range, and ~18% and 29% higher than a group 
of heart failure and PAD patients [153,456], using the same analyses techniques. 
 Although beyond the scope of this paper, a lower than expected peak RHBF response 
suggests alterations in the main factors that govern reactive hyperemia. More recently,
14
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researchers have also used peak limb vascular conductance immediately after a period of cuff 
arterial occlusion as an indirect measure of the structural limitations placed on limb muscle blood  
 flow [457]. The values for peak vascular conductance, in the present study, were considerably  
lower than those reported for a group of men free of overt disease [457].  
 
     Figure 4.2. Association between peak reactive hyperemia blood flow (peak RHBF)    
     responses and the maximal walking distance cut-off points. Difference is significant at   
     p=0.05 
 
 Thus, a lower than expected peak vascular conductance in these patients could reflect, in 
part, structural changes related to the arterial vasculature of the limbs (e.g. a reduction in 
vascular density and or number) that limit the extent of vasodilation. Together, these findings 
suggest that the arterial vasculature in individuals with peripheral neuropathy is compromised. 
Such a compromised system could certainly contribute to the progression of the disease. In fact, 
the literature provides significant evidence that conditions of acute and chronic ischemia  
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contribute to changes in peripheral nerve function and structure [445]. In fact, Laghi Pasini et al., 
[445] reported a strong correlation between severity of nerve damage and stage of vascular 
insufficiency. It is not currently known what underlying mechanisms may contribute to  
deterioration of peripheral nerve function, but an increase in intracellular calcium [458], and/or 
reduced oxygen species [459] could disrupt myelin and lead to axonal fiber degeneration.                          
 In regards to venous circulation, several investigators have reported a reduction in venous 
function with advancing age [460] and in patients with heart failure [461]. It is not clear what 
mechanisms are involved in this reduced function, but impaired muscle activation and 
generalized deconditioning may be involved. In addition, it is important to consider the changes 
in the structure and function of the vasculature and peripheral nerves as a result of the aging 
process. In that regard, Fu et al., [460] reported an age-related decline in venous filling and 
emptying. It is not known if the progression of peripheral neuropathy may accelerate the decline 
in venous function, or if a decrease in venous function contributes to the progression of the 
disease. Given the important contribution of the venous system in metabolic waste removal and 
end-diastolic volume, changes in this part of the circulation may be quite significant in terms of 
overall vascular function. The present data confirms an association between venous outflow half 
time and age in individuals with peripheral neuropathy.                                                             
4.4.2 Physical Function Assessment                                                                                                
 A decline in functional performance in individuals with peripheral neuropathy is widely 
accepted, although the rate of decline and contributing mechanisms are much less understood.  
The six-minute walk test is an easily implemented test that determines the maximum distance a 
person can walk in 6-min. This test is a valid measure of “functional capacity” as it evaluates the 
integrated response of all systems involved during physical activity [73].                                            
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 It is therefore frequently used in both elderly and diseased populations, and was therefore 
chosen for the current study. The total group average for the 6MWD (373±106m) in this study 
appears to be quite typical for those seen in patients with heart failure [64], indicating significant 
functional limitations. Importantly, based on the literature indicating that a walking distance less 
than 400 meters is associated with higher prevalence of institutionalization, morbidity, mortality, 
hospitalization and transplantation [462], the results of the present study suggest 50% of the 
neuropathy patients are at elevated risk for complications. 
 
           Figure 4.3. Association between peak vascular conductance and the timed up and go           
           (TUG) tertiles. * indicates significant difference from slowest tertile (p=0.003).  
           † indicates significant difference from middle tertile (p=0.05) 
 
The TUG test has been suggested to be a measure of basic mobility skills [454]. The test 
assesses the time it takes a participant to stand up from a chair, walk around a cone 3 m away, 
walk back to the chair, and sit down. Data regarding norms and threshold scores for the TUG-test 
are available but are somewhat conflicting. For example, Steffen et al.,[463] reported average 
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TUG-test times on a group of 60 to 69 years old men and women around 8sec. Bischoff et al., 
[455] recommended the need for early evaluation and intervention for community-dwelling 
elderly women between 65-85years of age, who scored above 12 s on the TUG-test. Others 
identified a cutoff point of 24 s as a parameter that significantly predicted falls during a 6-month 
follow-up period. In the present study, 26% of participants scored above the 12s mark, 
suggesting these patients may be at elevated risk.  
 
          Figure 4.4. Association between peak vascular conductance and the maximal                 
          walking distance cut-off points. Difference is significant at p=0.007 
 
Maximal isokinetic knee strength is a common measure of muscular strength and thus 
chosen for the current study. It has been shown to decline with advancing age [464,465]. The 
average KE for this cohort (104.71±56.83 N·m) is approximately 10% lower than those reported 
for 60 to 69 year old individuals participating in NHANES 1999-2000 [465]. In addition, the 
average KF in the present study (51.38±25.09 N·m) is 17% lower than those reported for men 
and women aged 70 to 79 years from the Health, Aging, and Body Composition Study [464]. 
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These data suggest that patients with peripheral neuropathy have lower than expected leg 
strength. Lack of measurement of muscle mass, composition, or more sophisticated tests to 




            Figure 4.5. Association between venous outflow halftime (VOt1/2) and peak knee 
                 flexion torque (KF) tertiles. * indicates significant difference from other tertiles            
                 (p<0.05)  
 
4.4.3 Associations between Vascular and Physical Function                                                  
 The major focus of this study was to examine the relationship between measures of lower 
leg vascular and physical function in individuals with peripheral neuropathy. The data are 
consistent with the stated hypothesis that individuals who have greater peak RHBF responses 
and vascular conductance following occlusion have higher scores on the TUG and 6MWD tests. 
In contrast, no significant associations were noted between the measures of vascular reactivity 
and knee flexion and extension.  
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 It is important to notice the relationship between peak RHBF responses, vascular 
conductance and the 6MWD. Both vascular indices studied provide evidence of the ability of the 
vasculature to respond to an increase in metabolic demand (i.e. 5 minutes of occlusion). 
Arguably, the physiologic demands associated with the walking test would also serve to 
challenge the vasculature, and consequently individuals who have evidence of vascular 
impairments would have a reduced motor capacity. Importantly, this study used 400 m as the 
differentiating point. Studies have indicated the prognostic value of this threshold as it relates to 
institutionalization, morbidity, mortality, hospitalization and transplantation [462]. It is 
interesting to speculate that the increased risk in patients with peripheral neuropathy, who score 
below 400m on the walk test, may in part be secondary to diminished vascular function.                 
 It is also important to notice the relationship between peak RHBF responses, vascular 
conductance and the TUG-test. The TUG-test is a basic test used to examine mobility and 
balance. Arguably performance of the TUG-test is a more complex interplay between 
physiological systems than the walk test. It is generally accepted that the TUG-test does not 
focus on independent effects of organ impairments, such as low muscle strength, decreased 
balance and other impairments, but measures the interaction of these factors on the performance 
of activities of daily living. It is not clear what influence a diminished vasculature has during the 
TUG-test in the peripheral neuropathy patients. However, we speculate that the initiation and 
subsequent continuation of a movement pattern is very much dependent on the ability to 
immediately increase blood flow to the working muscle. A major factor in the acute rise in 
muscle blood flow is the muscle pump, and subsequent distribution of cardiac output toward the 
working muscle. Thus, if the factors involved in the initial rise in blood flow with the onset of 
activity are impaired this could result in the increase time needed to perform the TUG-test. We 
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are unaware of studies that have examined blood flow at the onset of exercise in peripheral 
neuropathy, but do recognize that such responses are blunted in the elderly. Thus, we encourage 
further studies to explore the link between muscle blood flow and functionality in the peripheral 
neuropathy patient.               
 The lack of significant associations between peak RHBF responses, vascular conductance 
and the isokinetic strength tests was not surprising. The strength tests probably are more specific 
in regards to the physiologic systems involved in the movement (e.g. muscle mass and neural 
innervation), and more than likely does not rely heavily on the delivery of blood to perform the 
test. In contrast, both KE and KF were significantly related to the VOt1/2. These findings further 
confirm data from our laboratory suggesting that muscular fitness is related to venous function. 
The associations suggest the contribution of the venous system to motor function is beyond the 
typical role as a “passive volume reservoir”. Importantly, the venous system is controlled 
primarily by the sympathetic nervous system. Generally, patients with chronic degenerative 
conditions tend to be hyperadrenergic. It is certainly possible that muscle deconditioning in some 
patients with peripheral neuropathy contributes to modifications in venous function.                   
 We remain cautious in our interpretations considering the limitations inherent to a cross 
sectional design and the lack of causality presented. It is also recognized that the lack of 
longitudinal data regarding vascular and physical function and many other important factors in 
individuals with peripheral neuropathy are not accounted for in the present study. However, the 
present observations are unique in a sense that it is the first study to establish a link between 
vascular and physical function in patients with peripheral neuropathy, and consequently 
contributes to the existing literature in identifying several unique aspects that warrant further 
discussion and research. 
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It is also recognized that the present data do not elucidate possible mechanisms why 
individuals with the variables under interest are linked. The lack of a mechanistic approach in the 
current study prevents more sophisticated speculation regarding the development of possible 
preventive or compensatory interventions. However, given data indicating that exercise training  
can improve vascular function [433] we hypothesize that physical training may be an excellent 
way to preserve functional ability and independence in certain patients with peripheral 
neuropathy.                                                                                                                                      
 In summary, the present findings strongly suggest that diminished vascular function 
contributes to a decrease in physical function in individuals with peripheral neuropathy. These 
findings are particularly interesting in light of recent data that clearly indicates that lower 
cardiorespiratory fitness is a significant predictor of dependence [466] and that ABI is a strong 
predictor of the degree of functional decline in patients with PAD [219].                                       
 The newly published “International Classification of Impairments, Disabilities, and 
Handicaps” (ICF) by the World Health Organization (www.who.int/classification/icf) 
emphasizes the influence of human body function and structure on the level of functioning, 
activity and participation. People with peripheral neuropathy have little activity and participation 
due to limited by mobility, and this in turn have a negative effect on their quality of life. The 
recognition of a relationship between vascular and physical functions enables us to further 
investigate the mechanisms that underlie the functional limitations. These future studies may 
provide us the information necessary for the development of effective interventions.               
4.4.4 Conclusion                                                                                                                                   
 The purpose of the present investigation was to examine the relationship between 
measures of leg vascular and physical function in individuals with peripheral neuropathy. The 
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results support a relationship between measures of vascular and physical function where 
individuals with greater physical function scores exhibited more favorable measures of arterial 
inflow and venous outflow. The lower physical function may, in part, be a consequence of 
deterioration of peripheral vascular function in individuals with peripheral neuropathy. 
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Chapter 5  
Effects of an Acute Bout of Exercise on Nitric Oxide Bioavailability, Oxidative Stress, and 
Anti-oxidant Defense Markers in Trained Individuals    
 
5.1 Introduction                                                                                                                            
  The endothelium controls vascular tone, coagulation, and inflammatory responses.  
Indeed, normal endothelial function includes control of antithrombotic and thrombolytic activity, 
vascular architecture and permeability, leukocyte interactions with the vessel wall, and vascular 
tone regulation during rest and exercise [237]. Vascular endothelial cells play an important role 
in maintaining cardiovascular homeostasis primarily through the release of protective bioactive 
substances, the most widely studied being nitric oxide [467]. The capacity of the endothelium to 
release nitric oxide has been recognized as an important surrogate marker of general endothelial 
health [468]. Cardiovascular diseases, diabetes, aging, and smoking, among other factors, have 
been associated with reduced vascular endothelial nitric oxide function [469]. In addition, 
disturbances of nitric oxide bioavailability have been suggested to play a key role in vascular 
dysfunction and the development of atherosclerotic lesions [470].  
 Nitric oxide is a labile, lipid soluble gas synthesized in endothelial cells from amino-acid 
L-arginine through the action of endothelial nitric oxide synthase [471]. Three distinct nitric 
oxide synthase isoforms have been identified: (a) neuronal nitric oxide synthase (type I), (b) 
inducible nitric oxide synthase (type II), and (c) endothelial nitric oxide synthase (type III) [470].  
 There are two major compartments for nitric oxide metabolism; the blood plasma and the 
red blood cells compartment. The major immediate breakdown product of nitric oxide in human 
plasma is nitrite. Plasma nitrite can be taken up by red blood cells, where it is oxidized in a 
hemoglobin-dependent manner to nitrate, which may subsequently redistribute into plasma 
153 
 
[472]. The term ‘free radical species’ summarizes a variety of highly reactive molecules that can 
be divided into different categories, e.g. reactive oxygen species, reactive nitrogen species, and 
reactive chlorine species [473]. In addition, oxidative stress species, more generally, reactive 
oxygen species, as well as reactive nitrogen species, are products of normal cellular metabolism 
[474]. Indeed, reactive oxygen species and reactive nitrogen species are well recognized for 
playing a dual role as both deleterious and beneficial species, since they can be either harmful or 
beneficial to living systems [475].                                                                                                
 The beneficial effects of reactive oxygen species occur at low/moderate concentrations 
and involve physiological roles in cellular responses to noxia; for example in defense against 
infectious agents and in the induction of a mitogenic response [474]. On the other hand, the 
harmful effect of free radicals causing potential biological damage is termed oxidative stress and 
nitrosative stress [476]. Therefore, oxidative stress refers to the situation of an imbalance 
between the production of free radicals and the antioxidant defense mechanisms.                                                                                                                                      
 In addition, Davies et al., [477] have reported that free radicals are formed also in 
response to physical exercise. In fact, there is significant evidence that an acute bout of exercise 
results in a significant increase in oxidative stress markers [478]. Interestingly, we are aware of 
only one study that has examined markers of oxidative stress and anti-oxidants molecules in 
conjunction with nitric oxide bioavailability [479]. This is particularly important as nitric oxide 
can neutralize or become neutralized by reactive oxygen species. The neutralizing capabilities of 
nitric oxide may to some extent protect the endothelial environment, but excess reactive oxygen 
species may also reduce the other functions of nitric oxide, thereby increasing vascular 
vulnerability [470].  The study by Di Massimo et al., [479] evaluated the ratio between 
nitrite/nitrate or NOx, as a marker of nitric oxide bioavailability. Their results indicated an 
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increase in NOx and oxidative stress markers, and a decrease in total antioxidant systems from 
baseline to peak exercise, returning to baseline values within 24 hrs. These findings suggest that 
endothelial balance may be altered with acute exercise. However, it is well known that plasma 
nitrate levels are influenced by a variety of nitric oxide synthase- independent factors (dietary 
intake, saliva formation, denitrifying liver enzymes, and inhaled atmospheric gaseous nitrogen).                 
 Furthermore, Lauer et al., [470] have reported that nitrate and/or NOx do not generally 
represent useful markers of endogenous nitric oxide production. According to Lauer et al.,[470] a 
better marker of nitric oxide bioavailability is the nitric oxide stored on the hemoglobin of the 
red blood cells; nitrosylated hemoglobin. Indeed, this marker has been suggested to have a 
potential role in transport and delivery of nitric oxide [480].                                                                                          
 Given the current shortcomings in the literature regarding our understanding of 
endothelial balance, the purpose of the present study was to examine the effects of an acute bout 
of exercise on nitric oxide bioavailability, oxidative stress markers, and anti-oxidants markers at 
three time points, before, at peak exercise, and at 20 minutes into the recovery phase in aerobic 
trained individuals. It was hypothesized that an acute bout of exercise would result in a decrease 
in nitric oxide bioavailability and an increase in oxidative stress markers from baseline to peak 
exercise, with a gradual return to baseline in the recovery phase. In addition, on the basis of 
previous investigations [479] it was hypothesized that the total anti-oxidants markers would 
decrease from baseline to peak exercise, and return to pre-exercise levels in recovery. It was 
speculated that the changes in the biological markers of nitric oxide, oxidative stress, and anti-
oxidant defenses, in part, reflect the endothelial responses to an acute bout of exercise and 
represent a marker of the ability to maintain endothelial balance during and following physical 
stress. In addition, this study also examined the effects of acute exercise on vascular reactivity, 
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defined as brachial artery flow mediated dilation. It was hypothesized that vascular reactivity 
would decrease from baseline to immediately after 30 minutes of high intensity cycling, and 
return to pre-exercise levels within 20 minutes of recovery.                                                          
5.2 Methods                                                                                                                                         
5.2.1 Participants                                                                                                                                
 Aerobically trained individuals were recruited to participate in this study. Individuals 
with any unstable manifestations of cardiovascular, metabolic, orthopedic, neurological disease, 
or at risk for adverse responses to exercise, and/or taking any medication which may affect 
cardiovascular function were excluded from participating. The current study was reviewed and 
approved by the Louisiana State University Institutional Review Board.                                          
5.2.2 Experimental Design                                                                                                      
 The study was a prospective design consisting of two separated visits. Both visits 
involved a bike time trial of 30 minutes. During the first visit, prior to, at peak exercise (30min) 
and at 20 minutes in recovery blood samples were obtained for the purpose of examining 
reactive oxygen species, anti-oxidants, and nitrosylated hemoglobin. In addition, gas analyses 
were used for the determination of oxygen consumption, carbon dioxide production, and 
ventilation. During visit two, vascular reactivity of the brachial artery was assessed prior to, 
immediately following peak exercise and at 20 minutes in recovery.                                              
5.2.3 Experimental Protocol                                                                                                     
 5.2.3.1 Visit 1                                                                                                                   
 Participants reported to the laboratory, and were provided with the details, risks, and 
potential benefits of the study. Following explanation and signing of the informed consent the 
participant was provided a short questionnaire to determine the training status of the individual. 
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Given the participants were all trained the questions dealt specifically with their average volume 
of training per week, and schedule of competition, and their rankings.                                            
 After the assessment a nurse clinician placed an indwelling catheter in an antecubital vein 
for the purpose of blood sampling. After securing the catheter the participant was given the 
opportunity to relax for approximately 15 minutes before the initial sample was obtained. 
 Subsequently, the participant was asked to mount their bicycle which was placed in a 
high performance, microprocessor controlled indoor trainer (Race Mate Compu Trainer). The 
participant was then fitted with head-gear for the purpose of gas analyses and a Polar heart rate 
monitor. After a brief calibration period heart rate and blood pressure were assessed, and the 
breath-by-breath respiratory gas analyses system (Sensormedics software, Yorba Linda, CA) 
started, and baseline measures obtained for five minutes. Then the time trial commenced with the 
participant pedaling at a speed of 80 to 90 revolutions per minute. Resistance was increased over 
the first 5 minutes to achieve 80 to 85% of the participant’s estimated heart rate reserve. 
Throughout the test breath-by -breath measures of oxygen consumption, carbon dioxide 
production, and pulmonary ventilation were obtained. In addition, before, during and after the 
test, heart rate, blood pressure, and ratings of perceived exertion were obtained at five minute 
intervals using a standard sphygmomanometer, Polar heart rate monitor, and Borg’s perceived 
exertion scale (RPE, Borg’s 20-point scale) [481], respectively.                                                       
 Blood sampling was performed prior to, at peak exercise (30min) and at 20 minutes in 
recovery, from an antecubital vein. Each sample was approximately seven milliliters (7 mL). 
Following each draw the sample line was flushed with saline. Prior to the second and third draw 
approximately 2 to 3 ml were drawn and discarded to prevent any saline in the sample to be 
analyzed. Following each draw approximately 3 ml of blood was immediately treated with 
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specific spin trap probes and subsequently frozen in liquid nitrogen and kept at -80°C for 
analyses. The remaining sample was centrifuged and separated and subsequently frozen for the 
analyses.                                                                                                                                   
 5.2.3.2 Visit 2                                                                                                                     
 Participants reported to the laboratory and were placed on an examination table in 
preparation for the assessment of brachial artery reactivity prior to, immediately following peak 
exercise and at 20 minutes in recovery. Following a 15 minute resting period, ultrasound images 
were obtained using high resolution ultrasonography (Hewell Packer, Sonos 2000, 7.5-MHz 
linear array transducer). Images were obtained in the longitudinal view, approximately 4 cm 
proximal to the olecranon process, in the anterior/medial plane, with the participant's arm 
immobilized and slightly supinated. Image depth was initially set at 4 cm, and gain settings were 
adjusted to provide an optimal view of the anterior and posterior intimal interfaces of the artery 
and kept constant throughout. Subsequently, brachial artery reactivity was tested by inflating a 
blood pressure cuff, positioned approximately 1 cm distal to the olecranon process, to 240 mm 
Hg for five minutes. Images were obtained immediately before forearm occlusion, and 
continuously from the final 30 seconds of occlusion until three minutes following the release of 
the blood pressure cuff.                                                                                                                           
 After the vasoreactivity test, the participant was asked to mount their bicycle which was 
again placed in a high performance, microprocessor controlled indoor trainer (Race Mate Compu 
Trainer) and the bike was properly calibrated. The time trial commenced with the participant 
pedaling at a speed of 80 to 90 revolutions per minute. Resistance was increased over the first 5 
minutes to achieve 80 to 85% of the participant’s estimated heart rate reserve. Before, during and 
after the test, heart rate, blood pressure, and ratings of perceived exertion were obtained at five 
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minute intervals using a standard sphygmomanometer, Polar heart rate monitor, and Borg’s 
perceived exertion scale (RPE, Borg’s 20-point scale) [481], respectively.                               
 Immediately following the time trial the participant was again re-positioned on the 
examination table, and the exact same procedures were used to examine brachial artery 
vasoreactivity. This test was then again conducted at 20 min in recovery.                                 
 5.2.3.3 Data Analyses                                                                                                 
 The blood markers that were analyzed include: (a) reactive oxygen species, including 
peroxynitrite, (b) specific endogenous anti-oxidants such as the enzymes glutathione, glutathione 
peroxidase and catalase, (c) nitrosylated hemoglobin, a method for in vivo nitric oxide detection. 
It is important to emphasize that nitrosylated hemoglobin have been reported as indicator of the 
potential role in transport and delivery of nitric oxide [480]. The biochemical variables were 
analyzed using the electron paramagnetic resonance (EPR) spectroscopy.  
 EPR has the potential to provide unique information on free radicals and other species 
with unpaired electrons, because of its unique ability to detect unpaired electron species (reactive 
oxygen species, nitric oxide) [482]. In fact, EPR is the most direct and unambiguous method to 
measure free radicals and thiols [483]. Under some circumstances the concentration of these 
species or their magnetic properties may make it difficult to measure them directly with EPR. 
Consequently, a technique termed “spin trapping” has been developed in which a detecting 
molecule ( usually termed a “spin trap”, e.g., a nitrone or nitroso compound) is added to the 
system, which, upon reaction with a free radical, can form a product that is another free radical 
that is considerably more stable that the initial radical [484]. The concentration of nitrosylated 
hemoglobin was recorded with an X-band EPR spectrometer. The amount of detected nitric 
oxide was determined from the calibration curve for intensity of the EPR signal of erythrocytes 
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treated with known concentrations of nitrite (1–25 µM) and Na2S2O4 (20 mM) [485].                                                                                                   
 The quantification of reactive oxygen species was as follow: cyclic hydroxylamine 1-
hydroxy-3-carboxy-pyrrolidine (CP-H) was used for the quantification of reactive oxygen 
species. During the reaction of CP-H with reactive oxygen species (lifetime more than 4 h), 
reducing agent-resistant nitroxide radicals are formed. The amount of trapped reactive oxygen 
species was obtained by quantifying the concentration of the corresponding nitroxide radical 3-
carboxyproxyl (CP). Quantification of reactive oxygen species released from blood samples 
(non-stimulated reactive oxygen species formation) was performed after incubation at 37°C for 
30 min using 500 µM CP-H and the low-field component of electron spin resonance spectra in 
50 µl quartz capillaries (Noxygen Science Transfer & Diagnostics GmbH, Elzach, Germany) 
[486].                                                                                                                                        
 All brachial artery imaging and analyses were conducted in accordance with the 
Guidelines set forth by the Brachial Artery Reactivity Task Force [487]. Images were analyzed 
using specifically developed edge-detecting software (Medical Imaging Applications, LLC). 
Visual inspection was used to ensure consistent selection of the blood-vessel interface. Arterial 
diameters were calculated as the mean distance between the anterior and posterior wall at the 
blood vessel interface, with the image in diastole, defined as the peak of the r-wave. Brachial 
artery flow mediated dilation was defined as the absolute (mm) and percent change in vessel 
diameter from rest to peak dilation, as seen at 45, 60 and 90 seconds following cuff release. The 
resolution of the brachial image in the current study allowed for a caliper accuracy of 0.028mm. 
The reproducibility of this technique in our laboratory has yielded average mean differences in 
brachial artery diameter change for days, testers, and readers of 1.91%, 1.40%, and 0.21mm 
respectively, with intra-class correlation coefficients of 0.92, 0.94, and 0.90, respectively [488].                                                                                                                                 
160 
 
5.2.4 Statistical Analysis                                                                                                                             
Data was analyzed using SPSS for Windows (version 15.0). Data was expressed as mean + SD. 
To examine the changes in nitrosylated hemoglobin, total reactive oxidative stress, peroxynitrite 
and anti-oxidant molecules between baseline, after exercise and during recovery data were 
analyzed using ANOVA with repeated measures. A value of p<0.05 was considered statistically 
significant.                                                                                                                                                    
5.3 Results                                                                                                                                             
5.3.1 Participants Characteristics                                                                                                                    
 Ten aerobically trained men (Age 33.3 ±7.3 years; Height 73.38 ± 2.72 inches; Weight 
188.75 ± 17.32 lbs) participated in the study. The majority of the athletes were either regionally 
or nationally ranked triathletes. Two of the athletes were strictly cyclists, one was an 
ultradistance runner. All athletes had been involved in regular training for at least 3 years, but the 
majority had over 5 years of competitive training experience.                                                                 
5.3.2 Exercise Measures                                                                                                                      
 The group averages for oxygen consumption, ventilation, and respiratory exchange ratios 
during the final 10 minutes of the bike trial conducted in visit 1, were 38.51±6 ml/kg/min, 
106.55±25.89 l/min, and 1.05±0.04U, respectively. In addition the average heart rate over the 
course of the bike trial was 160±12 bpm, and the target heart rate was achieved approximately 5 
minutes into the trial for all participants. The average heart rate over the course of the second 
bike trial was 157±13 bpm, and was not significantly different from the bike trial in visit 1.                
5.3.3 Biochemical Variables                                                                                                              
 The group averages for all the biochemical variables are presented in Table 5.1. Group 
averages for production rate of reactive oxygen species increased from baseline (0.06±0.02 
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Units/uL) to peak exercise (0.10±0.05 Units/uL), and return to pre-exercise values after 20 
minutes or recovery (0.05±0.03 Units/uL). The group average for peroxynitrite increased from 
baseline (0.24 ±0.81 Units/min) to peak exercise (0.31±0.11 Units/min) and returned to pre-
exercise levels after 20 minutes of recovery (0.23±0.10 Units/min).  
               Table 5.1 Biochemical variables 
 
Biochemical variable Baseline Peak exercise Recovery  
Reactive Oxygen Species 
(Units/uL) 0.06±0.02 0.10±0.05* 0.05±0.03 
Peroxynitrite  
(Units/min) 0.24 ±0.81 0.31±0.11* 0.23±0.10 
Glutathione Peroxidase 
(nmoles/mg protein/min) 97.63±19.28 71.94 ±15.93* 100.16 ±25.81 
Glutathione assay 
(nmoles/mg protein) 13.58±1.52 10.62±4.69 18.96±4.37 
Catalase assay 
(Units/mg protein/min) 5.90-05±2.30 3.27-05±0.84 5.40-05±1.76 
                 Data are presented as mean ± SD., *p<0.05 
 
 The average for the anti-oxidant glutathione peroxidase decreased from baseline 
(97.63±19.28 nmoles/mg protein/min) to peak exercise (71.94 ±15.93 nmoles/mg protein/min) 
and returned to pre-exercise values at 20 minutes after recovery (100.16 ±25.81 nmoles/mg 
protein/min). The average for the anti-oxidant glutathione was 13.58±1.52 nmole/mg protein at 
baseline, 10.62±4.69 nmole/mg protein at peak exercise, and 18.96±4.37 nmole/mg protein after 
20 minutes of recovery. In addition, catalase average was 5.90-05±2.30 Units/mg protein/min at 
baseline, 3.27-05±0.84 Units/mg protein/min at peak exercise, and 5.40-05±1.76 Units/mg 
protein/min into the recovery phase. However, there were no significant changes in glutathione 
and catalase.                                                                                                                                
 Unfortunately at this moment we are not able to report the results for the nitrosylated 
hemoglobin measurements as was intended due to technical difficulties when the samples were 
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analyzed using the electron paramagnetic resonance spectrometry. The major reason was the 
insufficient sensitivity of the electron paramagnetic resonance spectrometry used to detect 
nitrosylated hemoglobin under basal conditions. The same equipment was used previously to 
detect easily approximadetely 400 nM of nitrosylated hemoglobin in rodent blood. However, in 
order to detect nitrosylated hemoglobin in human blood (40 - 100 nM) it is required to increase 
the sensitivity of equipment up to 10 times. Several strategies were attempted to allow for a 
representation of this variable but as of yet to no avail. In particular red blood cells’ packing 
through a second centrifuge period was attempted but the sensitivity remained too low for 
accurate detection.                                                                                                                       
5.3.4 Brachial Artery Diameter and Vascular Reactivity                                                    
 Group averages for the brachial artery diameters before, immediately after and 20 
minutes in recovery are depicted in Table 5.2. Group averages for the combined averages for 
brachial artery flow mediated dilation (BAFMD) at 45, 60 and 90 seconds post release are also 
presented in Table 5.2.                                                                                                                   
 The repeated measure ANOVA for brachial artery diameters yielded a significant main 
effect (p=0.0001) indicating a significant increase in brachial artery diameter after forearm 
occlusion. However, the ANOVA also revealed a factor by condition effect (p=0.009) indicating 
that the increase in brachial artery diameter post-occlusion was only seen in the pre-bike trial and 
at 20 minutes after the bike-trial. In contrast, no significant changes in brachial artery diameter 
were observed immediately after the time trial, even though there were no significant changes in 
the pre-occlusion diameters between conditions. 
 The ANOVA for brachial artery reactivity yielded a significant condition effect 
(p=0.002), with a significant blunted response immediately post bike trial (BAFMD = 0.38%), 
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compared to pre bike trial values (BAFMD = 5.24%), and 20 minutes in recovery (BAFMD = 
3.93%), indicating a temporal pattern of reactivity.    
                 Table 5.2 Brachial artery diameter and vascular reactivity  
 




20 min after 
Bike Trial  
Base Diameter (mm) 
45sec Post release (mm) 
60sec Post release (mm) 
90sec Post release (mm) 
BAFMD (%) 
     4.43±0.36 
     4.60±0.38* 
     4.64±0.40* 
     4.67±0.38* 
     5.24±2.78 
     4.68±0.21 
     4.64±0.24 
     4.70±0.22 
     4.71±0.20 
     0.38±1.17** 





    
      Data are presented as mean ± SD., *p<0.05 vs. base; **p<0.05 vs. Pre Bike and     
      20min Post Bike trial 
 
The ANOVA for brachial artery reactivity yielded a significant condition effect 
(p=0.002), with a significant blunted response immediately post bike trial (BAFMD = 0.38%), 
compared to pre bike trial values (BAFMD = 5.24%), and 20 minutes in recovery (BAFMD = 
3.93%), indicating a temporal pattern of reactivity.                                                                                         
5.4 Discussion                                                                                                                                       
 The major purpose of this study was to examine the effects of an acute bout of exercise 
on nitric oxide bioavailability, oxidative stress and anti-oxidants markers, and brachial artery 
reactivity. Specifically these dependent measures were examined before, at peak exercise, and at 
20 minutes into the recovery phase, in aerobically trained individuals. The two major unique 
outcomes of the present study indicate a significant increase in the production rate of reactive 
oxygen species and peroxynitrite, and a decrease in the anti-oxidant glutathione peroxidase at 
peak exercise. In addition, brachial artery reactivity revealed a temporal pattern, with a blunted 
response immediately after exercise, but near complete recovery after 20 minutes of recovery. 
These findings support the a-priori hypotheses, and suggest an acute bout of exercise contributes 
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to a significant rise in reactive oxygen stress on the vasculature, which can in part be buffered by 
anti-oxidants systems, but may cause temporary blunting of arterial reactivity.                                   
5.4.1 Exercise Measures                                                                                                                    
 The present study utilized a time trial to examine the effects of exercise on pro- and anti-
oxidants and vascular function. The exercise protocol in the present study was similar to the 
study by Shing et al., [489]. The average oxygen consumption (VO2) during the bike trial in visit 
1 was 38.51±6 ml/kg/min. This average was lower than the subjects in the study by Shing et al., 
[489] who reported a VO2 average of 44.60 ml/kg/min among their participants. The differences 
in the VO2 average may in part be due to an older population in the present study (Age= 33 ±7.3 
years), compared to Shing et al., [489] (Age= 25±4 Years). Interestingly, a study by Laursen et 
al., [490] aimed to compare the cycling performance of cyclists and triathletes found that cyclists 
may be able to perform better than triathletes in cycling time-trial events. This finding is 
important in trying to explain the VO2 differences. As mentioned before, the participants in the 
study by Shing et al., [489] were all trained cyclists, whilst the majority of the participants in the 
present study were triathletes.                                                                                                     
 Regardless whether the VO2 averages are somewhat lower than perhaps expected, the 
heart rate responses were consistent with an 80 to 85% of the participant’s heart rate reserve. In 
doing so, all the participants were exercising at the same intensity, which mimicks a competitive 
ride as reported by most of the riders. The decision to use the heart rate reserve method in this 
population is based on work done by Lounana et al., [491]. These investigators stated that the use 
of percentage heart rate reserve is a better indicator of exercise intensity among cyclists. Finally, 
the findings that the averages heart rate did not show significant differences between the bike 
time trials; provides strong evidence that both tests were performed equally as planned.             
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5.4.2 Reactive Oxygen Species                                                                                               
 This study found that the production rate of reactive oxygen species and the pro-oxidant 
peroxynitrite increased from baseline to peak exercise and then returned to pre-exercise values 
after 20 minutes of recovery. Previous studies that have investigated oxidative stress markers 
among trained individuals report similar trends. For example, Shing et al., [489] found an 
increase in biomarkers of oxidative stress among trained cyclists after high-intensity exercise. 
The major aim of the study by Shing et al., [489] was to determine the influence of consecutive 
days of high-intensity aerobic bike exercise on oxidative stress markers. The blood samples were 
taken 10 minutes before and 5 minutes after the exercise. Their results indicated a significant 
increase (18%) in plasma malondialdehyde post-exercise. In addition, Lovlin et al., [492] 
investigated the relationship between exercise intensity and lipid peroxidation in moderately 
trained males. These investigators reported that maximal exercise resulted in a 26% increase in 
plasma malondialdehyde post-exercise. These previous studies clearly show a similar pattern, 
albeit to a lower magnitude, as reported in the present study, where the production rate of 
reactive oxygen species increased 66%, and peroxinitrite 29%, from baseline to peak exercise. 
Interestingly, the production rate of reactive oxygen species and peroxinitrite were not different 
from baseline values at the 20 minutes mark in recovery. This stands in contrast with several 
studies which report that secondary measures of oxidative stress remain elevated for a period of 
time after exercise. For example, Michailidis et al., [493] reported that lipid peroxidation, as 
measured by thiobarbituric acid reactive substances was elevated immediately and up to 3 hours 
after 45 minutes of running on a treadmill at an intensity corresponding to 70-75% of subjects’ 
VO2max. The subjects in the study by Michailidis et al., [493] were low to moderately trained 
.Further confirmation that secondary measures of oxidative stress remain elevated comes from a 
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study by Alessio et al., [494]. These investigators also reported an elevated (46%) in plasma 
thiobarbituric acid reacting substances among moderately trained individuals after 30 minutes 
submaximal exercise. Participants in a study by Watson et al., [495] utilized trained individuals 
who ran for 30 minutes at a submaximal speed corresponding to 60% of their VO2max. Again, 
Watson et al., [495] reported that plasma lipid peroxidation, as measured by F2-isoprostanes 
concentration (marker of oxidative stress) was significantly higher after the submaximal bout of 
exercise (38%), and remained significantly elevated one hour into recovery (31%). However, the 
findings in the current study were similar to those observed by Steensberg et al., [496]. Those 
investigators reported that the concentration of plasma F2- isoprostanes increased approximately 
1.6-fold in response to a treadmill exercise, but declined towards pre-exercise values within the 
first hour of recovery. Obviously the differences in observations between studies are often 
secondary to study design, study population and methodological issues, and are therefore 
difficult to reconcile. However, the present study is particularly unique in that the production rate 
of reactive oxygen species was a direct measure rather than a secondary marker of oxidative 
stress.                                                                                                                                                     
 In fact, it is important to recognize that many of the referenced studies have indeed used 
secondary biomarkers to report oxidative stress (e.g. plasma malondialdehyde, thiobarbituric 
acid reactive substances, and F2-isoprostanes). Arguably a major problem with those studies and 
methods is that the measures of oxidative stress are indirect and reflect tissue damage rather than 
production of oxidative stress. Consequently, many of those studies lack specificity. For 
example, it is well-known that thiobarbituric acid reactive substances react with a wide variety of 
compounds, including sugars and DNA [497]. Indeed, there is concern about the validity of 
thiobarbituric acid reactive substances assay in detecting lipid perodixation in vivo, because  
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thiobarbituric acid reactive substances assay is not specific to malondialdehyde, and lipid 
peroxidation is not the exclusive source of malondialdehyde [498]. Furthermore, oxidation 
products are typically present at low levels in biological material. Finally, normal concentrations 
of F2-isoprostanes in human plasma have been proposed to range from 5 to 40 pg·mL-1 [499]. 
However, the clinical significance of concentrations outside this range has not been described 
because no direct casual relationship between F2-isoprostanes and exercise performance has been 
found [499]. Such assays therefore are prone to artifacts and cannot provide strong evidence of 
the actual oxidative stress in vivo [497].                                                                                         
 The unique contribution of the present study is that the production rate of reactive oxygen 
species was examined before, at peak exercise, and 20 minutes after recovery. This is the first 
such study in exercising humans, and may represent a more direct method of determining the 
total pool of reactive oxygen species produced under stressful conditions, such as an acute bout 
of exercise. However, some caution is needed at this point. The present study reports the 
production rate of reactive oxygen species as measured from the red blood cell. Obviously future 
studies must determine if a change in the production rate in the red blood cell is indeed a 
reflection of other physiological systems that may also produce oxidative species at a high rate 
during exercise. In addition, the rate of production of the reactive oxygen species is not taken in 
real-time but is measured after obtaining a blood sample and immediately adding the sample to a 
buffer and frozen in liquid nitrogen.                                                                                                   
 Given these possible limitations, it must also be appreciated that reactive oxygen species 
can be produced during exercise from several potential cellular sources. Some sources may be 
more important that others in a certain organ, at a specific time, or with a specific exercise mode. 
However, these sources are not mutually exclusive and can be activated simultaneously [500]. In 
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fact, extensive reviews regarding the sources of reactive oxygen species during exercise [501] 
clearly suggests a major source of free radical production during exercise is the mitochondrial 
electron transport chain [497]. Indeed, superoxide is produced during the oxidation of reduced 
nicotinamide adenine dinucleotide to oxidize nicotinamide adenine dinucleotide [502]. Under 
normal metabolic conditions, it has estimated that for every 25 oxygen molecules reduced by 
normal respiration, one free radical is produced [503]. Given that the rate of whole body oxygen 
consumption during exercise may increase 10–15 fold, and oxygen flux in an active muscle may 
increase about 100 fold [504], the rate of production of several oxidative species is sure to rise. 
With this rise in production a greater number of these species are sure to leak out of the electron 
transport chain [503] and leave surrounding tissues vulnerable to their damaging effects. Several 
candidates of oxidative species have been identified, including hydrogen peroxide, hydroxyl 
radicals, and others [505]. Approximately 4% of electrons that enter the respiratory chain lead to 
the formation of superoxide, whereas hydrogen peroxide is produced after the spontaneous or 
superoxide dismutase-catalyzed dismutation of superoxide as well as many others enzymatic 
reactions. Unlike superoxide, which remains at the site of production, hydrogen peroxide can 
diffuse across membranes and through the cytosol [506].  
 More recently, nitric oxide has also been linked to the formation of pro-oxidants. In fact, 
at higher levels of production, nitric oxide reacts with radicals such as superoxide to form 
peroxynitrite, a powerful pro-oxidant [507]. Interestingly in the present study a significant rise in 
the production rate of peroxynitrite was seen from pre- to peak exercise, and returned to pre-
exercise levels at 20 minutes into recovery. This provides direct evidence of a significant rise in 




 In addition to mitochondrial production of oxidative species, some studies have reported 
an extramitochondrial source of free radicals. There is significant amount of information on 
putative reactive species that could contribute to exercise-induced oxidative injury or post-
exercise vascular injury [497]. Central to such oxidative damage are xanthine dehydrogenase and 
oxidase and calcium. For instance, Vina et al., [508] have hypothesized that activation of 
xanthine oxidase could be important in the generation of free radicals during exercise. Xanthine 
dehydrogenase is found mainly in endothelial cells of blood vessels and in skeletal and cardiac 
muscle [497]. Xanthine dehydrogenase may convert nicotinamide adenine dinucleotide to 
reduced nicotinamide adenine dinucleotide, whereas xanthine oxidase utilizes oxygen and 
xanthine, a purine degradation product, to produce superoxide and hydrogen peroxide. In 
addition, xanthine oxidase catalyzed reactions have been well established as one of the major 
sources of free radical generation in the ischemia and reperfused heart [509]. Duarte et al., [510] 
pointed out that the endothelium might contribute to muscle damage induced by exercise. These 
investigators stated that the xanthine oxidase located in capillary endothelium is one of the 
possible sources for the production of reactive oxygen species. In addition, Vina et al., [511] 
showed that inhibition of xanthine oxidase with allopurinol protects against exercise-induced 
oxidation of glutathione in humans.  
 Finally, an increase in the release of calcium by pro-oxidants stimulates calcium-
dependent enzymes such as calcium-dependent proteases, nucleases, and phospholipases, which 
subsequently trigger apoptosis of the cells [512]. Once calcium efflux has been triggered, a series 
of common pathways of apoptosis are initiated, each of which may be sufficient to destroy the 
cell [512]. Given the rise in the production rate of pro-oxidants from the red blood cell as shown 
in this study, this is yet another extramitochondrial source of free radicals. Future studies must 
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determine if the production rate of free radicals from the red blood cell is indeed similar, or at 
least a reflection of other free radical generating sources.  
 It is important to reflect on the necessity of the production of reactive oxygen species in 
the human body. Certainly not all effects of these pro-oxidants are negative. In fact they can be 
beneficial to living systems [475]. The beneficial effects of reactive oxygen species occur at 
low/moderate concentrations and involve physiological roles in cellular responses to noxia; for 
example in defense against infectious agents and in the induction of a mitogenic response [474]. 
On the other hand, the harmful effect of free radicals may contribute to biological damage and is 
termed oxidative stress [476]. Indeed, these radicals can cause damage to cardinal cellular 
components such as lipids [513] proteins [514] and nucleic acids [515].                                        
 In summary the present study indicates a significant rise in pro-oxidants with exercise in 
trained individuals, which is quickly resolved within 20 minutes of recovery. These data suggest 
a potential increase in vulnerability to oxidative stress with exercise, but only for a limited time 
perhaps indicating a significant ability to buffer against oxidative species.                                       
5.4.3 Anti-oxidants                                                                                                                             
 It is, indeed, imperative to emphasize that oxidative status is controlled by a wide 
spectrum of exogenous and endogenous anti-oxidants [473]. In general, the body has adequate 
anti-oxidant reserves to cope with the production of reactive oxygen species under most normal 
physiological conditions. For example, the system consists of anti-oxidant vitamins, glutathione 
and thiols, and anti-oxidant enzymes [502]. Each of these anti-oxidants plays a unique role in the 
cell and complements each other functionally. Furthermore, inter-organ transport of certain anti-
oxidants is likely to occur. These anti-oxidant protection systems preserve homeostasis for 
normal cell functions at rest and perhaps during mild exercise [501]. However, when reactive 
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oxygen species production is excessive, or anti-oxidant capacity insufficient, oxidative stress will 
develop, potentially leading to cellular damage. Indeed, the extent of oxidative damage during 
physical exercise is determined not only by the level of free radical generation, but also by the 
defense capacity of anti-oxidants.  
 The possible mechanisms by which anti-oxidants protect against pro-oxidants are 
complex and multifactorial [516], and they may include; (a) prevention of reactive oxygen 
species formation, (b) interception of reactive oxygen species attack by scavenging the reactive 
metabolites and converting them to less reactive molecules and/or by enhancing the resistance of 
sensitive biological targets to reactive oxygen species attack, (c) avoiding the transformation of 
less reactive oxygen species (e.g., superoxide ) to more deleterious forms (e.g., hydroxyl), (d) 
facilitating the repair of damage caused by reactive oxygen species and triggering the expression 
of genes that encode anti-oxidant proteins, and (e) providing a favorable environment for the 
effective functioning of other anti-oxidants (e.g., as a cofactor or by acting to maintain a suitable 
redox status) [517]. Therefore examination of a disturbance in the equilibrium status of pro-
oxidant/anti-oxidant reactions in living organisms is quite important to determine the organism’s 
vulnerability [474].                                                     
 As discussed above, the present study clearly indicates that the oxidative stress increases 
with exercise, but quickly returns to pre-exercise levels suggesting the overall exposure to the 
pro-oxidants is short. Importantly this study also reports that some anti-oxidant systems are 
modified during and after exercise. In fact, glutathione peroxidase concentrations decreased from 
baseline to peak exercise and then returned to pre-exercise values at 20 minutes of recovery. 
However, no such changes were noted for catalase and glutathione. The manner in which anti-
oxidants operate will be briefly discussed in this next section. Glutathione (gamma-
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glutamylcysteinylglycine) is a tripeptide of glycine, glutamic acid and cysteine that plays a 
central role in metabolic pathways, as well as in the anti-oxidant system of most aerobic cells. 
Indeed, glutathione is the most abundant non-protein thiol source in the cell and serves multiples 
functions in protecting tissues from oxidative damage and keeping the intracellular environment 
in the reduced state [518]. Glutathione acts as an anti-oxidant both intra- and extracellularly and 
is required as a coenzyme by a variety of enzymes including glutathione peroxidase, glutathione 
S-transferase and thioltransferase [502]. In the red blood cell, the reduced form of glutathione is 
vital in maintaining hemoglobin in a reduced state and hence protecting the cells from oxidative 
damage [519]. In addition, glutathione is involved in detoxification of hydrogen peroxide 
through glutathione peroxidase. Glutathione peroxidases are selenoenzymes which catalyze the 
reduction of hydroperoxides in the presence of glutathione. Hydrogen peroxide, a reactive 
oxygen species, is a harmful by-product of many normal metabolic processes. In order to prevent 
damage, it must be quickly converted into other, less dangerous substances [520]. Both, 
glutathione peroxidase and catalase (an intracellular enzyme) are frequently used by cells to 
rapidly catalyze the decomposition of hydrogen peroxide into less reactive gaseous oxygen and 
water molecules [520]. In addition, glutathione peroxidase and catalase provide the primary 
defense against reactive oxygen species generated during exercise, and activities of these 
enzymes are known to increase in response to exercise in both animal and human studies [521].                                                                                                                       
 In regard to our findings, previous studies [522] have also reported a decrease in 
glutathione peroxidase after an acute bout of exercise. For example, the study by Bloomer et al., 
[523] reported a decrease in glutathione peroxidase immediately following exercise, and it 
returned to pre-exercise values at 60 minutes into the recovery phase. This study was conducted 
among trained individuals performing an aerobic cycling activity for 30 minutes. The same 
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investigators [523] suggested that after exercise, hepatic glutathione (coenzyme for glutathione 
peroxidase formation) supply may not be sufficient to match the enhanced use resulting in 
reduction of blood glutathione concentration. In addition, the decrease in anti-oxidant enzyme 
activity observed may reflect allosteric downregulation of the enzymes in addition to enzyme 
inactivation attributable to overwhelming oxidative stress. Indeed, Elosua et al., [524] have also 
shown that there is a transient decrease in whole-blood glutathione peroxidase after 30-min 
exercise cycling bout, and a tendency to recover the basal values within two hours. These 
investigators [524] concluded that exercise-induced reactive oxygen species production leads to 
the consumption of enzyme activity with a subsequent rebound recovery. Clearly, the above 
studies reported a decrease in glutathione peroxidase immediately after an acute bout of exercise.   
 Furthermore, in the present study, the anti-oxidant catalase did not exhibit significant 
changes after the acute bout of exercise. This finding is consistent with most of the previous 
studies concerning muscle catalase [500]. However, studies that have examined the effect of a 
single bout of aerobic exercise on blood catalase activity have reported mixed results. Some of 
them have reported an increase [522], whilst others reported no differences [478]. It is important 
to notice that our study was performed by aerobically trained individuals that did not exhibit 
significant changes in the anti-oxidant catalase. On the contrary, those studies that have reported 
an increase in catalase after an acute bout of exercise [522] were done among untrained 
individuals performing exhaustive aerobic exercise of moderate duration. The discrepancy 
among the results may be explained by the trained status of the participants. Indeed, several 
studies have found that trained individuals responded differently to oxidative stress induced by 
an acute exercise bout compared with untrained subjects [478]. In that regard, Vollaard et al., 
[498] suggested that the degree of oxidative stress may be attenuated by chronic aerobic and 
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anaerobic training, through an increase in endogenous anti-oxidant production, a decrease in free 
radical generation, or a combination of both processes. Furthermore, individuals engaged in 
long-term heavy exercise become more resistant to oxidative stress mainly due to the adaptation 
of their anti-oxidant defense systems [521].                                                                                         
 In addition, Chakraborti et al., [525] have reported that an acute bout of exercise 
increases the activities of anti-oxidant enzymes, including glutathione peroxidase and catalase in 
skeletal muscle, heart and liver, which may result in a transient reduction in their blood 
concentration. Indeed, plasma and muscle glutathione peroxidase content may be decreased 
eventually during prolonged exhaustive exercise when hepatic glutathione reserve is diminished 
and glutathione peroxidase use exceeds glutathione uptake [526]. Finally, Chakraborti et al., 
[525] concluded that the threshold and magnitude of activation appear different among enzymes 
and tissues. The mechanisms by which anti-oxidant enzymes are activated within a relatively 
short period of time during exercise are largely unknown. However, reactive oxygen species 
have long been postulated to stimulate the expression of anti-oxidant enzymes [504].                      
 The findings of the present study suggest that the anti-oxidant defenses among 
aerobically trained individuals are critical in the efforts to buffer the increase in the rate of 
production of pro-oxidants. In addition, the present findings clearly show a significant rebound 
effect following exercise in aerobically trained individuals. However, understanding the 
mechanisms involved in the increased anti-oxidant enzyme activity during exercise remains a 
great challenge. Obviously, further studies are needed to determine if this apparent rebound is 
similar in less trained individuals or those who are older or suffering from chronic disease. 
Evidence of the beneficial effect of physical exercise on minimizing oxidative stress might be 
related to increased anti-oxidant defenses [527]. In the same manner, Franzoni et al., [528] have 
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demonstrated that chronic endurance training is associated with increased plasma anti-oxidant 
activity in young and older men.                                                                                                                   
 In summary, the current study suggests that some anti-oxidant defenses in aerobically 
trained individuals are critical in the efforts to buffer the increase in the rate of production of pro-
oxidants. However, it appears that some anti-oxidant systems are depleted at peak exercise, but 
rebound to pre-exercise levels within 20 minutes of recovery in aerobically trained individuals.   
5.4.4 Brachial Artery Diameter and Vascular Reactivity                                                                 
 A unique objective of this study was to determine the effects of an acute bout of exercise 
on brachial artery diameter and reactivity. The basis for this examination was evidence from 
other studies that an acute assault to the vasculature results in a transient reduction in vascular 
function as defined by brachial artery flow mediated dilation. For example, several studies 
indicate that a single high fat [529] and or high glucose meal [530], cigarette smoke [531], and 
mental stress [532] transiently blunt vascular function.  
 Interestingly, no studies have examined the effects of an acute bout of exercise on 
vascular function in trained individuals, despite significant evidence that chronic exercise 
training improves vascular health. So the idea that chronic consumption of high fat, high glucose, 
tobacco, and mental stress may have a chronic detrimental effect on the vasculature, chronic 
exercise training appears to benefit vascular health. Thus the examination of potential factors that 
may be produced during an acute bout of exercise may eventually provide insight about the 
manner in which exercise may protect the vasculature. To that extent the discussion so far has 
centered on the effects of an acute bout of exercise on pro- and anti-oxidants. This section of the 
discussion will center on the vascular responses. The unique finding of the study is a transient 
reduction in brachial reactivity at peak exercise which is restored within 20 minutes.                                                                                                                        
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 This is the first study to show a blunted response in brachial vascular reactivity 
immediately following acute exercise in aerobically trained individuals. In fact, only one other 
study [533] has reported on post exercise vasoreactivity. In that study the authors report a 2.3 
fold reduction in brachial vascular reactivity among persons with intermittent claudication 
following a single bout of maximal treadmill exercise. Interestingly along with the reduction in 
vasoreactivity (from 8.5±0.9 to 3.7±0.8%, p<0.01), the authors found an increased plasma levels 
of thiobarbituric acid-reactive substances (from 1.93±0.06 to 2.22±0.1 nmol/ml, P<0.02) and of 
soluble intercellular adhesion molecule-1 (from 282±17 to 323±19 ng/ml, P<0.01). More 
importantly, vitamin C prevented the acute, systemic impairment in endothelial function induced 
by maximal exercise, suggesting a role for anti-oxidant therapy [533]. In fact, these investigators 
recommend that there is a need for future studies aimed at assessing whether chronic oral 
treatment with anti-oxidant agents improves systemic endothelial function in patients with 
intermittent claudication.                                                                                                                   
 The potential mechanism that a change in pro-oxidant/anti-oxidant balance could mediate 
vascular reactivity is obviously pertinent to the current study as well, and will be discussed in 
greater detail in the next section of the paper. However, prior to this discussion it is also critical 
to discuss additional factors which could have contributed to the temporal pattern, of 
vasoreactivity during and following exercise.  
 Generally vasoreactivity as defined by brachial artery flow mediated dilation is thought to 
be in part controlled by endothelial derived vasodilators (esp. nitric oxide), local metabolites, 
autonomic influences, and structural components of the vessel [534]. To that extent, a change in 
or utilization of nitric oxide immediately after exercise could indeed affect vasoreactivity. 
However, it is important to appreciate that previous data from this laboratory consistently reports 
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a significant inverse relationship between arterial diameter and vasoreactivity [535]. Given the 
evidence that the brachial artery diameter after exercise was larger than the pre-exercise 
diameters (p<0.05) would in part explain why the reactivity would be less. However, this does 
not fully explain the loss of reactivity as the brachial diameters immediately after exercise were 
not significantly different from the 20 minute recovery mark.  
 Probably the major factor that contributed to a larger artery immediately after exercise is 
a dramatic increase in blood flow and/or flow velocity. In fact, Tanaka et al., [536] reported that 
the brachial artery is exposed to an increase in blood flow even though work is performed by the 
lower extremities. This augmented blood flow, through local regulatory mechanisms, causes 
vasodilation; which can persist for at least one hour after cessation of exercise [537], depending 
on the exercise intensity. Thus one could argue that the reason for the reduced vasoreactivity 
immediately after exercise is due to the artery being close to its “maximal” physiological value. 
The lack of response may therefore be a consequence of a “ceiling effect”, rather than other 
factors.                                                                                 
 In summary, the present study indicates that brachial artery reactivity revealed a temporal 
pattern, with a blunted response immediately after exercise, but near complete recovery after 20 
minutes of recovery. These findings are consistent with other studies that report that certain 
stressors may contribute to decreased vascular performance for a period of time. Future studies 
are necessary to further determine why exposure to some stressors (e.g. high triglyceride, and 
hyperglycemic meals, and cigarette smoke) causes vascular erosion, and other stressors (such as 
exercise) contributes to improved vascular function. Within such an exploration it is 
hypothesized that the maintenance and/or return to a favorable balance of pro- and anti-oxidant is 
critical.                                                                                                                                                         
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5.4.5 The Connection between Pro- and Anti-oxidants and Vascular Reactivity                                
 In a recent provocative review by Deanfield et al., [9] perturbations to endothelial 
homeostasis was suggested as a major factor in the development of arterial disease. A major 
point of discussion within the review was endothelial activation. Endothelial activation [9] was 
defined as a switch from a quiescent phenotype toward one that invokes activation of molecular 
machinery that result in the expression of chemokines, cytokines, and adhesion molecules 
designed to interact with leukocytes and platelets and target inflammation [538]. The 
fundamental change involved in this process is a switch in signaling from a nitric oxide-mediated 
silencing of cellular processes toward activation by redox signaling. Reactive oxygen species in 
the presence of superoxide dismutase, lead to generation of hydrogen peroxide, which, like nitric 
oxide, can diffuse rapidly throughout the cell and react with cysteine groups in proteins to alter 
their function [9]. However, because of the different chemistry involved, this results in very 
different consequences, such as phosphorylation of transcription factors, induction of nuclear 
chromatin remodeling and transcription genes, and protease activation [9]. It is intriguing that 
endothelial nitric oxide synthase, which normally helps maintain the quiescent state of the 
endothelium, can switch to generate reactive oxygen species in appropriate circumstances as part 
of endothelial activation [9]. This is termed endothelial nitric oxide synthase uncoupling, and 
results in superoxide formation if the key cofactor tetrahydrobiopterin is not present or 
generation of hydrogen peroxide if the substrate L-arginine is deficient [539]. The ability of 
endothelial nitric oxide synthase to regulate both the quiescent and activated endothelial 
phenotype puts this enzyme at the center of endothelial homeostasis [9], and the maintenance of 
vascular health. In fact, it is hypothesized that prolonged and/or repeated exposure to factors that 
ultimately exhaust the protective effect of endogenous anti-inflammatory systems within 
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endothelial cells, will contribute to endothelial dysfunction, loss of endothelial cell integrity, 
accelerated cell senescence, and detachment into the circulation. 
 Central to this paper is the manner in which an acute bout of exercise can alter 
endothelial homeostasis. This information is thought to be critical in developing a better 
understanding of how chronic exercise may help maintain vascular health as implied from the 
available literature [540]. The present study clearly shows an increase in the production rate of 
reactive oxygen species and to some extent a reduction of anti-oxidant systems at peak exercise. 
In fact, examination of the ratio between glutathione peroxidase and reactive oxygen species (Pre 
Exercise: 1701±485; Peak Exercise: 669±221; 20 min Recovery: 2093±1543, p<0.05), and 
glutathione peroxidase and peroxynitrite (Pre Exercise: 515±415; Peak Exercise: 225±71; 20 min 
Recovery: 471±143, p<0.05) shows a significant decline in these ratios at peak exercise, 
suggesting a significant change of the balance of pro-oxidant/anti-oxidants, in favor of oxidative 
stress. Purportedly such a change in oxidative stress may be sufficient to trigger endothelial 
activation, and contribute to a more vulnerable endothelial environment. Obviously, it is 
recognized that the derived ratio within this study, is merely a gross measure of the balance of 
pro-oxidant/anti-oxidants, and only serves as a point of illustration. However, the fact the present 
study also shows an association between the levels of glutathione peroxidase and brachial artery 
flow mediated dilation (r=0.578, p<0.05), and reactive oxygen species and brachial artery flow 
mediated dilation (r=-0.431, p<0.05) certainly keeps the hypothesis alive that the pro-
oxidant/anti-oxidant balance is a critical component in maintaining vascular reactivity. 
 Theoretically the ability of an acute bout of exercise to trigger endothelial activation 
seems to defy intuition; in the face of a plethora of evidence of the benefits of exercise on the 
cardiovascular system is undeniable [541]. Thus, the current finding beckons the question how 
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chronic exercise protects the vasculature. Obviously, the present study was not designed to 
answer this question, but future study designs should attempt to examine this directly. However, 
it is perhaps within the discretion of this paper to speculate how chronic exercise may eventually 
produce a protective endothelial environment. Using this discretion, it is perhaps important to 
revisit Selye’s theory of stress-response-adaptation [542]. Applied to vascular physiology this 
theory suggests that an acute exercise stress, when applied to the vascular system, will initially 
contribute to a period of reduced function. However, if the exercise stress is repeated over a 
period of time, the vasculature adapts to allow for an increased delivery of blood flow to active 
skeletal muscle, thereby contributing to a greater functional ability. Thus the initial decline in 
vascular performance with acute exercise could be a consequence of a perturbation of endothelial 
homeostasis. In fact, the exercise-induced endothelial activation may serve as a significant 
trigger for vascular modification, similar to exercise-induced mRNA activation, which may lead 
to skeletal muscle hypertrophy [543]. Typically, when exercise-induced activation is too frequent 
or infrequent, too excessive or not intense enough, or too long or not long enough the process 
may lead too insufficient adaptations or maladaptation. It is subsequently no surprise that the 
optimal dose-response for exercise training among different populations is not entirely 
understood.                                                                                                                                       
 However, it is interesting to consider studies that reported less evidence of oxidative 
damage among trained individuals [516]. Moreover, Leeuwenburgh et al., [497] reported that an 
acute bout of exercise in untrained subjects’ increased oxidative stress considerably. These 
studies imply that chronic exercise training may in fact create an environment that allows for the 
maintenance of endothelial balance. Future studies are needed to further appreciate this 
speculation. It is intriguing that the subject’s in the present study showed a considerably rebound 
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effect in recovery from exercise, in terms of pro-oxidant/anti-oxidant balance and vascular 
reactivity. This suggests that the exposure to oxidative stress was significant but short-lived in 
these subjects. Further data is needed to appreciate whether this rebound is different in less 
trained individuals. In addition, it is intriguing to speculate what might be seen in individuals 
who already have endothelial activation pre-exercise, due to risk factors, or disease, or in older 
individuals. Thus this study may have set the stage for a series of additional experiments with 
endothelial homeostasis as its focus.                                                                                               
 In that regard, a review by Lum et al., [544] acknowledged that acute and chronic oxidant 
stress to the vascular endothelium is a serious causative factor of vascular endothelial 
dysfunction (or “endothelial activation”), and plays an important role in the pathophysiology of 
several vascular diseases. Indeed, endothelial activation may endanger normal synthesis and 
release of nitric oxide by endothelial cells. However, under ‘normal’ physiological conditions, 
reactive oxygen species production is low and the endogenous anti-oxidant systems are sufficient 
to maintain the pro-oxidant/anti-oxidant balance. This vital action would uphold superoxide 
production and elimination under tight control, thus preventing the breakdown of nitric oxide 
[545]. On the other hand, in disease states in which the production of reactive oxygen species is 
increased and/or the anti-oxidant capacity of the vessel is decreased, nitric oxide is transformed 
to peroxynitrite, resulting in inhibition of endothelial-dependent relaxation [546].  
 Interestingly, it has been reported that reactive oxygen species are also frequently 
elevated in patients with one or more cardiovascular risk factors, for example in smokers or in 
patients with hypercholesterolemia [545]. Thus one could argue that the increased production of 
reactive oxygen species in individuals at risk for disease or already with a disease is a key 
component in the pathogenesis of endothelial activation. In addition, one could speculate that 
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any further overwhelming exposure to oxidative stress may compromise seriously the already 
tenuous pro-oxidant/anti-oxidant balance in these individuals.  
 Likewise, there is a growing amount of evidence that aging is associated with increasing 
systemic imbalance between the generation and the scavenging of pro-oxidants [546]. 
Furthermore, it has been proposed that increased oxidative stress may play a role in premature 
aging [547]. It is important also to emphasize that a progressive impairment of endothelial 
vascular function, nitric oxide related, is a peculiar aspect of the physiological aging process 
[548]. Thus it seems to be an important interaction between age-associated pro-oxidant/anti-
oxidant balance and the ability of vasculature to preserve nitric oxide bioavailability. Once again, 
one could suggest that endothelial activation, as reported in disease states, is also a keystone in 
the age-associated changes in humans.                                                                                  
 Arguably, it could be speculated that conditions where endothelial activation is already 
present (e.g. end-stage chronic diseases) oxidative stress on the vasculature is chronic rather than 
acute. Such a condition could lead to a chronic imbalance and place individuals at great risk for 
the consequences of such imbalance. In such situations the use of exercise may in fact be 
counterproductive as it would merely add to the oxidative stress rather than serve as a stimulus 
for adaptation. However, given the plethora of evidence of the beneficial effects of chronic 
exercise in many disease states [549] the threshold where exercise training is harmful appears to 
be set quite high.  
 In summary, the present study reports a significant increase in pro-oxidants, a decrease in 
anti-oxidants, suggesting a change in the environment that may trigger endothelial activation. 
Moreover, the study reports a blunted brachial artery reactivity at peak exercise. Interestingly, 
the decline in pro-oxidants and return to pre-exercise levels for anti-oxidants and vasoreactivity 
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implies a rapid return of endothelial homeostasis, within 20 minutes after exercise within these 
trained individuals. Therefore, the present study provides an excellent model to study the 
dynamic balance between pro-oxidant challenge and anti-oxidant defense in the biological 
system.   
5.4.6 Limitations of the Study                                                                                                             
 As with all studies, certain limitations prevent stronger inferences at this time. Generally, 
limitations are a consequence of the study design, study population and methodologies. The 
present study limitations within each of those categories will be briefly discussed.                                     
 In regards to the study design, there is no doubt that the use of only three measures to 
detect a pattern in biological systems is a limitation. A true detection of a temporal pattern of any 
system must involve more data points. However, due to feasibility issues this first ‘look-and-
see’-study elected to examine three time points. It is recognized future studies are needed to 
examine the inferred pattern discussed within this paper with greater care.                                          
 In regards to the selected participants, this study is certainly limited in scope. A stronger 
design may have been one that compared individuals with different fitness levels or a wider age 
range. The basis of the selection was one of convenience in terms of recruitment, finances, and 
internal review board concerns. Despite this limitation, the current study did find consistency 
within the responses among the subjects. Clearly this consistency in the response gives the study 
a lot more strength. It is also important to understand that the selection of the participants was 
done with the knowledge that the participants were willing to push themselves through an 
arduous protocol that involved blood sampling at high levels of exercise. It was thought that this 
strategy may allow for the greatest chance to see a consistent response as these athletes are 
generally used to such high levels of performance. Obviously, it is important to take the next step 
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and examine these responses among a greater number of populations where vascular issues can 
be of major concern as it relates to physical performance. 
 Finally, the inability to accurately quantify the changes in nitrosylated hemoglobin, due  
to technical difficulties experienced with the electron paramagnetic resonance spectroscopy 
equipment, merely allows us to indirectly discuss what is believed to be happening with 
endothelial balance. Several strategies were attempted to allow for a representation of this 
variable but as of yet to no avail. Nevertheless, it is important to reinforce that this study is 
reporting peroxynitrite, (interaction of superoxide with nitric oxide). This biochemical variable 
may in some way provide some insights of the activities of superoxide and nitric oxide. Although 
these limitations, the present findings regarding the dynamics of the pro-oxidant /anti-oxidant are 
quiet exciting and deserve future follow up.                                                                                         
5.4.7 Conclusion                                                                                                                                 
 The major purpose of this study was to examine the effects of an acute bout of exercise 
on nitric oxide bioavailability, oxidative stress and anti-oxidants markers, and brachial artery 
reactivity. Specifically these dependent measures were examined before, at peak exercise, and at 
20 minutes into the recovery phase, in aerobically trained individuals.  
 The two major unique outcomes of the present study indicate a significant increase in 
reactive oxygen species and peroxynitrite, and a decrease in the anti-oxidant glutathione 
peroxidase at peak exercise. In addition, brachial artery vasoreactivity revealed a temporal 
pattern, with a blunted response immediately after exercise, but near complete recovery after 20 
minutes of recovery.  
 These findings are quiet important if we take in consideration that increased vascular 
oxidative stress represents a major cause of reduced endothelial nitric oxide bioavailability, and 
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it compromises the pro-oxidant/anti-oxidant balance. Clearly, the present study provides an 
excellent model to study the dynamic balance between pro-oxidant challenge and anti-oxidant 





 Cardiovascular diseases remain the leading cause of death in the United States and most 
western countries [11]. Indeed, cardiovascular disease is the underlying cause of death for 36.3% 
of all deaths in 2004, or 1 of every 2.8 deaths in the United States. Among these cardiovascular 
diseases, coronary heart disease caused 1 of every 5 deaths in the United States in 2004 [11]. An 
estimated 79 million American adults (1 in 3) have 1 or more types of cardiovascular disease. Of 
these, 37 million are estimated to be age 65 or older [11]. Finally, the economic burden of 
cardiovascular disease is enormous [12], with the costs of cardiovascular disease totaling an 
estimated $352 billion dollars in the United States, in 2004 [12].                                                       
 Early identification of risk factors and subsequent risk factor modification represents an 
important tool to fight back and try to decrease the incidence and prevalence of cardiovascular 
diseases. Among the modifiable behaviors that increase risk of cardiovascular disease are 
cigarette smoking, high blood pressure, obesity, and physical inactivity. Interestingly, exercise 
training is an excellent and beneficial strategy to improve overall health. In fact, epidemiologic 
studies have shown that physical activity reduces cardiovascular morbidity and mortality in the 
general population [549-551], and in patients with coronary artery disease/myocardial infarction 
[13,14]. The evidence clearly shows that regular exercise has a favorable effect on many 
established risk factors for cardiovascular disease. For example, exercise training is associated 
with beneficial changes in blood pressure, lipid metabolism, glucose metabolism, neurohormonal 
factors, weight loss, etc. [552]. In addition, exercise training improves muscular function and 
strength, the ability to utilize oxygen (“maximal oxygen consumption or aerobic capacity”), 
muscle blood flow, and many other physiologic systems. Furthermore, although the effect of an 
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exercise program on any single risk factor is generally small, the effects of continued, moderate 
exercise training on overall cardiovascular risk, when combined with other lifestyle 
modifications (e.g. proper nutrition, smoking cessation), can be dramatic [553].                  
 Nevertheless, it is important to emphasize that despite the fact that exercise training is 
beneficial; the mechanisms underlying the protective effect of physical activity on cardiovascular 
disease are still not fully understood. It is, however, clear that there are distinct changes in the 
vasculature, which could contribute to the protective effect of physical activity on cardiovascular 
disease [554]. In that regard, the vascular benefits of long-term physical activity appear to be 
mediated in part by improvements in endothelial structure and endothelial function in the 
systemic, coronary, and pulmonary beds [528,555], as well as by increased bioavailability of 
nitric oxide [556,557]. Indeed, several studies have shown that regular physical training 
enhances endothelium-dependent vasodilation in the forearm and coronary circulation in patients 
with hypertension and patients with coronary heart disease as well in healthy individuals 
[13,194,558].                                                                                                                                
 Thus one could argue that preserving healthy endothelial function may play a major role 
in vascular tone, vascular smooth muscle proliferation and migration, inflammation, innate 
immunity, and anticoagulation [557]. In fact, impaired endothelial function has been associated 
with several risk factors for the development of atherosclerosis [554], and is associated with a 
significantly higher incidence of cardiovascular events [559]. Given the changes in the 
endothelium are associated with these events serial measures of markers of endothelial function 
may prove to be important in monitoring individuals’ risk. In that regard, high-resolution 
ultrasound has been used as a non-invasive technique to assess endothelial function in peripheral 
arteries [560]. Indeed, non-invasive evaluation of brachial artery flow-mediated dilation has 
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emerged as a useful tool to study vascular function. This method assesses the ability of the 
endothelium to dilate in response to shear-induced increase in nitric oxide. The dilatory response 
associated with increased flow is thought to be endothelium dependent, and is subsequently used 
as a marker of endothelial function. For example, it has been reported that brachial artery flow 
mediated dilation is reduced in the presence of numerous cardiovascular risk factors [561-563] 
and holds predictive value for cardiovascular events [564]. In addition, aging is associated with a 
progressive decline in endothelial-dependent vasodilation [565]. Finally, there is also evidence of 
a link between decreased vascular reactivity and physical function [292,376].                             
 Clearly, the assessment of vascular function in clinical research has emerged as a 
powerful tool on vascular biology. Indeed, its determination might provide significant insight 
about vascular “health”. It is this underlying assumption that has led to the overall idea of this 
dissertation. Indeed, this work was motivated with the idea to continue to explore the effects of 
exercise on the vasculature. The outcomes within each of the projects within this dissertation in 
some unique way have contributed to a slightly better understanding of the possible underlying 
mechanisms and/or controllers that govern vascular function. Clearly, this information is not 
only important from a research point of view, but also may help health professionals from 
different background to improve their delivery as health providers. Ultimately, the main focus of 
this work was to determine how the vasculature may be influenced or may influence physical 
function.                                                                                                                                  
 The first step in the research process started with a follow-up study of previous work 
from this laboratory. Indeed, those studies showed several associations between strength and 
vascular measures [4] and improvements in vasoreactivity following isolated resistive types of 
exercises [6]. Importantly, these adaptations occurred within four weeks of training. These 
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studies were used as a foundation to keep exploring the effects of training on the vasculature, 
specifically the effects of resistance training on blood flow responses. Resistance training not 
only impacts strength and endurance, but also contributes to the maintenance of functional ability 
[425]. Thus the initial study was aimed to investigate the influence of two volumes (high and 
low) of whole-body circuit weight training on forearm vascular function in younger healthy 
college individuals. The findings revealed significant and similar increases in strength for the 
high and low volume groups. However, despite the increases in strength, vascular changes were 
only seen in the subjects who had lower vascular function prior to training [566]. Thus the study 
finding indicated that individuals with evidence of low vascular function may respond favorably 
to whole-body circuit weight training.                                                                                         
 So it is perhaps not a surprise that the second project in this dissertation focused on 
individuals who may have lower vascular function due to some sort of pathologic condition. The 
population selected for the second study was a group of individuals with peripheral neuropathy. 
The major reason for that selection is the fact that irrespective of etiology, pathological changes 
associated with the disease are in many cases consistent with ischemia, secondary to vascular 
insufficiencies [8]. The main focus of the second study was to examine the link between vascular 
and physical function. The importance of such a link is to recognize that a large component of 
physical decline could be secondary to a loss of vascular function. If such a link can be found the 
development of strategies aimed at preserving vascular function could eventually help 
individuals remain physically able, even in the face of certain pathologic conditions. The 
findings of the second study confirmed a relationship between measures of vascular and physical 
function in peripheral neuropathy. Indeed, individuals with greater physical function scores 
exhibited more favorable measures of arterial inflow and venous outflow. Specifically, 
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individuals in the lowest tertile of the time up and go and those with a 6 minute walk distance 
score <400m had significantly lower peak reactive hyperemia blood flow responses and peak 
vascular conductance compared to the other groups. In addition, individuals in the top tertile of 
knee extension and knee flexion exhibited faster venous outflow half-time than the other tertiles. 
These findings fit “The Disablement Pathway” and suggest that lower physical function may, in 
part, be a consequence of deterioration of peripheral vascular function in individuals with 
peripheral neuropathy. Future longitudinal studies are needed to confirm the relationship 
between vascular and physical function and to determine whether exercise interventions can 
maintain and/or improve vascular function and contribute to the preservation of functional ability 
in individuals with peripheral neuropathy.                                                                             
 Although the previous studies were able to provide important information on how the 
vasculature may be influenced or may influence physical function, these findings also 
demonstrated how complex the study of vascular function could be. In fact, the initial studies 
could only speculate regarding the true “controllers” that could mediate vascular function. So the 
last step in this process was to begin the exploration in some putative factors thought to control 
vascular function. Within this last step the work by Deanfield et al., [9] was particularly 
motivating and stimulating. Indeed, Deanfield et al., [9] have speculated the vascular function is 
very much influenced by the balance of pro- and anti-oxidants. In fact, a negative balance, which 
is termed oxidative stress, has been implicated in a number of human diseases as well as in 
accelerated aging [544,567].  
 Interestingly, it appears that the balance is very much controlled by a molecule that is 
released by the vascular endothelium under different conditions, which is nitric oxide. Thus the 
third project was the initial development of the idea that the balance between pro- and anti- 
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oxidants would be very much influenced by the nitric oxide status of an individual. If the balance 
is in favor of oxidative stress this might mean that the vasculature would be more vulnerable as 
defined by less reactive.                                                                                
 Clearly this step was a significant extension from the previous studies, and because of 
that it was thought that these investigations should first be conducted in healthy trained 
individuals which hopefully would allow for the establishment of a data set to which other 
populations could ultimately be compared. Thus the last project was intended to examine the 
effects of an acute bout of exercise on nitric oxide bioavailability, oxidative stress and anti-
oxidants markers, and brachial artery reactivity before, at peak exercise, and in recovery. The 
two major unique outcomes of this final study indicated a significant increase in reactive oxygen 
species and peroxynitrite, and a decrease in the anti-oxidant glutathione peroxidase at peak 
exercise. In addition, brachial vasoreactivity revealed a temporal pattern, with a blunted response 
immediately after exercise, and near complete recovery after 20 minutes of recovery. These 
findings support the a-priori hypotheses, and suggest an acute bout of exercise contributes to a 
significant rise in reactive oxygen stress on the brachial artery, which can in part be buffered by 
anti-oxidants systems, but may cause temporary blunting of the reactivity of the brachial artery. 
 In summary the findings of this dissertation further add to the current understanding of 
the role of the vasculature in physical function. It appears that physical function is very much 
influenced by the vasculature even in individuals with significant disease. Moreover, the 
vasculature can be acutely modified, and may improve over time in individuals involved in 
physical training. The acute modification of exercise appears to be at least in part negative (i.e. 
reduced vascular reactivity) due to oxidative stress. However, the ‘negative’ effects of acute 
exercise on the vasculature are short-lived in highly trained athletes suggesting a significant 
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buffering capacity. Obviously future studies will have to determine if these effects are in part a 
component of the signaling pathways that may enhance vascular function as is evident within the 
literature. The improvements in vascular function following training were again noted in this 
dissertation, although those benefits were seen only in those who had evidence of low function 
prior to training. Futures studies will continue this line of research in order to improve the 
current understanding of vascular function. In the same manner, it is imperative to recognize that 
the implementation of proper exercise programs is necessary to keep blood vessels healthy. 
Clearly, these findings have set the stage for a series of additional experiments with endothelial 
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Appendix: Consent Form 
CONSENT TO PARTICIPATE IN A RESEARCH STUDY 
1. Title of Study: Effects of an Acute Bout of Exercise on Nitric Oxide Bioavailability, 
Oxidative Stress, and Antioxidant Defense Markers in Trained Individuals 
      2.   Performance Sites:                                                                                                                                                      
 LSU-Department of Kinesiology                                                                                                                 
 Room 54 and 58, Exercise Laboratory and Vascular Laboratory                                                                                         
 112 Huey P. Long Fieldhouse                                                                                                                                     
 Baton Rouge, LA 70803                                                                                                           
3.   Contacts:                                                                                                                                                
      The following investigators are available for questions at the telephone numbers listed  
      below: 
  Principal Investigator:  Michael A. Welsch, Ph.D.                                                          
  Department:    Kinesiology                                                                      
  Telephone Number:   (225)578-9143 
  Co-Investigator   Arturo Arce, M.D.                                                                       
  Department:    Kinesiology                                                                      
  Telephone Number:   (225)578-20 
      4.   Purpose of the Study:                                                                                                                                      
   The purpose of the present study is to examine the effects of an acute bout of exercise on   
             nitric oxide bioavailability, oxidative stress markers, and antioxidants markers, before,       
             immediately and 20 minutes after, in trained individuals.  
      5.   Subjects:      
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       A.  Inclusion Criteria You must be at least 18 years of age. Apparently healthy    
             highly trained cyclist.  
       B.  Exclusion Criteria If you have unstable manifestations of cardiovascular,   
             metabolic, orthopedic, and/or neurological disease; active infection; risk for  
             adverse responses to exercise; taking any  medication which may affect   
             cardiovascular function. 
       C.  Maximum number of subjects: 20 
      6.   Study Procedures:                                                                                                                                   
If you are selected to participate in this study you will be involved for a total of 2 distinct 
visits. They include a series of tests at the beginning, during and the end of the study.             
On the first visit you will be asked to perform a bike time trial and we will take some 
pictures of an artery in your arm.  
 The bike time trial will be performed on a stationary bike. You will begin pedaling at a 
speed that would allow you to regulate your workload by pedaling cadence, just as you 
would on a real cycle in a real competition. During the test we will measure the amount 
of oxygen you consume and carbon dioxide you produce to allow us to more precisely 
determine your fitness. We will measure oxygen and carbon dioxide using a metabolic 
analyzer. You will breathe regular room air, but when you exhale, a machine will 
measure how much air you are actually breathing out, and how much oxygen and carbon 
dioxide is in your breath. We will also measure your heart rate and blood pressure at the 
beginning, during and after the exercise. 
In addition to the bike time trial, we will also take some pictures of an artery in your arm. 
This will be done right before and immediately after the exercise test. To perform this test 
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you will be asked to lie down on an examination bed. A laboratory technician will place 4 
electrodes and 2 blood pressure cuffs on your chest and both arms, respectively. The 
electrodes are used to examine your heartbeat. The cuffs are used to measure blood 
pressure in the one arm and change blood flow to the hand in the other arm to allow us to 
test how your arteries react. After all the equipment is in place an ultrasound technician 
will be taking pictures of an artery in your arm before and after inflating a blood pressure 
cuff on the forearm for 5-minutes. Throughout the procedure, heart rate, and blood 
pressures will also be recorded. This test is called the brachial artery dilation test. 
On the second visit you will again be asked to perform a bike time trial similar to the test 
on the first visit. However, prior to the test a certified phlebotomist will place a Heparin-
Lock in the antecubital vein of the left arm for the purpose of blood sampling prior to the 
start of the exercise, at peak exercise, and 20 minutes after. The amount of blood drawn 
at each time point will be about 10ml. The blood samples will be processed and prepared 
for analyses. The purpose of the blood samples is to examine the influence of the exercise 
test on factors that have an effect on the health of the blood vessels.     
      7.   Benefits:                                                                                                                                                                
 We cannot promise any benefits from being in the study.  However, participation in this 
 study may assist the investigators in gathering information leading to better treatments for 
 cardiovascular disease. You will have the opportunity of having the required tests and 
 procedures performed during your participation in this study.   
 All clinic visits, physical examinations, study medication, laboratory tests, 
 electrocardiograms, and any other procedures associated with the conduct of this study 
 are free if you participate.  
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      8.   Risks/Discomforts:                                                                                                                                       
 The possible risks and discomforts for this trial are detailed in this informed consent. 
             Blood sampling will be conducted by a certified and trained phlebotomist. The 
 discomforts and risks  of a blood test are the pain of a needle going into the vein, possible 
 bruising and the remote risk of infection. However, if venipuncture is done properly, 
 there should be little pain and little risk for adverse reactions. The phlebotomist will 
 constantly monitor your condition during the course of the  test. Inflation of the blood 
 pressure cuff on the forearm may cause some temporary discomfort in the forearm and 
 hand. If the discomfort is too severe you may terminate the procedure immediately by 
 asking the technician to stop the test. Temporary numbness and tingling in the hand 
 similar to the sensation of having your hand “fall asleep” may occur. There is no known 
 risk to the use of ultrasound to measure the size of the blood vessel. There is no 
 theoretical risk to blocking blood flow in the artery through inflation of the blood 
 pressure cuff. Not a single permanent adverse event  has been associated with this 
 procedure in over 100,000 examinations reported in the medical literature. In addition to 
 the risks listed above, the procedures may have unknown, unforeseen or unanticipated 
 side effects. There is always the possibility that you will have a reaction that is currently 
 not known and not expected. The risks of the bike time trail test using the methods 
 described are minimal in this population but include: muscle soreness, stiffness or 
 tightness, or in some rare cases muscle injuries or more severe complications.   
      9.   Measures taken to reduce risk                                                                                                           
 The risk in this study will be minimized as a result of proper evaluation, education, and  
 appropriate assessment of exercise responses and the presence of well trained personnel 
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 capable of monitoring exercise equipment. 
    10. Right to Refuse:                                                                                                                                 
 Your participation is voluntary. If you decide not to participate in this study you will not 
 suffer a penalty or loss of benefits to which you are otherwise entitled. If you decide to 
 participate in this study you may discontinue your participation at any time, without 
 penalty or loss of benefits. 
    11. Privacy:                                                                                                                                                
 Every effort will be made to keep the information we learn about you private.                                        
 Records of your participation in this study will be kept confidential except as required by 
 law. Any publication of the data will not identify you. 
    12. Financial Information:                                                                                                                            
 You will have no financial obligations. 
    13. Withdrawal:                                                                                                                                                             
 If you decide to participate in this study you may discontinue your participation at any 
 time, without  penalty or loss of benefits and it will have no effect on the quality of your 
 medical care, academic standing, job status, etc.  
    14.   Removal:                                                                                                                                             
 You will have completed the study after finishing the two visits. The length of each visit 
 will be approximately one hour.  
 The study has been discussed with me and all my questions have been answered. I may 
 direct additional questions regarding study specifics to the investigators. If I have  
 questions about subjects' rights or other concerns, I can contact Robert C. Mathews, 
 Chairman, LSU Institutional Review Board, (225)578-8692. I agree to participate in the 
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 study described above and acknowledge the researchers’ obligation to    
 provide me with a copy of this consent form if signed by me. 
Subject Signature: ________________________________ Date: ___________  
The study subject has indicated to me that he/she is unable to read. I certify that I have read this 
consent form to the subject and explained that by completing the signature line above, the subject 
has agreed to participate. 
Signature of Reader: _______________________________ Date: ___________ 




Arturo Arce was born in Arequipa, Peru, on January 31, 1968. He received his Medical Degree 
(M.D.) from Universidad Nacional de Cordoba, Argentina, in December of 1993. He currently is 
a post-doctoral fellow at the University of Missouri-Columbia. At the May 2008 commencement 
ceremony he will be awarded the Doctor of Philosophy in kinesiology from the graduate school 
at Louisiana State University. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
